[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fFamB_-gd8g-AggS_lnj26RU3_UqMAg3Pw4TOxeToaLI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":85,"rows":92},"European Organisation for Research and Treatment of Cancer - EORTC",[4],351,false,40,139,110935,65,57,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Breast Cancer",28,{"name":18,"count":19},"Leukemia",25,{"name":21,"count":22},"Lymphoma",23,{"name":24,"count":25},"Lung Cancer",22,{"name":27,"count":25},"Brain and Central Nervous System Tumors",{"name":29,"count":30},"Colorectal Cancer",20,{"name":32,"count":30},"Sarcoma",{"name":34,"count":35},"Prostate Cancer",19,[37,42,46,50,55,60,65,70,75,80],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT00379041","Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma","1998-10-01","bleomycin sulfate",{"nctId":43,"briefTitle":44,"date":45,"intervention":41},"NCT00002462","RT or No RT Following Chemotherapy in Treating Patients With Stage III\u002FIV Hodgkin's Disease","2000-05",{"nctId":47,"briefTitle":48,"date":49,"intervention":41},"NCT00005584","Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma","2004-05",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT00626990","Phase III Trial of Anaplastic Glioma Without 1p\u002F19q Loss of Heterozygosity (LOH)","2018-09-05","temozolomide",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT02834884","SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access","2022-08-29","RP-1828 IMMUcan",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT02972060","ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer","2023-01-13","ODM-201",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT02799706","Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer","2023-08-23","Degarelix",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT03517137","Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study","2023-08-28","Brentuximab Vedotin",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT03134118","Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)","2023-09-05","Nivolumab",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT03235245","Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib","2023-10-24","Nivolumab + Ipilimumab",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,238,319,377,528,590,621,643,688,873,940,990,1041,1087,1109,1131,1153,1181,1206,1224,1246,1264,1291,1309,1334,1352,1377,1409,1427,1445,1463,1481,1499,1517,1535,1553,1689,1797,1929,1958,1991,2025,2043,2061,2079,2103,2129,2155,2179,2197,2215,2241,2266,2288,2306,2331,2349,2367,2385,2411,2429,2454,2472,2490,2508,2526,2855,2953,3061,3127,3200,3262,3340,3406,3457,3518,3564,3610,3671,3710,3768,3828,3879,3935,3969,4015,4052,4096,4129,4162,4212,4242,4275,4301,4327,4353,4379,4408,4434,4460,4491,4522,4550,4572,4598,4620,4642,4668,4699,4721,4743,4765,4787,4809,4843,4870,4892,4914,4946,4973,4997,5019,5037,5055,5080,5098,5116,5142,5160,5178,5196,5214,5232,5250,5268,5286,5316,5334,5352,5370,5388,5406,5424,5442,5465,5488,5506,5524,5548,5566,5584,5605,5623,5647,5665,5683,5707,5725,5743,5766,5784,5809,5827,5849,5867,5885,5903,5921,5945,5963,5981,5999,6024,6046,6070,6088,6106,6124,6154,6194,6236,6273,6305,6338,6370,6401,6435,6471,6505,6539,6565,6587,6609,6631,6659,6695,6717,6742,6764,6786,6814,6832,6855,6879,6903,6921,6948,6966,6984,7002,7020,7038,7056,7080,7098,7116,7139,7157,7175,7193,7211,7236,7254,7272,7298,7316,7334,7352,7370,7388,7409,7427,7445,7467,7485,7506,7524,7542,7566,7584,7607,7625,7643,7661,7679,7697,7715,7733,7751,7769,7791,7809,7827,7849,7879,7897,7922,7940,7958,7984,8002,8026,8047,8065,8088,8106,8124,8149,8167,8188,8209,8227,8248,8266,8287,8308,8326,8459,8504,8539,8561,8579,8597,8622,8640],{"intervention":94,"totalTrials":95,"cells":96},"prednisone",11,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":128,"PHASE4":234,"NA":236},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[104,119],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"start":110,"enrollment":19,"conditions":111,"interventions":113},"NCT00079261","Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma","COMPLETED",[88],"2007-03","2004-01",[21,112],"Small Intestine Cancer",[114,115,116,117,94,118],"CHOP regimen","cyclophosphamide","doxorubicin hydrochloride","gemcitabine hydrochloride","vincristine sulfate",{"nctId":120,"briefTitle":121,"status":107,"phases":122,"primaryCompletion":123,"start":124,"enrollment":125,"conditions":126,"interventions":127},"NCT00039351","Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma",[88],"2005-01","2002-03",32,[21],[115,94,118],{"trials":129,"activeCount":192,"soonestReadout":40},[130,141,160,177,185,196,211,218,228],{"nctId":131,"briefTitle":132,"status":107,"phases":133,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":139},"NCT00004179","Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma",[89],"2004-04","2017-07-19","1999-05",475,[21],[140,114,115,116,94,118],"rituximab",{"nctId":142,"briefTitle":143,"status":107,"phases":144,"primaryCompletion":145,"start":146,"enrollment":147,"conditions":148,"interventions":149},"NCT00002700","Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia",[89],"2004-03","1995-08",392,[18,21],[150,115,151,152,153,116,154,155,156,157,158,94,159,118],"asparaginase","cytarabine","daunorubicin hydrochloride","dexamethasone","leucovorin calcium","mercaptopurine","methotrexate","mitoxantrone hydrochloride","prednisolone","therapeutic hydrocortisone",{"nctId":161,"briefTitle":162,"status":107,"phases":163,"primaryCompletion":164,"start":165,"enrollment":166,"conditions":167,"interventions":168},"NCT00049595","Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma",[89],"2010-01","2002-08",552,[21],[41,169,170,171,172,115,173,116,174,94,175,176,118],"filgrastim","pegfilgrastim","ABVD regimen","BEACOPP regimen","dacarbazine","etoposide","procarbazine hydrochloride","vinblastine sulfate",{"nctId":38,"briefTitle":39,"status":178,"phases":179,"primaryCompletion":40,"start":180,"enrollment":181,"conditions":182,"interventions":183},"ACTIVE_NOT_RECRUITING",[89],"1993-09-01",1158,[21],[41,116,184,94,175,176,118],"mechlorethamine hydrochloride",{"nctId":186,"briefTitle":187,"status":188,"phases":189,"primaryCompletion":190,"start":191,"enrollment":192,"conditions":193,"interventions":194},"NCT00060385","Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma","TERMINATED",[88,89],"2004-08","2003-03",3,[21],[114,195,115,116,174,94,118],"EPOCH regimen",{"nctId":197,"briefTitle":198,"status":188,"phases":199,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":206},"NCT04780464","A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma",[89],"2023-09-22","2023-11-11","2022-04-11",14,[205],"Advanced Soft-tissue Sarcoma",[207,207,208,209,210],"Doxorubicin","Cyclophosphamide Oral Product","Prednisolone","Prednisone",{"nctId":47,"briefTitle":48,"status":178,"phases":212,"primaryCompletion":49,"start":213,"enrollment":214,"conditions":215,"interventions":216},[89],"1998-10",1649,[21],[41,171,172,217,94,176],"epirubicin hydrochloride",{"nctId":219,"briefTitle":220,"status":188,"phases":221,"primaryCompletion":222,"start":223,"enrollment":224,"conditions":225,"interventions":226},"NCT00003152","Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma",[89],"1999-11","1997-03",469,[21],[169,227,115,94,118],"recombinant interferon alfa",{"nctId":43,"briefTitle":44,"status":178,"phases":229,"primaryCompletion":45,"start":230,"enrollment":231,"conditions":232,"interventions":233},[89],"1989-09",615,[21],[41,116,184,94,175,176,118],{"trials":235,"activeCount":99},[],{"trials":237,"activeCount":99},[],{"intervention":176,"totalTrials":239,"cells":240},8,{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":258,"PHASE4":315,"NA":317},{"trials":242,"activeCount":99},[],{"trials":244,"activeCount":99},[],{"trials":246,"activeCount":99},[247],{"nctId":248,"briefTitle":249,"status":188,"phases":250,"primaryCompletion":251,"start":252,"enrollment":253,"conditions":254,"interventions":256},"NCT00003640","Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer",[88],"2000-11","1998-09",73,[255],"Bladder Cancer",[169,257,116,156,176],"cisplatin",{"trials":259,"activeCount":192,"soonestReadout":40},[260,274,278,290,294,298,311],{"nctId":261,"briefTitle":262,"status":107,"phases":263,"primaryCompletion":264,"start":265,"enrollment":266,"conditions":267,"interventions":269},"NCT00003209","Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer",[89],"1999-12","1997-12",700,[268],"Cervical Cancer",[41,257,270,271,156,272,176,273],"fluorouracil","ifosfamide","mitomycin C","vindesine",{"nctId":161,"briefTitle":162,"status":107,"phases":275,"primaryCompletion":164,"start":165,"enrollment":166,"conditions":276,"interventions":277},[89],[21],[41,169,170,171,172,115,173,116,174,94,175,176,118],{"nctId":279,"briefTitle":280,"status":107,"phases":281,"primaryCompletion":282,"start":283,"enrollment":284,"conditions":285,"interventions":288},"NCT00014274","Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium",[88,89],"2008-03","2001-01",238,[255,286,287],"Transitional Cell Cancer of the Renal Pelvis and Ureter","Urethral Cancer",[289,117,156,176],"carboplatin",{"nctId":38,"briefTitle":39,"status":178,"phases":291,"primaryCompletion":40,"start":180,"enrollment":181,"conditions":292,"interventions":293},[89],[21],[41,116,184,94,175,176,118],{"nctId":47,"briefTitle":48,"status":178,"phases":295,"primaryCompletion":49,"start":213,"enrollment":214,"conditions":296,"interventions":297},[89],[21],[41,171,172,217,94,176],{"nctId":299,"briefTitle":300,"status":107,"phases":301,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":310},"NCT00028756","Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium",[89],"2014-01","2014-07","2001-10",285,[307,308,309],"Stage III Bladder Cancer","Stage IV Bladder Cancer","Transitional Cell Carcinoma of the Bladder",[116,117,176,156,257,169],{"nctId":43,"briefTitle":44,"status":178,"phases":312,"primaryCompletion":45,"start":230,"enrollment":231,"conditions":313,"interventions":314},[89],[21],[41,116,184,94,175,176,118],{"trials":316,"activeCount":99},[],{"trials":318,"activeCount":99},[],{"intervention":41,"totalTrials":320,"cells":321},7,{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":328,"PHASE4":373,"NA":375},{"trials":323,"activeCount":99},[],{"trials":325,"activeCount":99},[],{"trials":327,"activeCount":99},[],{"trials":329,"activeCount":192,"soonestReadout":40},[330,334,338,342,354,358,369],{"nctId":261,"briefTitle":262,"status":107,"phases":331,"primaryCompletion":264,"start":265,"enrollment":266,"conditions":332,"interventions":333},[89],[268],[41,257,270,271,156,272,176,273],{"nctId":161,"briefTitle":162,"status":107,"phases":335,"primaryCompletion":164,"start":165,"enrollment":166,"conditions":336,"interventions":337},[89],[21],[41,169,170,171,172,115,173,116,174,94,175,176,118],{"nctId":38,"briefTitle":39,"status":178,"phases":339,"primaryCompletion":40,"start":180,"enrollment":181,"conditions":340,"interventions":341},[89],[21],[41,116,184,94,175,176,118],{"nctId":343,"briefTitle":344,"status":107,"phases":345,"primaryCompletion":346,"start":347,"enrollment":348,"conditions":349,"interventions":353},"NCT00003941","Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer",[89],"2007-06","1999-04",222,[350,351,352],"Mediastinal Cancer","Metastatic Cancer","Testicular Germ Cell Tumor",[41,169,257,174,271],{"nctId":47,"briefTitle":48,"status":178,"phases":355,"primaryCompletion":49,"start":213,"enrollment":214,"conditions":356,"interventions":357},[89],[21],[41,171,172,217,94,176],{"nctId":359,"briefTitle":360,"status":361,"phases":362,"start":213,"enrollment":363,"conditions":364,"interventions":367},"NCT00003643","Combination Chemotherapy in Treating Men With Germ Cell Cancer","UNKNOWN",[88,89],498,[365,366,352],"Extragonadal Germ Cell Tumor","Teratoma",[41,169,257,174,368],"paclitaxel",{"nctId":43,"briefTitle":44,"status":178,"phases":370,"primaryCompletion":45,"start":230,"enrollment":231,"conditions":371,"interventions":372},[89],[21],[41,116,184,94,175,176,118],{"trials":374,"activeCount":99},[],{"trials":376,"activeCount":99},[],{"intervention":116,"totalTrials":35,"cells":378},{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":414,"PHASE4":524,"NA":526},{"trials":380,"activeCount":99},[],{"trials":382,"activeCount":99},[],{"trials":384,"activeCount":99},[385,389,393,404],{"nctId":248,"briefTitle":249,"status":188,"phases":386,"primaryCompletion":251,"start":252,"enrollment":253,"conditions":387,"interventions":388},[88],[255],[169,257,116,156,176],{"nctId":105,"briefTitle":106,"status":107,"phases":390,"primaryCompletion":109,"start":110,"enrollment":19,"conditions":391,"interventions":392},[88],[21,112],[114,115,116,117,94,118],{"nctId":394,"briefTitle":395,"status":361,"phases":396,"primaryCompletion":397,"start":398,"enrollment":399,"conditions":400,"interventions":402},"NCT00410462","Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma",[88],"2008-09","2006-10",118,[401,32,112],"Ovarian Cancer",[403,116],"brostallicin",{"nctId":405,"briefTitle":406,"status":107,"phases":407,"primaryCompletion":408,"start":409,"enrollment":410,"conditions":411,"interventions":413},"NCT00052312","Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and\u002For Relapsed Endometrial Cancer",[88],"2006-09","2002-09",141,[412],"Endometrial Cancer",[257,116,368],{"trials":415,"activeCount":523,"soonestReadout":40},[416,420,424,433,442,446,455,459,470,474,485,495,499,503,512],{"nctId":131,"briefTitle":132,"status":107,"phases":417,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":418,"interventions":419},[89],[21],[140,114,115,116,94,118],{"nctId":142,"briefTitle":143,"status":107,"phases":421,"primaryCompletion":145,"start":146,"enrollment":147,"conditions":422,"interventions":423},[89],[18,21],[150,115,151,152,153,116,154,155,156,157,158,94,159,118],{"nctId":425,"briefTitle":426,"status":107,"phases":427,"primaryCompletion":428,"start":429,"enrollment":430,"conditions":431,"interventions":432},"NCT00003212","Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma",[89],"2001-11","1998-01",780,[32],[116,271],{"nctId":434,"briefTitle":435,"status":107,"phases":436,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":441},"NCT00003052","Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma",[89],"2010-06","1997-07",340,[32],[116,174,271],{"nctId":161,"briefTitle":162,"status":107,"phases":443,"primaryCompletion":164,"start":165,"enrollment":166,"conditions":444,"interventions":445},[89],[21],[41,169,170,171,172,115,173,116,174,94,175,176,118],{"nctId":447,"briefTitle":448,"status":107,"phases":449,"primaryCompletion":251,"start":450,"enrollment":439,"conditions":451,"interventions":454},"NCT00002764","Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma",[89],"1996-04",[412,452,351,401,453,32],"Kidney Cancer","Pheochromocytoma",[169,116,271],{"nctId":38,"briefTitle":39,"status":178,"phases":456,"primaryCompletion":40,"start":180,"enrollment":181,"conditions":457,"interventions":458},[89],[21],[41,116,184,94,175,176,118],{"nctId":460,"briefTitle":461,"status":188,"phases":462,"primaryCompletion":463,"completion":464,"start":465,"enrollment":466,"conditions":467,"interventions":468},"NCT01189253","Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma",[88,89],"2013-06","2015-06","2011-05",133,[32],[116,469],"trabectedin",{"nctId":186,"briefTitle":187,"status":188,"phases":471,"primaryCompletion":190,"start":191,"enrollment":192,"conditions":472,"interventions":473},[88,89],[21],[114,195,115,116,174,94,118],{"nctId":475,"briefTitle":476,"status":107,"phases":477,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":483},"NCT00002641","Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma",[89],"2006-02","2012-06","1995-02",350,[412,452,401,453,32],[169,116,271,484],"isolated perfusion",{"nctId":486,"briefTitle":487,"status":107,"phases":488,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":493,"interventions":494},"NCT00061984","Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma",[89],"2010-05","2012-07","2003-04",455,[32],[170,116,271],{"nctId":299,"briefTitle":300,"status":107,"phases":496,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":497,"interventions":498},[89],[307,308,309],[116,117,176,156,257,169],{"nctId":43,"briefTitle":44,"status":178,"phases":500,"primaryCompletion":45,"start":230,"enrollment":231,"conditions":501,"interventions":502},[89],[21],[41,116,184,94,175,176,118],{"nctId":504,"briefTitle":505,"status":107,"phases":506,"primaryCompletion":507,"start":508,"enrollment":509,"conditions":510,"interventions":511},"NCT00002539","Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma",[89],"2002-10","1993-08",214,[32],[169,257,116],{"nctId":513,"briefTitle":514,"status":361,"phases":515,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":519,"interventions":520},"NCT00003728","Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma",[89],"2008-05","1998-12",1500,[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],"methylprednisolone","thioguanine",2,{"trials":525,"activeCount":99},[],{"trials":527,"activeCount":99},[],{"intervention":118,"totalTrials":95,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":544,"PHASE4":586,"NA":588},{"trials":531,"activeCount":99},[],{"trials":533,"activeCount":99},[],{"trials":535,"activeCount":99},[536,540],{"nctId":105,"briefTitle":106,"status":107,"phases":537,"primaryCompletion":109,"start":110,"enrollment":19,"conditions":538,"interventions":539},[88],[21,112],[114,115,116,117,94,118],{"nctId":120,"briefTitle":121,"status":107,"phases":541,"primaryCompletion":123,"start":124,"enrollment":125,"conditions":542,"interventions":543},[88],[21],[115,94,118],{"trials":545,"activeCount":523,"soonestReadout":40},[546,550,554,558,562,566,570,574,582],{"nctId":131,"briefTitle":132,"status":107,"phases":547,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":548,"interventions":549},[89],[21],[140,114,115,116,94,118],{"nctId":142,"briefTitle":143,"status":107,"phases":551,"primaryCompletion":145,"start":146,"enrollment":147,"conditions":552,"interventions":553},[89],[18,21],[150,115,151,152,153,116,154,155,156,157,158,94,159,118],{"nctId":161,"briefTitle":162,"status":107,"phases":555,"primaryCompletion":164,"start":165,"enrollment":166,"conditions":556,"interventions":557},[89],[21],[41,169,170,171,172,115,173,116,174,94,175,176,118],{"nctId":38,"briefTitle":39,"status":178,"phases":559,"primaryCompletion":40,"start":180,"enrollment":181,"conditions":560,"interventions":561},[89],[21],[41,116,184,94,175,176,118],{"nctId":186,"briefTitle":187,"status":188,"phases":563,"primaryCompletion":190,"start":191,"enrollment":192,"conditions":564,"interventions":565},[88,89],[21],[114,195,115,116,174,94,118],{"nctId":219,"briefTitle":220,"status":188,"phases":567,"primaryCompletion":222,"start":223,"enrollment":224,"conditions":568,"interventions":569},[89],[21],[169,227,115,94,118],{"nctId":43,"briefTitle":44,"status":178,"phases":571,"primaryCompletion":45,"start":230,"enrollment":231,"conditions":572,"interventions":573},[89],[21],[41,116,184,94,175,176,118],{"nctId":575,"briefTitle":576,"status":107,"phases":577,"primaryCompletion":124,"start":578,"enrollment":481,"conditions":579,"interventions":580},"NCT00002840","Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma",[89],"1996-08",[27],[581,175,118],"lomustine",{"nctId":513,"briefTitle":514,"status":361,"phases":583,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":584,"interventions":585},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":587,"activeCount":99},[],{"trials":589,"activeCount":99},[],{"intervention":175,"totalTrials":591,"cells":592},4,{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":617,"NA":619},{"trials":594,"activeCount":99},[],{"trials":596,"activeCount":99},[],{"trials":598,"activeCount":99},[],{"trials":600,"activeCount":523,"soonestReadout":40},[601,605,609,613],{"nctId":161,"briefTitle":162,"status":107,"phases":602,"primaryCompletion":164,"start":165,"enrollment":166,"conditions":603,"interventions":604},[89],[21],[41,169,170,171,172,115,173,116,174,94,175,176,118],{"nctId":38,"briefTitle":39,"status":178,"phases":606,"primaryCompletion":40,"start":180,"enrollment":181,"conditions":607,"interventions":608},[89],[21],[41,116,184,94,175,176,118],{"nctId":43,"briefTitle":44,"status":178,"phases":610,"primaryCompletion":45,"start":230,"enrollment":231,"conditions":611,"interventions":612},[89],[21],[41,116,184,94,175,176,118],{"nctId":575,"briefTitle":576,"status":107,"phases":614,"primaryCompletion":124,"start":578,"enrollment":481,"conditions":615,"interventions":616},[89],[27],[581,175,118],{"trials":618,"activeCount":99},[],{"trials":620,"activeCount":99},[],{"intervention":184,"totalTrials":523,"cells":622},{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":629,"PHASE4":639,"NA":641},{"trials":624,"activeCount":99},[],{"trials":626,"activeCount":99},[],{"trials":628,"activeCount":99},[],{"trials":630,"activeCount":523,"soonestReadout":40},[631,635],{"nctId":38,"briefTitle":39,"status":178,"phases":632,"primaryCompletion":40,"start":180,"enrollment":181,"conditions":633,"interventions":634},[89],[21],[41,116,184,94,175,176,118],{"nctId":43,"briefTitle":44,"status":178,"phases":636,"primaryCompletion":45,"start":230,"enrollment":231,"conditions":637,"interventions":638},[89],[21],[41,116,184,94,175,176,118],{"trials":640,"activeCount":99},[],{"trials":642,"activeCount":99},[],{"intervention":644,"totalTrials":523,"cells":645},"Local standard of Care",{"EARLY_PHASE1":646,"PHASE1":648,"PHASE2":650,"PHASE3":666,"PHASE4":684,"NA":686},{"trials":647,"activeCount":99},[],{"trials":649,"activeCount":99},[],{"trials":651,"activeCount":665,"soonestReadout":657},[652],{"nctId":653,"briefTitle":654,"status":655,"phases":656,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":663},"NCT06326190","177Lu-DOTATATE for Recurrent Meningioma","RECRUITING",[88],"2027-04-14","2028-12-22","2025-03-10",136,[662],"Recurrent Meningioma",[644,664],"177Lu-DOTATATE",1,{"trials":667,"activeCount":665,"soonestReadout":673},[668],{"nctId":669,"briefTitle":670,"status":671,"phases":672,"primaryCompletion":673,"completion":674,"start":675,"enrollment":676,"conditions":677,"interventions":679},"NCT07425808","FLT3-ITD Targeted Therapy in Fit AML Patients","NOT_YET_RECRUITING",[88,89],"2028-10-01","2032-02-01","2026-12-01",230,[678],"AML (Acute Myeloid Leukemia)",[680,681,682,683],"Gilteritinib","Venetoclax","Azacitidine","Local standard of care",{"trials":685,"activeCount":99},[],{"trials":687,"activeCount":99},[],{"intervention":54,"totalTrials":689,"cells":690},17,{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":726,"PHASE3":809,"PHASE4":869,"NA":871},{"trials":692,"activeCount":99},[],{"trials":694,"activeCount":99},[695,704,717],{"nctId":696,"briefTitle":697,"status":361,"phases":698,"primaryCompletion":699,"start":700,"enrollment":16,"conditions":701,"interventions":702},"NCT00516607","Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas",[87],"2008-11","2007-07",[27],[703,54],"enzastaurin hydrochloride",{"nctId":705,"briefTitle":706,"status":107,"phases":707,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":711,"interventions":714},"NCT03224104","Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.",[87],"2022-05-05","2018-06-12",71,[712,713],"Astrocytoma, Grade III","Glioblastoma",[715,716],"TG02","Temozolomide",{"nctId":718,"briefTitle":719,"status":361,"phases":720,"primaryCompletion":721,"start":145,"enrollment":722,"conditions":723,"interventions":724},"NCT00083096","Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas",[87],"2009-06",30,[27],[725,54],"lonafarnib",{"trials":727,"activeCount":99},[728,735,743,755,763,772,783,798],{"nctId":729,"briefTitle":730,"status":107,"phases":731,"primaryCompletion":283,"start":517,"enrollment":732,"conditions":733,"interventions":734},"NCT00003731","Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors",[88],39,[27],[54],{"nctId":736,"briefTitle":730,"status":107,"phases":737,"primaryCompletion":738,"start":739,"enrollment":740,"conditions":741,"interventions":742},"NCT00003304",[88],"2000-03","1998-04",29,[27],[54],{"nctId":744,"briefTitle":745,"status":107,"phases":746,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":751,"interventions":753},"NCT01164189","Bevacizumab in Recurrent Grade II and III Glioma",[88],"2017-01-19","2017-09-24","2011-02",155,[752],"Central Nervous System Tumors",[754,716],"Bevacizumab",{"nctId":756,"briefTitle":757,"status":107,"phases":758,"primaryCompletion":759,"start":438,"enrollment":760,"conditions":761,"interventions":762},"NCT00003062","Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer",[88],"2002-01",70,[24],[54],{"nctId":764,"briefTitle":765,"status":107,"phases":766,"primaryCompletion":767,"start":768,"enrollment":30,"conditions":769,"interventions":770},"NCT00128700","Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[87,88],"2007-11","2005-06",[27],[54,771],"vatalanib",{"nctId":773,"briefTitle":774,"status":107,"phases":775,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":780,"interventions":781},"NCT01019434","Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma",[88],"2013-12","2014-03","2009-10",111,[27],[54,782],"temsirolimus",{"nctId":784,"briefTitle":785,"status":786,"phases":787,"primaryCompletion":788,"completion":789,"start":790,"enrollment":99,"conditions":791,"interventions":793},"NCT04796454","Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer","WITHDRAWN",[88],"2026-07","2026-08","2022-05",[792],"Platinum-Sensitive Biliary Tract Cancer",[794,795,796,797,716],"Cisplatin","Gemcitabine","Oxaliplatin","Pamiparib",{"nctId":799,"briefTitle":800,"status":107,"phases":801,"primaryCompletion":802,"completion":803,"start":49,"enrollment":804,"conditions":805,"interventions":806},"NCT00086879","Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme",[88],"2006-03","2011-03",110,[27],[807,808,54],"carmustine","erlotinib hydrochloride",{"trials":810,"activeCount":665,"soonestReadout":53},[811,819,828,840,851,859],{"nctId":812,"briefTitle":813,"status":107,"phases":814,"primaryCompletion":124,"start":815,"enrollment":816,"conditions":817,"interventions":818},"NCT00006353","Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[89],"2000-07",575,[27],[54],{"nctId":820,"briefTitle":821,"status":188,"phases":822,"primaryCompletion":823,"start":824,"enrollment":22,"conditions":825,"interventions":827},"NCT00020839","Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain",[89],"2003-05","2001-04",[826,351],"Melanoma (Skin)",[54],{"nctId":829,"briefTitle":830,"status":107,"phases":831,"primaryCompletion":832,"completion":833,"start":834,"enrollment":835,"conditions":836,"interventions":838},"NCT03345095","A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma",[89],"2022-08-23","2023-06-30","2018-07-26",749,[837],"Newly Diagnosed Glioblastoma",[839,716],"Marizomib",{"nctId":841,"briefTitle":842,"status":188,"phases":843,"primaryCompletion":844,"completion":844,"start":845,"enrollment":35,"conditions":846,"interventions":850},"NCT03763422","Trial in Low Grade Glioma Patients: Wait or Treat",[89],"2021-12-29","2020-03-16",[847,716,848,849],"Low-grade Glioma","Phase III","Wait or Treat",[716],{"nctId":51,"briefTitle":52,"status":178,"phases":852,"primaryCompletion":53,"completion":853,"start":854,"enrollment":855,"conditions":856,"interventions":857},[89],"2029-12","2007-12",751,[27],[54,858],"DNA methylation analysis",{"nctId":860,"briefTitle":861,"status":107,"phases":862,"primaryCompletion":863,"completion":864,"start":865,"enrollment":866,"conditions":867,"interventions":868},"NCT00182819","Radiation Therapy or Temozolomide in Treating Patients With Gliomas",[89],"2013-08","2014-05","2005-07",709,[27],[54],{"trials":870,"activeCount":99},[],{"trials":872,"activeCount":99},[],{"intervention":874,"totalTrials":875,"cells":876},"Lomustine",5,{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":905,"PHASE4":936,"NA":938},{"trials":878,"activeCount":99},[],{"trials":880,"activeCount":99},[],{"trials":882,"activeCount":99},[883,895],{"nctId":884,"briefTitle":885,"status":188,"phases":886,"primaryCompletion":887,"completion":888,"start":889,"enrollment":30,"conditions":890,"interventions":892},"NCT04402073","Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma",[88],"2025-06-16","2025-09-10","2022-11-11",[891],"Medulloblastoma",[893,794,874,894],"Sonidegib","Vincristine",{"nctId":896,"briefTitle":897,"status":786,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":99,"conditions":901,"interventions":903},"NCT04933942","Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma",[88],"2022-12-19","2022-09-13",[902],"First Progression of MGMT Promoter-methylated Glioblastoma",[874,904],"Romiplostim",{"trials":906,"activeCount":665,"soonestReadout":911},[907,918,922],{"nctId":908,"briefTitle":909,"status":655,"phases":910,"primaryCompletion":911,"completion":912,"start":913,"enrollment":914,"conditions":915,"interventions":917},"NCT05904119","Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study",[89],"2027-09","2028-02","2024-03-15",411,[916],"First Progression of Glioblastoma",[874],{"nctId":575,"briefTitle":576,"status":107,"phases":919,"primaryCompletion":124,"start":578,"enrollment":481,"conditions":920,"interventions":921},[89],[27],[581,175,118],{"nctId":923,"briefTitle":924,"status":107,"phases":925,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":934},"NCT01290939","Bevacizumab and Lomustine for Recurrent GBM",[89],"2015-10","2020-04","2011-10",592,[931,932,933],"Glioblastoma Multiforme","Cognition Disorders","Disability Evaluation",[935,581,858],"bevacizumab",{"trials":937,"activeCount":99},[],{"trials":939,"activeCount":99},[],{"intervention":217,"totalTrials":591,"cells":941},{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":956,"PHASE3":969,"PHASE4":986,"NA":988},{"trials":943,"activeCount":99},[],{"trials":945,"activeCount":99},[946],{"nctId":947,"briefTitle":948,"status":107,"phases":949,"primaryCompletion":950,"start":951,"enrollment":952,"conditions":953,"interventions":954},"NCT00008034","Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer",[87],"2000-12","2000-02",15,[15],[955,115,217],"capecitabine",{"trials":957,"activeCount":99},[958],{"nctId":959,"briefTitle":960,"status":188,"phases":961,"primaryCompletion":863,"completion":962,"start":963,"enrollment":740,"conditions":964,"interventions":967},"NCT01123473","Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer",[88],"2014-09","2010-12",[965,966],"Adenocarcinoma of the Gastroesophageal Junction","Gastric Cancer",[955,257,217,270,968],"lapatinib ditosylate",{"trials":970,"activeCount":665,"soonestReadout":49},[971,982],{"nctId":972,"briefTitle":973,"status":107,"phases":974,"primaryCompletion":975,"start":976,"enrollment":977,"conditions":978,"interventions":979},"NCT00017095","Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer",[89],"2006-11","2001-03",1856,[15],[169,115,980,217,270,981],"docetaxel","microarray analysis",{"nctId":47,"briefTitle":48,"status":178,"phases":983,"primaryCompletion":49,"start":213,"enrollment":214,"conditions":984,"interventions":985},[89],[21],[41,171,172,217,94,176],{"trials":987,"activeCount":99},[],{"trials":989,"activeCount":99},[],{"intervention":991,"totalTrials":192,"cells":992},"Pembrolizumab",{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":1024,"PHASE4":1037,"NA":1039},{"trials":994,"activeCount":99},[],{"trials":996,"activeCount":99},[],{"trials":998,"activeCount":99},[999,1011],{"nctId":1000,"briefTitle":1001,"status":107,"phases":1002,"primaryCompletion":1003,"completion":1004,"start":1005,"enrollment":1006,"conditions":1007,"interventions":1009},"NCT02580994","Pembrolizumab in Untreated Extensive SCLC",[88],"2020-09-22","2022-06-22","2017-12-08",125,[1008],"Small Cell Lung Cancer (SCLC)",[991,1010],"cis\u002Fcarboplatin and etoposide",{"nctId":1012,"briefTitle":1013,"status":107,"phases":1014,"primaryCompletion":1015,"completion":1016,"start":1017,"enrollment":1018,"conditions":1019,"interventions":1023},"NCT03260712","Pembrolizumab in Biliary Tract Cancer",[88],"2023-04-27","2023-08-31","2020-01-07",50,[1020,351,1021,1022],"Biliary Tract Cancer","Advanced Cancer","Gallbladder Cancer",[991,794,795],{"trials":1025,"activeCount":665,"soonestReadout":1030},[1026],{"nctId":1027,"briefTitle":1028,"status":655,"phases":1029,"primaryCompletion":1030,"completion":1031,"start":1032,"enrollment":1033,"conditions":1034,"interventions":1036},"NCT05815927","Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer",[89],"2027-07-15","2030-03-30","2025-05-23",200,[1035],"Oligometastatic Squamous Cell Carcinoma of the Head and Neck",[991],{"trials":1038,"activeCount":99},[],{"trials":1040,"activeCount":99},[],{"intervention":1042,"totalTrials":523,"cells":1043},"tamoxifen",{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1048,"PHASE3":1050,"PHASE4":1083,"NA":1085},{"trials":1045,"activeCount":99},[],{"trials":1047,"activeCount":99},[],{"trials":1049,"activeCount":99},[],{"trials":1051,"activeCount":665,"soonestReadout":1068},[1052,1064],{"nctId":1053,"briefTitle":1054,"status":107,"phases":1055,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":1058,"conditions":1059,"interventions":1060},"NCT00433589","Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes",[89],"2020-03","2007-02",6600,[15],[1061,1062,1042,1063],"anthracycline-based","docetaxel and capecitabine","Letrozole",{"nctId":1065,"briefTitle":1066,"status":655,"phases":1067,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1077},"NCT05512364","Elacestrant for Treating ER+\u002FHER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)",[89],"2032-11-01","2035-11-01","2023-12-15",220,[1073,1074,1075,1076],"ER-positive Breast Cancer","HER2-negative Breast Cancer","Stage IIB Breast Cancer","Stage III Breast Cancer",[1078,1079,1080,1081,1082],"Elacestrant","Tamoxifen","Letrozole 2.5mg","Anastrozole 1mg","Exemestane 25 MG",{"trials":1084,"activeCount":99},[],{"trials":1086,"activeCount":99},[],{"intervention":171,"totalTrials":523,"cells":1088},{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1093,"PHASE3":1095,"PHASE4":1105,"NA":1107},{"trials":1090,"activeCount":99},[],{"trials":1092,"activeCount":99},[],{"trials":1094,"activeCount":99},[],{"trials":1096,"activeCount":665,"soonestReadout":49},[1097,1101],{"nctId":161,"briefTitle":162,"status":107,"phases":1098,"primaryCompletion":164,"start":165,"enrollment":166,"conditions":1099,"interventions":1100},[89],[21],[41,169,170,171,172,115,173,116,174,94,175,176,118],{"nctId":47,"briefTitle":48,"status":178,"phases":1102,"primaryCompletion":49,"start":213,"enrollment":214,"conditions":1103,"interventions":1104},[89],[21],[41,171,172,217,94,176],{"trials":1106,"activeCount":99},[],{"trials":1108,"activeCount":99},[],{"intervention":172,"totalTrials":523,"cells":1110},{"EARLY_PHASE1":1111,"PHASE1":1113,"PHASE2":1115,"PHASE3":1117,"PHASE4":1127,"NA":1129},{"trials":1112,"activeCount":99},[],{"trials":1114,"activeCount":99},[],{"trials":1116,"activeCount":99},[],{"trials":1118,"activeCount":665,"soonestReadout":49},[1119,1123],{"nctId":161,"briefTitle":162,"status":107,"phases":1120,"primaryCompletion":164,"start":165,"enrollment":166,"conditions":1121,"interventions":1122},[89],[21],[41,169,170,171,172,115,173,116,174,94,175,176,118],{"nctId":47,"briefTitle":48,"status":178,"phases":1124,"primaryCompletion":49,"start":213,"enrollment":214,"conditions":1125,"interventions":1126},[89],[21],[41,171,172,217,94,176],{"trials":1128,"activeCount":99},[],{"trials":1130,"activeCount":99},[],{"intervention":858,"totalTrials":523,"cells":1132},{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1137,"PHASE3":1139,"PHASE4":1149,"NA":1151},{"trials":1134,"activeCount":99},[],{"trials":1136,"activeCount":99},[],{"trials":1138,"activeCount":99},[],{"trials":1140,"activeCount":665,"soonestReadout":53},[1141,1145],{"nctId":51,"briefTitle":52,"status":178,"phases":1142,"primaryCompletion":53,"completion":853,"start":854,"enrollment":855,"conditions":1143,"interventions":1144},[89],[27],[54,858],{"nctId":923,"briefTitle":924,"status":107,"phases":1146,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":1147,"interventions":1148},[89],[931,932,933],[935,581,858],{"trials":1150,"activeCount":99},[],{"trials":1152,"activeCount":99},[],{"intervention":1154,"totalTrials":665,"cells":1155},"Preoperative chemotherapy",{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1162,"PHASE4":1177,"NA":1179},{"trials":1157,"activeCount":99},[],{"trials":1159,"activeCount":99},[],{"trials":1161,"activeCount":99},[],{"trials":1163,"activeCount":665,"soonestReadout":1168},[1164],{"nctId":1165,"briefTitle":1166,"status":655,"phases":1167,"primaryCompletion":1168,"completion":1169,"start":1170,"enrollment":1171,"conditions":1172,"interventions":1176},"NCT04031677","Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma",[89],"2027-04-21","2028-04-21","2021-01-20",250,[1173,1174,1175],"Retroperitoneal Sarcoma","Liposarcoma","Leiomyosarcoma",[1154],{"trials":1178,"activeCount":99},[],{"trials":1180,"activeCount":99},[],{"intervention":1182,"totalTrials":665,"cells":1183},"Ra223",{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1190,"PHASE4":1202,"NA":1204},{"trials":1185,"activeCount":99},[],{"trials":1187,"activeCount":99},[],{"trials":1189,"activeCount":99},[],{"trials":1191,"activeCount":665,"soonestReadout":1196},[1192],{"nctId":1193,"briefTitle":1194,"status":178,"phases":1195,"primaryCompletion":1196,"completion":1197,"start":926,"enrollment":1198,"conditions":1199,"interventions":1200},"NCT02194842","Phase III Radium 223 mCRPC-PEACE III",[89],"2024-02-19","2028-12",446,[34],[1182,1201],"Enzalutamide",{"trials":1203,"activeCount":99},[],{"trials":1205,"activeCount":99},[],{"intervention":1201,"totalTrials":665,"cells":1207},{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1212,"PHASE3":1214,"PHASE4":1220,"NA":1222},{"trials":1209,"activeCount":99},[],{"trials":1211,"activeCount":99},[],{"trials":1213,"activeCount":99},[],{"trials":1215,"activeCount":665,"soonestReadout":1196},[1216],{"nctId":1193,"briefTitle":1194,"status":178,"phases":1217,"primaryCompletion":1196,"completion":1197,"start":926,"enrollment":1198,"conditions":1218,"interventions":1219},[89],[34],[1182,1201],{"trials":1221,"activeCount":99},[],{"trials":1223,"activeCount":99},[],{"intervention":69,"totalTrials":665,"cells":1225},{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1232,"PHASE4":1242,"NA":1244},{"trials":1227,"activeCount":99},[],{"trials":1229,"activeCount":99},[],{"trials":1231,"activeCount":99},[],{"trials":1233,"activeCount":665,"soonestReadout":68},[1234],{"nctId":66,"briefTitle":67,"status":178,"phases":1235,"primaryCompletion":68,"completion":1236,"start":1237,"enrollment":1238,"conditions":1239,"interventions":1240},[89],"2026-06-30","2017-09-25",885,[34],[69,1241],"approved GnRH agonist",{"trials":1243,"activeCount":99},[],{"trials":1245,"activeCount":99},[],{"intervention":1241,"totalTrials":665,"cells":1247},{"EARLY_PHASE1":1248,"PHASE1":1250,"PHASE2":1252,"PHASE3":1254,"PHASE4":1260,"NA":1262},{"trials":1249,"activeCount":99},[],{"trials":1251,"activeCount":99},[],{"trials":1253,"activeCount":99},[],{"trials":1255,"activeCount":665,"soonestReadout":68},[1256],{"nctId":66,"briefTitle":67,"status":178,"phases":1257,"primaryCompletion":68,"completion":1236,"start":1237,"enrollment":1238,"conditions":1258,"interventions":1259},[89],[34],[69,1241],{"trials":1261,"activeCount":99},[],{"trials":1263,"activeCount":99},[],{"intervention":1265,"totalTrials":665,"cells":1266},"Vorasidenib",{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1271,"PHASE3":1273,"PHASE4":1287,"NA":1289},{"trials":1268,"activeCount":99},[],{"trials":1270,"activeCount":99},[],{"trials":1272,"activeCount":99},[],{"trials":1274,"activeCount":665,"soonestReadout":1279},[1275],{"nctId":1276,"briefTitle":1277,"status":655,"phases":1278,"primaryCompletion":1279,"completion":1280,"start":1281,"enrollment":1282,"conditions":1283,"interventions":1285},"NCT06809322","Vorasidenib Maintenance for IDH Mutant Astrocytoma",[89],"2035-04-13","2037-05-31","2026-01-16",468,[1284],"IDH-mutant Grade 2 or 3 Astrocytoma",[1265,1286],"Vorasidenib Placebo",{"trials":1288,"activeCount":99},[],{"trials":1290,"activeCount":99},[],{"intervention":1286,"totalTrials":665,"cells":1292},{"EARLY_PHASE1":1293,"PHASE1":1295,"PHASE2":1297,"PHASE3":1299,"PHASE4":1305,"NA":1307},{"trials":1294,"activeCount":99},[],{"trials":1296,"activeCount":99},[],{"trials":1298,"activeCount":99},[],{"trials":1300,"activeCount":665,"soonestReadout":1279},[1301],{"nctId":1276,"briefTitle":1277,"status":655,"phases":1302,"primaryCompletion":1279,"completion":1280,"start":1281,"enrollment":1282,"conditions":1303,"interventions":1304},[89],[1284],[1265,1286],{"trials":1306,"activeCount":99},[],{"trials":1308,"activeCount":99},[],{"intervention":1310,"totalTrials":665,"cells":1311},"iMAB",{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1316,"PHASE3":1318,"PHASE4":1330,"NA":1332},{"trials":1313,"activeCount":99},[],{"trials":1315,"activeCount":99},[],{"trials":1317,"activeCount":99},[],{"trials":1319,"activeCount":665,"soonestReadout":1324},[1320],{"nctId":1321,"briefTitle":1322,"status":655,"phases":1323,"primaryCompletion":1324,"completion":1325,"start":1032,"enrollment":1326,"conditions":1327,"interventions":1328},"NCT05974774","Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors",[89],"2035-05-23","2039-06-01",1600,[34],[1310,1329],"cMAB",{"trials":1331,"activeCount":99},[],{"trials":1333,"activeCount":99},[],{"intervention":1329,"totalTrials":665,"cells":1335},{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1342,"PHASE4":1348,"NA":1350},{"trials":1337,"activeCount":99},[],{"trials":1339,"activeCount":99},[],{"trials":1341,"activeCount":99},[],{"trials":1343,"activeCount":665,"soonestReadout":1324},[1344],{"nctId":1321,"briefTitle":1322,"status":655,"phases":1345,"primaryCompletion":1324,"completion":1325,"start":1032,"enrollment":1326,"conditions":1346,"interventions":1347},[89],[34],[1310,1329],{"trials":1349,"activeCount":99},[],{"trials":1351,"activeCount":99},[],{"intervention":1353,"totalTrials":665,"cells":1354},"Tebentafusp",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1361,"PHASE4":1373,"NA":1375},{"trials":1356,"activeCount":99},[],{"trials":1358,"activeCount":99},[],{"trials":1360,"activeCount":99},[],{"trials":1362,"activeCount":665,"soonestReadout":1367},[1363],{"nctId":1364,"briefTitle":1365,"status":655,"phases":1366,"primaryCompletion":1367,"completion":1367,"start":1368,"enrollment":1369,"conditions":1370,"interventions":1372},"NCT06246149","Adjuvant Tebentafusp in High Risk Ocular Melanoma",[89],"2032-11","2024-11-11",290,[1371],"Uveal Melanoma",[1353],{"trials":1374,"activeCount":99},[],{"trials":1376,"activeCount":99},[],{"intervention":1378,"totalTrials":665,"cells":1379},"Duloxetine 60 MG",{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1405,"NA":1407},{"trials":1381,"activeCount":99},[],{"trials":1383,"activeCount":99},[],{"trials":1385,"activeCount":99},[],{"trials":1387,"activeCount":665,"soonestReadout":1392},[1388],{"nctId":1389,"briefTitle":1390,"status":671,"phases":1391,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":1396,"interventions":1403},"NCT06407401","Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer",[89],"2028-04-18","2028-11-30","2024-12",399,[1397,1074,1398,1399,1400,1401,1402],"ER+ Breast Cancer","Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III","Drug-Related Side Effects and Adverse Reactions","Musculoskeletal Pain",[1378,1404],"Furosemide 40 mg",{"trials":1406,"activeCount":99},[],{"trials":1408,"activeCount":99},[],{"intervention":1404,"totalTrials":665,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1417,"PHASE4":1423,"NA":1425},{"trials":1412,"activeCount":99},[],{"trials":1414,"activeCount":99},[],{"trials":1416,"activeCount":99},[],{"trials":1418,"activeCount":665,"soonestReadout":1392},[1419],{"nctId":1389,"briefTitle":1390,"status":671,"phases":1420,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":1421,"interventions":1422},[89],[1397,1074,1398,1399,1400,1401,1402],[1378,1404],{"trials":1424,"activeCount":99},[],{"trials":1426,"activeCount":99},[],{"intervention":1078,"totalTrials":665,"cells":1428},{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1435,"PHASE4":1441,"NA":1443},{"trials":1430,"activeCount":99},[],{"trials":1432,"activeCount":99},[],{"trials":1434,"activeCount":99},[],{"trials":1436,"activeCount":665,"soonestReadout":1068},[1437],{"nctId":1065,"briefTitle":1066,"status":655,"phases":1438,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1439,"interventions":1440},[89],[1073,1074,1075,1076],[1078,1079,1080,1081,1082],{"trials":1442,"activeCount":99},[],{"trials":1444,"activeCount":99},[],{"intervention":1080,"totalTrials":665,"cells":1446},{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1451,"PHASE3":1453,"PHASE4":1459,"NA":1461},{"trials":1448,"activeCount":99},[],{"trials":1450,"activeCount":99},[],{"trials":1452,"activeCount":99},[],{"trials":1454,"activeCount":665,"soonestReadout":1068},[1455],{"nctId":1065,"briefTitle":1066,"status":655,"phases":1456,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1457,"interventions":1458},[89],[1073,1074,1075,1076],[1078,1079,1080,1081,1082],{"trials":1460,"activeCount":99},[],{"trials":1462,"activeCount":99},[],{"intervention":1081,"totalTrials":665,"cells":1464},{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1469,"PHASE3":1471,"PHASE4":1477,"NA":1479},{"trials":1466,"activeCount":99},[],{"trials":1468,"activeCount":99},[],{"trials":1470,"activeCount":99},[],{"trials":1472,"activeCount":665,"soonestReadout":1068},[1473],{"nctId":1065,"briefTitle":1066,"status":655,"phases":1474,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1475,"interventions":1476},[89],[1073,1074,1075,1076],[1078,1079,1080,1081,1082],{"trials":1478,"activeCount":99},[],{"trials":1480,"activeCount":99},[],{"intervention":1082,"totalTrials":665,"cells":1482},{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1487,"PHASE3":1489,"PHASE4":1495,"NA":1497},{"trials":1484,"activeCount":99},[],{"trials":1486,"activeCount":99},[],{"trials":1488,"activeCount":99},[],{"trials":1490,"activeCount":665,"soonestReadout":1068},[1491],{"nctId":1065,"briefTitle":1066,"status":655,"phases":1492,"primaryCompletion":1068,"completion":1069,"start":1070,"enrollment":1071,"conditions":1493,"interventions":1494},[89],[1073,1074,1075,1076],[1078,1079,1080,1081,1082],{"trials":1496,"activeCount":99},[],{"trials":1498,"activeCount":99},[],{"intervention":680,"totalTrials":665,"cells":1500},{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1505,"PHASE3":1507,"PHASE4":1513,"NA":1515},{"trials":1502,"activeCount":99},[],{"trials":1504,"activeCount":99},[],{"trials":1506,"activeCount":99},[],{"trials":1508,"activeCount":665,"soonestReadout":673},[1509],{"nctId":669,"briefTitle":670,"status":671,"phases":1510,"primaryCompletion":673,"completion":674,"start":675,"enrollment":676,"conditions":1511,"interventions":1512},[88,89],[678],[680,681,682,683],{"trials":1514,"activeCount":99},[],{"trials":1516,"activeCount":99},[],{"intervention":681,"totalTrials":665,"cells":1518},{"EARLY_PHASE1":1519,"PHASE1":1521,"PHASE2":1523,"PHASE3":1525,"PHASE4":1531,"NA":1533},{"trials":1520,"activeCount":99},[],{"trials":1522,"activeCount":99},[],{"trials":1524,"activeCount":99},[],{"trials":1526,"activeCount":665,"soonestReadout":673},[1527],{"nctId":669,"briefTitle":670,"status":671,"phases":1528,"primaryCompletion":673,"completion":674,"start":675,"enrollment":676,"conditions":1529,"interventions":1530},[88,89],[678],[680,681,682,683],{"trials":1532,"activeCount":99},[],{"trials":1534,"activeCount":99},[],{"intervention":682,"totalTrials":665,"cells":1536},{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1543,"PHASE4":1549,"NA":1551},{"trials":1538,"activeCount":99},[],{"trials":1540,"activeCount":99},[],{"trials":1542,"activeCount":99},[],{"trials":1544,"activeCount":665,"soonestReadout":673},[1545],{"nctId":669,"briefTitle":670,"status":671,"phases":1546,"primaryCompletion":673,"completion":674,"start":675,"enrollment":676,"conditions":1547,"interventions":1548},[88,89],[678],[680,681,682,683],{"trials":1550,"activeCount":99},[],{"trials":1552,"activeCount":99},[],{"intervention":115,"totalTrials":1554,"cells":1555},18,{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1564,"PHASE3":1610,"PHASE4":1685,"NA":1687},{"trials":1557,"activeCount":99},[],{"trials":1559,"activeCount":99},[1560],{"nctId":947,"briefTitle":948,"status":107,"phases":1561,"primaryCompletion":950,"start":951,"enrollment":952,"conditions":1562,"interventions":1563},[87],[15],[955,115,217],{"trials":1565,"activeCount":665,"soonestReadout":73},[1566,1570,1582,1593,1606],{"nctId":105,"briefTitle":106,"status":107,"phases":1567,"primaryCompletion":109,"start":110,"enrollment":19,"conditions":1568,"interventions":1569},[88],[21,112],[114,115,116,117,94,118],{"nctId":1571,"briefTitle":1572,"status":107,"phases":1573,"primaryCompletion":975,"start":1574,"enrollment":1575,"conditions":1576,"interventions":1578},"NCT00077116","Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome",[88],"2003-11",31,[18,1577],"Myelodysplastic Syndromes",[1579,115,151,1580,1581],"busulfan","gemtuzumab ozogamicin","idarubicin",{"nctId":1583,"briefTitle":1584,"status":107,"phases":1585,"primaryCompletion":721,"completion":1586,"start":1587,"enrollment":1588,"conditions":1589,"interventions":1590},"NCT00036868","Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer",[88],"2010-02","2002-02",90,[15],[1591,1592,115,270,156],"trastuzumab","CMF regimen",{"nctId":71,"briefTitle":72,"status":178,"phases":1594,"primaryCompletion":73,"completion":1595,"start":1596,"enrollment":1597,"conditions":1598,"interventions":1600},[88],"2026-11-16","2019-08-01",150,[1599],"Advanced Hodgkin Lymphoma",[74,1601,1602,1603,1604,1605],"Adriamycin","Vinblastine","Dacarbazine","Etoposide","Cyclophosphamide",{"nctId":120,"briefTitle":121,"status":107,"phases":1607,"primaryCompletion":123,"start":124,"enrollment":125,"conditions":1608,"interventions":1609},[88],[21],[115,94,118],{"trials":1611,"activeCount":99},[1612,1616,1620,1629,1638,1648,1652,1656,1665,1669,1677,1681],{"nctId":131,"briefTitle":132,"status":107,"phases":1613,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":1614,"interventions":1615},[89],[21],[140,114,115,116,94,118],{"nctId":142,"briefTitle":143,"status":107,"phases":1617,"primaryCompletion":145,"start":146,"enrollment":147,"conditions":1618,"interventions":1619},[89],[18,21],[150,115,151,152,153,116,154,155,156,157,158,94,159,118],{"nctId":1621,"briefTitle":1622,"status":361,"phases":1623,"start":1624,"enrollment":1625,"conditions":1626,"interventions":1627},"NCT00002701","Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia",[89],"1995-10",750,[18],[1579,115,151,174,1581,155,156,157,522,1628],"tretinoin",{"nctId":1630,"briefTitle":1631,"status":361,"phases":1632,"start":223,"enrollment":1633,"conditions":1634,"interventions":1636},"NCT00002989","Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome",[89],207,[18,21,1635,1577],"Multiple Myeloma and Plasma Cell Neoplasm",[1579,115,1581,1637],"melphalan",{"nctId":1639,"briefTitle":1640,"status":361,"phases":1641,"primaryCompletion":1642,"start":1643,"enrollment":1644,"conditions":1645,"interventions":1646},"NCT00004128","Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia",[89],"2008-01","1999-09",2000,[18],[1647,169,1579,115,151,152,174],"aldesleukin",{"nctId":972,"briefTitle":973,"status":107,"phases":1649,"primaryCompletion":975,"start":976,"enrollment":977,"conditions":1650,"interventions":1651},[89],[15],[169,115,980,217,270,981],{"nctId":161,"briefTitle":162,"status":107,"phases":1653,"primaryCompletion":164,"start":165,"enrollment":166,"conditions":1654,"interventions":1655},[89],[21],[41,169,170,171,172,115,173,116,174,94,175,176,118],{"nctId":1657,"briefTitle":1658,"status":361,"phases":1659,"start":1660,"enrollment":1661,"conditions":1662,"interventions":1663},"NCT00002549","Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia",[89],"1993-11",1520,[18],[169,1579,115,151,152,174,1581,1664,157],"mesna",{"nctId":186,"briefTitle":187,"status":188,"phases":1666,"primaryCompletion":190,"start":191,"enrollment":192,"conditions":1667,"interventions":1668},[88,89],[21],[114,195,115,116,174,94,118],{"nctId":1670,"briefTitle":1671,"status":361,"phases":1672,"start":976,"conditions":1673,"interventions":1674},"NCT00017108","Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia",[89],[18],[1675,115,1676],"chlorambucil","fludarabine phosphate",{"nctId":219,"briefTitle":220,"status":188,"phases":1678,"primaryCompletion":222,"start":223,"enrollment":224,"conditions":1679,"interventions":1680},[89],[21],[169,227,115,94,118],{"nctId":513,"briefTitle":514,"status":361,"phases":1682,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":1683,"interventions":1684},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":1686,"activeCount":99},[],{"trials":1688,"activeCount":99},[],{"intervention":174,"totalTrials":689,"cells":1690},{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1695,"PHASE3":1722,"PHASE4":1793,"NA":1795},{"trials":1692,"activeCount":99},[],{"trials":1694,"activeCount":99},[],{"trials":1696,"activeCount":665,"soonestReadout":73},[1697,1704,1710,1718],{"nctId":1698,"briefTitle":1699,"status":188,"phases":1700,"primaryCompletion":1701,"start":283,"enrollment":192,"conditions":1702,"interventions":1703},"NCT00014313","Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor",[88],"2002-12",[32],[257,174],{"nctId":1705,"briefTitle":1706,"status":188,"phases":1707,"primaryCompletion":507,"start":824,"enrollment":875,"conditions":1708,"interventions":1709},"NCT00021112","Combination Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer",[88],[24],[257,174],{"nctId":1711,"briefTitle":1712,"status":107,"phases":1713,"primaryCompletion":759,"start":1714,"enrollment":1715,"conditions":1716,"interventions":1717},"NCT00006122","Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia",[88],"2000-06",106,[18],[151,174,1580,1581,157],{"nctId":71,"briefTitle":72,"status":178,"phases":1719,"primaryCompletion":73,"completion":1595,"start":1596,"enrollment":1597,"conditions":1720,"interventions":1721},[88],[1599],[74,1601,1602,1603,1604,1605],{"trials":1723,"activeCount":99},[1724,1728,1732,1736,1740,1744,1752,1756,1760,1768,1778,1785,1789],{"nctId":1621,"briefTitle":1622,"status":361,"phases":1725,"start":1624,"enrollment":1625,"conditions":1726,"interventions":1727},[89],[18],[1579,115,151,174,1581,155,156,157,522,1628],{"nctId":1639,"briefTitle":1640,"status":361,"phases":1729,"primaryCompletion":1642,"start":1643,"enrollment":1644,"conditions":1730,"interventions":1731},[89],[18],[1647,169,1579,115,151,152,174],{"nctId":434,"briefTitle":435,"status":107,"phases":1733,"completion":437,"start":438,"enrollment":439,"conditions":1734,"interventions":1735},[89],[32],[116,174,271],{"nctId":161,"briefTitle":162,"status":107,"phases":1737,"primaryCompletion":164,"start":165,"enrollment":166,"conditions":1738,"interventions":1739},[89],[21],[41,169,170,171,172,115,173,116,174,94,175,176,118],{"nctId":1657,"briefTitle":1658,"status":361,"phases":1741,"start":1660,"enrollment":1661,"conditions":1742,"interventions":1743},[89],[18],[169,1579,115,151,152,174,1581,1664,157],{"nctId":1745,"briefTitle":1746,"status":361,"phases":1747,"start":1748,"enrollment":1749,"conditions":1750,"interventions":1751},"NCT00002926","Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia",[89],"1996-12",80,[18,1577],[151,174,1581],{"nctId":186,"briefTitle":187,"status":188,"phases":1753,"primaryCompletion":190,"start":191,"enrollment":192,"conditions":1754,"interventions":1755},[88,89],[21],[114,195,115,116,174,94,118],{"nctId":343,"briefTitle":344,"status":107,"phases":1757,"primaryCompletion":346,"start":347,"enrollment":348,"conditions":1758,"interventions":1759},[89],[350,351,352],[41,169,257,174,271],{"nctId":1761,"briefTitle":1762,"status":107,"phases":1763,"primaryCompletion":1642,"completion":1764,"start":409,"enrollment":1765,"conditions":1766,"interventions":1767},"NCT00052299","Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia",[89],"2012-02",472,[18],[151,174,1580,1581,157],{"nctId":1769,"briefTitle":1770,"status":107,"phases":1771,"primaryCompletion":428,"start":1772,"enrollment":1773,"conditions":1774,"interventions":1776},"NCT00002719","Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia",[89],"1995-12",500,[18,1775],"Neutropenia",[169,1777,807,151,174,1581,157],"amsacrine",{"nctId":1779,"briefTitle":1780,"status":107,"phases":1781,"primaryCompletion":489,"start":1782,"conditions":1783,"interventions":1784},"NCT00002517","Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome",[89],"1993-03",[18,1577],[151,152,153,174,1581,157,522],{"nctId":359,"briefTitle":360,"status":361,"phases":1786,"start":213,"enrollment":363,"conditions":1787,"interventions":1788},[88,89],[365,366,352],[41,169,257,174,368],{"nctId":513,"briefTitle":514,"status":361,"phases":1790,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":1791,"interventions":1792},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":1794,"activeCount":99},[],{"trials":1796,"activeCount":99},[],{"intervention":368,"totalTrials":1798,"cells":1799},13,{"EARLY_PHASE1":1800,"PHASE1":1802,"PHASE2":1811,"PHASE3":1902,"PHASE4":1925,"NA":1927},{"trials":1801,"activeCount":99},[],{"trials":1803,"activeCount":99},[1804],{"nctId":1805,"briefTitle":1806,"status":107,"phases":1807,"primaryCompletion":767,"start":1808,"enrollment":22,"conditions":1809,"interventions":1810},"NCT00068757","Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2\u002FNeu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer",[87],"2003-08",[15],[1591,725,368],{"trials":1812,"activeCount":665,"soonestReadout":1843},[1813,1820,1832,1839,1852,1856,1865,1875,1890],{"nctId":1814,"briefTitle":1815,"status":107,"phases":1816,"primaryCompletion":165,"start":1817,"enrollment":19,"conditions":1818,"interventions":1819},"NCT00002972","Paclitaxel in Treating Patients With Lung Cancer",[88],"1997-01",[24],[368],{"nctId":1821,"briefTitle":1822,"status":107,"phases":1823,"primaryCompletion":1824,"completion":1825,"start":490,"enrollment":1826,"conditions":1827,"interventions":1830},"NCT01402271","Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",[87,88],"2019-05-15","2020-07-13",88,[1828,401,1829],"Fallopian Tube Cancer","Primary Peritoneal Cavity Cancer",[289,368,1831],"pazopanib hydrochloride",{"nctId":1833,"briefTitle":1834,"status":107,"phases":1835,"primaryCompletion":507,"start":1836,"conditions":1837,"interventions":1838},"NCT00022620","Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer",[88],"2001-06",[412],[368],{"nctId":1840,"briefTitle":1841,"status":178,"phases":1842,"primaryCompletion":1843,"completion":1843,"start":1844,"enrollment":1845,"conditions":1846,"interventions":1847},"NCT03609047","Adjuvant Palbociclib in Elderly Patients With Breast Cancer",[88],"2026-09-30","2019-06-14",366,[1399,1400],[1848,1849,1850,1851,368],"Palbociclib","Docetaxel \u002F cyclophosphamide","doxorubicin\u002Fcyclophosphamide","epirubicin\u002Fcyclophosphamide",{"nctId":405,"briefTitle":406,"status":107,"phases":1853,"primaryCompletion":408,"start":409,"enrollment":410,"conditions":1854,"interventions":1855},[88],[412],[257,116,368],{"nctId":1857,"briefTitle":1858,"status":107,"phases":1859,"primaryCompletion":1860,"start":1861,"enrollment":1575,"conditions":1862,"interventions":1864},"NCT00014599","Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva",[88],"2005-02","2001-02",[1863],"Vulvar Cancer",[368],{"nctId":1866,"briefTitle":1867,"status":107,"phases":1868,"primaryCompletion":1869,"start":1870,"enrollment":1871,"conditions":1872,"interventions":1873},"NCT00028873","R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy",[88],"2002-06","2001-09",35,[15],[980,1874,368],"laniquidar",{"nctId":1876,"briefTitle":1877,"status":786,"phases":1878,"primaryCompletion":1879,"completion":1880,"start":1881,"enrollment":99,"conditions":1882,"interventions":1886},"NCT03818997","Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer",[88],"2021-04","2022-04","2019-12",[1883,1020,1884,1885],"Esophageal Cancer","GastroEsophageal Cancer","Hepatobiliary Neoplasm",[1887,1888,1889],"DKN-01","Atezolizumab","Paclitaxel",{"nctId":1891,"briefTitle":1892,"status":188,"phases":1893,"primaryCompletion":507,"start":1894,"enrollment":875,"conditions":1895,"interventions":1900},"NCT00025298","Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx",[88],"2001-07",[1896,1897,1898,1899],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Head and Neck Cancer","Oral Complications","Radiation Toxicity",[1901,289,257,368],"amifostine trihydrate",{"trials":1903,"activeCount":99},[1904,1913,1917],{"nctId":1905,"briefTitle":1906,"status":107,"phases":1907,"primaryCompletion":1908,"start":1909,"enrollment":1910,"conditions":1911,"interventions":1912},"NCT00022191","Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer",[89],"2004-06","2001-05",608,[255,286,287],[257,117,368],{"nctId":359,"briefTitle":360,"status":361,"phases":1914,"start":213,"enrollment":363,"conditions":1915,"interventions":1916},[88,89],[365,366,352],[41,169,257,174,368],{"nctId":1918,"briefTitle":1919,"status":107,"phases":1920,"primaryCompletion":815,"start":1921,"enrollment":1922,"conditions":1923,"interventions":1924},"NCT00003589","Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer",[89],"1998-08",450,[24],[257,117,368],{"trials":1926,"activeCount":99},[],{"trials":1928,"activeCount":99},[],{"intervention":173,"totalTrials":192,"cells":1930},{"EARLY_PHASE1":1931,"PHASE1":1933,"PHASE2":1935,"PHASE3":1948,"PHASE4":1954,"NA":1956},{"trials":1932,"activeCount":99},[],{"trials":1934,"activeCount":99},[],{"trials":1936,"activeCount":665,"soonestReadout":73},[1937,1944],{"nctId":1938,"briefTitle":1939,"status":107,"phases":1940,"primaryCompletion":165,"start":1941,"enrollment":1588,"conditions":1942,"interventions":1943},"NCT00002669","Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma",[88],"1995-06",[826],[1647,227,257,173],{"nctId":71,"briefTitle":72,"status":178,"phases":1945,"primaryCompletion":73,"completion":1595,"start":1596,"enrollment":1597,"conditions":1946,"interventions":1947},[88],[1599],[74,1601,1602,1603,1604,1605],{"trials":1949,"activeCount":99},[1950],{"nctId":161,"briefTitle":162,"status":107,"phases":1951,"primaryCompletion":164,"start":165,"enrollment":166,"conditions":1952,"interventions":1953},[89],[21],[41,169,170,171,172,115,173,116,174,94,175,176,118],{"trials":1955,"activeCount":99},[],{"trials":1957,"activeCount":99},[],{"intervention":79,"totalTrials":523,"cells":1959},{"EARLY_PHASE1":1960,"PHASE1":1962,"PHASE2":1964,"PHASE3":1985,"PHASE4":1987,"NA":1989},{"trials":1961,"activeCount":99},[],{"trials":1963,"activeCount":99},[],{"trials":1965,"activeCount":665,"soonestReadout":78},[1966,1976],{"nctId":1967,"briefTitle":1968,"status":188,"phases":1969,"primaryCompletion":1970,"completion":1970,"start":1971,"enrollment":239,"conditions":1972,"interventions":1974},"NCT03437200","Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer",[88],"2022-10-07","2019-01-17",[1973],"Inoperable œsophageal Cancer",[79,1975],"Ipilimumab",{"nctId":76,"briefTitle":77,"status":178,"phases":1977,"primaryCompletion":78,"completion":1978,"start":1979,"enrollment":1980,"conditions":1981,"interventions":1984},[88],"2027-12","2018-04-11",55,[1982,1983],"Thymoma Type B3","Thymic Carcinoma",[79],{"trials":1986,"activeCount":99},[],{"trials":1988,"activeCount":99},[],{"trials":1990,"activeCount":99},[],{"intervention":1848,"totalTrials":523,"cells":1992},{"EARLY_PHASE1":1993,"PHASE1":1995,"PHASE2":1997,"PHASE3":2019,"PHASE4":2021,"NA":2023},{"trials":1994,"activeCount":99},[],{"trials":1996,"activeCount":99},[],{"trials":1998,"activeCount":665,"soonestReadout":1843},[1999,2003],{"nctId":1840,"briefTitle":1841,"status":178,"phases":2000,"primaryCompletion":1843,"completion":1843,"start":1844,"enrollment":1845,"conditions":2001,"interventions":2002},[88],[1399,1400],[1848,1849,1850,1851,368],{"nctId":2004,"briefTitle":2005,"status":361,"phases":2006,"primaryCompletion":2007,"completion":2008,"start":2009,"enrollment":439,"conditions":2010,"interventions":2012},"NCT03088059","Biomarker-based Study in R\u002FM SCCHN",[88],"2025-06","2025-12","2017-11-16",[2011],"Carcinoma, Squamous Cell of Head and Neck",[2013,1848,2014,2015,2016,2017,2018],"Afatinib","standard of care","IPH2201","Durvalumab","Niraparib","INCAGN01876",{"trials":2020,"activeCount":99},[],{"trials":2022,"activeCount":99},[],{"trials":2024,"activeCount":99},[],{"intervention":1849,"totalTrials":665,"cells":2026},{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2031,"PHASE3":2037,"PHASE4":2039,"NA":2041},{"trials":2028,"activeCount":99},[],{"trials":2030,"activeCount":99},[],{"trials":2032,"activeCount":665,"soonestReadout":1843},[2033],{"nctId":1840,"briefTitle":1841,"status":178,"phases":2034,"primaryCompletion":1843,"completion":1843,"start":1844,"enrollment":1845,"conditions":2035,"interventions":2036},[88],[1399,1400],[1848,1849,1850,1851,368],{"trials":2038,"activeCount":99},[],{"trials":2040,"activeCount":99},[],{"trials":2042,"activeCount":99},[],{"intervention":1850,"totalTrials":665,"cells":2044},{"EARLY_PHASE1":2045,"PHASE1":2047,"PHASE2":2049,"PHASE3":2055,"PHASE4":2057,"NA":2059},{"trials":2046,"activeCount":99},[],{"trials":2048,"activeCount":99},[],{"trials":2050,"activeCount":665,"soonestReadout":1843},[2051],{"nctId":1840,"briefTitle":1841,"status":178,"phases":2052,"primaryCompletion":1843,"completion":1843,"start":1844,"enrollment":1845,"conditions":2053,"interventions":2054},[88],[1399,1400],[1848,1849,1850,1851,368],{"trials":2056,"activeCount":99},[],{"trials":2058,"activeCount":99},[],{"trials":2060,"activeCount":99},[],{"intervention":1851,"totalTrials":665,"cells":2062},{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2073,"PHASE4":2075,"NA":2077},{"trials":2064,"activeCount":99},[],{"trials":2066,"activeCount":99},[],{"trials":2068,"activeCount":665,"soonestReadout":1843},[2069],{"nctId":1840,"briefTitle":1841,"status":178,"phases":2070,"primaryCompletion":1843,"completion":1843,"start":1844,"enrollment":1845,"conditions":2071,"interventions":2072},[88],[1399,1400],[1848,1849,1850,1851,368],{"trials":2074,"activeCount":99},[],{"trials":2076,"activeCount":99},[],{"trials":2078,"activeCount":99},[],{"intervention":2080,"totalTrials":665,"cells":2081},"Cemiplimab",{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2086,"PHASE3":2097,"PHASE4":2099,"NA":2101},{"trials":2083,"activeCount":99},[],{"trials":2085,"activeCount":99},[],{"trials":2087,"activeCount":665,"soonestReadout":2092},[2088],{"nctId":2089,"briefTitle":2090,"status":655,"phases":2091,"primaryCompletion":2092,"completion":2092,"start":2093,"enrollment":660,"conditions":2094,"interventions":2096},"NCT06219317","Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC",[88],"2030-01","2025-01-14",[2095],"NSCLC Stage IV",[2080],{"trials":2098,"activeCount":99},[],{"trials":2100,"activeCount":99},[],{"trials":2102,"activeCount":99},[],{"intervention":2104,"totalTrials":665,"cells":2105},"177Lu-PSMA-617",{"EARLY_PHASE1":2106,"PHASE1":2108,"PHASE2":2110,"PHASE3":2123,"PHASE4":2125,"NA":2127},{"trials":2107,"activeCount":99},[],{"trials":2109,"activeCount":99},[],{"trials":2111,"activeCount":665,"soonestReadout":2116},[2112],{"nctId":2113,"briefTitle":2114,"status":671,"phases":2115,"primaryCompletion":2116,"completion":2117,"start":2118,"enrollment":2119,"conditions":2120,"interventions":2122},"NCT06783348","Radiopharmaceutical Treatment of Advanced Kidney Cancer",[88],"2028-01-30","2029-01-01","2025-10-30",48,[2121],"Metastatic Clear Cell Renal Cell Carcinoma",[2104],{"trials":2124,"activeCount":99},[],{"trials":2126,"activeCount":99},[],{"trials":2128,"activeCount":99},[],{"intervention":2130,"totalTrials":665,"cells":2131},"ivonescimab",{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2149,"PHASE4":2151,"NA":2153},{"trials":2133,"activeCount":99},[],{"trials":2135,"activeCount":99},[],{"trials":2137,"activeCount":665,"soonestReadout":2142},[2138],{"nctId":2139,"briefTitle":2140,"status":671,"phases":2141,"primaryCompletion":2142,"completion":2143,"start":2144,"enrollment":2145,"conditions":2146,"interventions":2148},"NCT07234877","A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemotherapy Versus Upfront Ivonescimab Plus Chemotherapy in Patients With Asymptomatic Active Brain Metastases From NSCLC",[88],"2031-01","2031-10","2026-04",158,[2147],"Non Small Cell Lung Cancer",[2130],{"trials":2150,"activeCount":99},[],{"trials":2152,"activeCount":99},[],{"trials":2154,"activeCount":99},[],{"intervention":84,"totalTrials":665,"cells":2156},{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2161,"PHASE3":2173,"PHASE4":2175,"NA":2177},{"trials":2158,"activeCount":99},[],{"trials":2160,"activeCount":99},[],{"trials":2162,"activeCount":665,"soonestReadout":83},[2163],{"nctId":81,"briefTitle":82,"status":178,"phases":2164,"primaryCompletion":83,"completion":2165,"start":2166,"enrollment":2167,"conditions":2168,"interventions":2171},[88],"2027-01","2018-10-30",271,[2169,2170],"Unresectable Stage III Melanoma","Stage IV Melanoma",[84,2172],"Encorafenib + Binimetinib",{"trials":2174,"activeCount":99},[],{"trials":2176,"activeCount":99},[],{"trials":2178,"activeCount":99},[],{"intervention":2172,"totalTrials":665,"cells":2180},{"EARLY_PHASE1":2181,"PHASE1":2183,"PHASE2":2185,"PHASE3":2191,"PHASE4":2193,"NA":2195},{"trials":2182,"activeCount":99},[],{"trials":2184,"activeCount":99},[],{"trials":2186,"activeCount":665,"soonestReadout":83},[2187],{"nctId":81,"briefTitle":82,"status":178,"phases":2188,"primaryCompletion":83,"completion":2165,"start":2166,"enrollment":2167,"conditions":2189,"interventions":2190},[88],[2169,2170],[84,2172],{"trials":2192,"activeCount":99},[],{"trials":2194,"activeCount":99},[],{"trials":2196,"activeCount":99},[],{"intervention":664,"totalTrials":665,"cells":2198},{"EARLY_PHASE1":2199,"PHASE1":2201,"PHASE2":2203,"PHASE3":2209,"PHASE4":2211,"NA":2213},{"trials":2200,"activeCount":99},[],{"trials":2202,"activeCount":99},[],{"trials":2204,"activeCount":665,"soonestReadout":657},[2205],{"nctId":653,"briefTitle":654,"status":655,"phases":2206,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":2207,"interventions":2208},[88],[662],[644,664],{"trials":2210,"activeCount":99},[],{"trials":2212,"activeCount":99},[],{"trials":2214,"activeCount":99},[],{"intervention":2216,"totalTrials":665,"cells":2217},"Nivolumab and Ipilimumab",{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2235,"PHASE4":2237,"NA":2239},{"trials":2219,"activeCount":99},[],{"trials":2221,"activeCount":99},[],{"trials":2223,"activeCount":665,"soonestReadout":2228},[2224],{"nctId":2225,"briefTitle":2226,"status":178,"phases":2227,"primaryCompletion":2228,"completion":2229,"start":2230,"enrollment":2231,"conditions":2232,"interventions":2234},"NCT03443856","Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence",[88],"2023-12-12","2026-06","2019-07-17",197,[2233],"Gastric and Esophagogastric Junction Adenocarcinoma",[2216],{"trials":2236,"activeCount":99},[],{"trials":2238,"activeCount":99},[],{"trials":2240,"activeCount":99},[],{"intervention":2242,"totalTrials":665,"cells":2243},"Mogamulizumab",{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2260,"PHASE4":2262,"NA":2264},{"trials":2245,"activeCount":99},[],{"trials":2247,"activeCount":99},[],{"trials":2249,"activeCount":665,"soonestReadout":2254},[2250],{"nctId":2251,"briefTitle":2252,"status":655,"phases":2253,"primaryCompletion":2254,"completion":2165,"start":2255,"enrollment":2256,"conditions":2257,"interventions":2259},"NCT04128072","Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma",[88],"2026-10","2023-03-07",43,[2258],"Stage IB-IIB Cutaneous T-Cell Lymphoma",[2242,2242],{"trials":2261,"activeCount":99},[],{"trials":2263,"activeCount":99},[],{"trials":2265,"activeCount":99},[],{"intervention":64,"totalTrials":665,"cells":2267},{"EARLY_PHASE1":2268,"PHASE1":2270,"PHASE2":2272,"PHASE3":2282,"PHASE4":2284,"NA":2286},{"trials":2269,"activeCount":99},[],{"trials":2271,"activeCount":99},[],{"trials":2273,"activeCount":665,"soonestReadout":63},[2274],{"nctId":61,"briefTitle":62,"status":178,"phases":2275,"primaryCompletion":63,"completion":2276,"start":2277,"enrollment":2278,"conditions":2279,"interventions":2280},[88],"2036-12","2017-12-01",61,[34],[64,2281],"ADT",{"trials":2283,"activeCount":99},[],{"trials":2285,"activeCount":99},[],{"trials":2287,"activeCount":99},[],{"intervention":2281,"totalTrials":665,"cells":2289},{"EARLY_PHASE1":2290,"PHASE1":2292,"PHASE2":2294,"PHASE3":2300,"PHASE4":2302,"NA":2304},{"trials":2291,"activeCount":99},[],{"trials":2293,"activeCount":99},[],{"trials":2295,"activeCount":665,"soonestReadout":63},[2296],{"nctId":61,"briefTitle":62,"status":178,"phases":2297,"primaryCompletion":63,"completion":2276,"start":2277,"enrollment":2278,"conditions":2298,"interventions":2299},[88],[34],[64,2281],{"trials":2301,"activeCount":99},[],{"trials":2303,"activeCount":99},[],{"trials":2305,"activeCount":99},[],{"intervention":2307,"totalTrials":665,"cells":2308},"Lorlatinib",{"EARLY_PHASE1":2309,"PHASE1":2311,"PHASE2":2313,"PHASE3":2325,"PHASE4":2327,"NA":2329},{"trials":2310,"activeCount":99},[],{"trials":2312,"activeCount":99},[],{"trials":2314,"activeCount":665,"soonestReadout":2319},[2315],{"nctId":2316,"briefTitle":2317,"status":178,"phases":2318,"primaryCompletion":2319,"completion":2320,"start":2321,"enrollment":2322,"conditions":2323,"interventions":2324},"NCT04127110","Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients",[88],"2024-07-31","2024-11","2020-11-17",68,[2147],[2307],{"trials":2326,"activeCount":99},[],{"trials":2328,"activeCount":99},[],{"trials":2330,"activeCount":99},[],{"intervention":74,"totalTrials":665,"cells":2332},{"EARLY_PHASE1":2333,"PHASE1":2335,"PHASE2":2337,"PHASE3":2343,"PHASE4":2345,"NA":2347},{"trials":2334,"activeCount":99},[],{"trials":2336,"activeCount":99},[],{"trials":2338,"activeCount":665,"soonestReadout":73},[2339],{"nctId":71,"briefTitle":72,"status":178,"phases":2340,"primaryCompletion":73,"completion":1595,"start":1596,"enrollment":1597,"conditions":2341,"interventions":2342},[88],[1599],[74,1601,1602,1603,1604,1605],{"trials":2344,"activeCount":99},[],{"trials":2346,"activeCount":99},[],{"trials":2348,"activeCount":99},[],{"intervention":1601,"totalTrials":665,"cells":2350},{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2361,"PHASE4":2363,"NA":2365},{"trials":2352,"activeCount":99},[],{"trials":2354,"activeCount":99},[],{"trials":2356,"activeCount":665,"soonestReadout":73},[2357],{"nctId":71,"briefTitle":72,"status":178,"phases":2358,"primaryCompletion":73,"completion":1595,"start":1596,"enrollment":1597,"conditions":2359,"interventions":2360},[88],[1599],[74,1601,1602,1603,1604,1605],{"trials":2362,"activeCount":99},[],{"trials":2364,"activeCount":99},[],{"trials":2366,"activeCount":99},[],{"intervention":1602,"totalTrials":665,"cells":2368},{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2379,"PHASE4":2381,"NA":2383},{"trials":2370,"activeCount":99},[],{"trials":2372,"activeCount":99},[],{"trials":2374,"activeCount":665,"soonestReadout":73},[2375],{"nctId":71,"briefTitle":72,"status":178,"phases":2376,"primaryCompletion":73,"completion":1595,"start":1596,"enrollment":1597,"conditions":2377,"interventions":2378},[88],[1599],[74,1601,1602,1603,1604,1605],{"trials":2380,"activeCount":99},[],{"trials":2382,"activeCount":99},[],{"trials":2384,"activeCount":99},[],{"intervention":2386,"totalTrials":665,"cells":2387},"Bemarituzumab",{"EARLY_PHASE1":2388,"PHASE1":2390,"PHASE2":2403,"PHASE3":2405,"PHASE4":2407,"NA":2409},{"trials":2389,"activeCount":99},[],{"trials":2391,"activeCount":665,"soonestReadout":2396},[2392],{"nctId":2393,"briefTitle":2394,"status":671,"phases":2395,"primaryCompletion":2396,"completion":2397,"start":2398,"enrollment":2399,"conditions":2400,"interventions":2401},"NCT06978062","Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment",[87],"2028-09-11","2029-09-28","2026-02-20",27,[1884],[2386,2402],"FLOT",{"trials":2404,"activeCount":99},[],{"trials":2406,"activeCount":99},[],{"trials":2408,"activeCount":99},[],{"trials":2410,"activeCount":99},[],{"intervention":2402,"totalTrials":665,"cells":2412},{"EARLY_PHASE1":2413,"PHASE1":2415,"PHASE2":2421,"PHASE3":2423,"PHASE4":2425,"NA":2427},{"trials":2414,"activeCount":99},[],{"trials":2416,"activeCount":665,"soonestReadout":2396},[2417],{"nctId":2393,"briefTitle":2394,"status":671,"phases":2418,"primaryCompletion":2396,"completion":2397,"start":2398,"enrollment":2399,"conditions":2419,"interventions":2420},[87],[1884],[2386,2402],{"trials":2422,"activeCount":99},[],{"trials":2424,"activeCount":99},[],{"trials":2426,"activeCount":99},[],{"trials":2428,"activeCount":99},[],{"intervention":59,"totalTrials":665,"cells":2430},{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2437,"PHASE4":2439,"NA":2441},{"trials":2432,"activeCount":99},[],{"trials":2434,"activeCount":99},[],{"trials":2436,"activeCount":99},[],{"trials":2438,"activeCount":99},[],{"trials":2440,"activeCount":99},[],{"trials":2442,"activeCount":665,"soonestReadout":58},[2443],{"nctId":56,"briefTitle":57,"status":655,"phases":2444,"primaryCompletion":58,"completion":2143,"start":2445,"enrollment":2446,"conditions":2447,"interventions":2449},[],"2017-05-03",4975,[2448],"All Tumor Types",[59,2450,2451,2452,2453],"RP-1759 AYA\u002FTYA","RP-1843 Arcagen","RP-1920 BioRadon","2148 MRD",{"intervention":2450,"totalTrials":665,"cells":2455},{"EARLY_PHASE1":2456,"PHASE1":2458,"PHASE2":2460,"PHASE3":2462,"PHASE4":2464,"NA":2466},{"trials":2457,"activeCount":99},[],{"trials":2459,"activeCount":99},[],{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":99},[],{"trials":2465,"activeCount":99},[],{"trials":2467,"activeCount":665,"soonestReadout":58},[2468],{"nctId":56,"briefTitle":57,"status":655,"phases":2469,"primaryCompletion":58,"completion":2143,"start":2445,"enrollment":2446,"conditions":2470,"interventions":2471},[],[2448],[59,2450,2451,2452,2453],{"intervention":2451,"totalTrials":665,"cells":2473},{"EARLY_PHASE1":2474,"PHASE1":2476,"PHASE2":2478,"PHASE3":2480,"PHASE4":2482,"NA":2484},{"trials":2475,"activeCount":99},[],{"trials":2477,"activeCount":99},[],{"trials":2479,"activeCount":99},[],{"trials":2481,"activeCount":99},[],{"trials":2483,"activeCount":99},[],{"trials":2485,"activeCount":665,"soonestReadout":58},[2486],{"nctId":56,"briefTitle":57,"status":655,"phases":2487,"primaryCompletion":58,"completion":2143,"start":2445,"enrollment":2446,"conditions":2488,"interventions":2489},[],[2448],[59,2450,2451,2452,2453],{"intervention":2452,"totalTrials":665,"cells":2491},{"EARLY_PHASE1":2492,"PHASE1":2494,"PHASE2":2496,"PHASE3":2498,"PHASE4":2500,"NA":2502},{"trials":2493,"activeCount":99},[],{"trials":2495,"activeCount":99},[],{"trials":2497,"activeCount":99},[],{"trials":2499,"activeCount":99},[],{"trials":2501,"activeCount":99},[],{"trials":2503,"activeCount":665,"soonestReadout":58},[2504],{"nctId":56,"briefTitle":57,"status":655,"phases":2505,"primaryCompletion":58,"completion":2143,"start":2445,"enrollment":2446,"conditions":2506,"interventions":2507},[],[2448],[59,2450,2451,2452,2453],{"intervention":2453,"totalTrials":665,"cells":2509},{"EARLY_PHASE1":2510,"PHASE1":2512,"PHASE2":2514,"PHASE3":2516,"PHASE4":2518,"NA":2520},{"trials":2511,"activeCount":99},[],{"trials":2513,"activeCount":99},[],{"trials":2515,"activeCount":99},[],{"trials":2517,"activeCount":99},[],{"trials":2519,"activeCount":99},[],{"trials":2521,"activeCount":665,"soonestReadout":58},[2522],{"nctId":56,"briefTitle":57,"status":655,"phases":2523,"primaryCompletion":58,"completion":2143,"start":2445,"enrollment":2446,"conditions":2524,"interventions":2525},[],[2448],[59,2450,2451,2452,2453],{"intervention":257,"totalTrials":2527,"cells":2528},45,{"EARLY_PHASE1":2529,"PHASE1":2531,"PHASE2":2540,"PHASE3":2699,"PHASE4":2851,"NA":2853},{"trials":2530,"activeCount":99},[],{"trials":2532,"activeCount":99},[2533],{"nctId":2534,"briefTitle":2535,"status":107,"phases":2536,"primaryCompletion":479,"completion":2537,"start":767,"enrollment":1554,"conditions":2538,"interventions":2539},"NCT00623064","Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer",[87],"2012-08",[255,286],[257,117,968],{"trials":2541,"activeCount":99},[2542,2546,2559,2570,2581,2587,2596,2605,2609,2613,2617,2626,2636,2640,2644,2648,2654,2658,2674,2683,2687,2695],{"nctId":884,"briefTitle":885,"status":188,"phases":2543,"primaryCompletion":887,"completion":888,"start":889,"enrollment":30,"conditions":2544,"interventions":2545},[88],[891],[893,794,874,894],{"nctId":2547,"briefTitle":2548,"status":188,"phases":2549,"primaryCompletion":489,"completion":2550,"start":2551,"enrollment":2552,"conditions":2553,"interventions":2554},"NCT00646659","Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery",[88],"2011-04","2008-02",47,[1897],[2555,289,257,980,270,2556,2557,2558],"cetuximab","fluorescence in situ hybridization","molecular genetic technique","reverse transcriptase-polymerase chain reaction",{"nctId":2560,"briefTitle":2561,"status":107,"phases":2562,"primaryCompletion":2563,"completion":2564,"start":1057,"enrollment":2565,"conditions":2566,"interventions":2568},"NCT00458913","Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma",[88],"2010-04","2012-03",82,[2567],"Malignant Mesothelioma",[2569,257],"bortezomib",{"nctId":2571,"briefTitle":2572,"status":107,"phases":2573,"primaryCompletion":699,"completion":2574,"start":2575,"enrollment":320,"conditions":2576,"interventions":2577},"NCT00498953","Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx",[87,88],"2009-03","2007-05",[1897],[289,257,980,270,968,2578,2556,2579,2580,2558],"cytogenetic analysis","in situ hybridization","polymerase chain reaction",{"nctId":2582,"briefTitle":2583,"status":107,"phases":2584,"primaryCompletion":165,"start":738,"enrollment":2552,"conditions":2585,"interventions":2586},"NCT00005868","Docetaxel and Cisplatin in Treating Patients With Untreated Stage IIIA Non-small Cell Lung Cancer",[88],[24],[257,980],{"nctId":2588,"briefTitle":2589,"status":107,"phases":2590,"primaryCompletion":2591,"start":2592,"enrollment":2593,"conditions":2594,"interventions":2595},"NCT00002722","High-Dose Chemotherapy in Treating Patients With Advanced Stomach Cancer",[88],"1999-08","1996-01",135,[966],[257,270,154],{"nctId":2597,"briefTitle":2598,"status":107,"phases":2599,"primaryCompletion":2600,"start":2601,"conditions":2602,"interventions":2603},"NCT00103051","Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer",[88],"2005-11","2004-12",[24],[257,2604,117],"gefitinib",{"nctId":248,"briefTitle":249,"status":188,"phases":2606,"primaryCompletion":251,"start":252,"enrollment":253,"conditions":2607,"interventions":2608},[88],[255],[169,257,116,156,176],{"nctId":1698,"briefTitle":1699,"status":188,"phases":2610,"primaryCompletion":1701,"start":283,"enrollment":192,"conditions":2611,"interventions":2612},[88],[32],[257,174],{"nctId":1705,"briefTitle":1706,"status":188,"phases":2614,"primaryCompletion":507,"start":824,"enrollment":875,"conditions":2615,"interventions":2616},[88],[24],[257,174],{"nctId":2618,"briefTitle":2619,"status":188,"phases":2620,"primaryCompletion":2621,"start":2622,"enrollment":1798,"conditions":2623,"interventions":2624},"NCT00389688","Pemetrexed Disodium and Cisplatin Before or After Surgery in Treating Patients With Stage IB or Stage II Non-Small Cell Lung Cancer That Can be Removed by Surgery",[88],"2008-07","2006-08",[24],[257,2625],"pemetrexed disodium",{"nctId":2627,"briefTitle":2628,"status":107,"phases":2629,"primaryCompletion":2630,"start":2631,"conditions":2632,"interventions":2634},"NCT00066391","Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer",[88],"2006-01","2003-06",[2633],"Penile Cancer",[257,2635],"irinotecan hydrochloride",{"nctId":405,"briefTitle":406,"status":107,"phases":2637,"primaryCompletion":408,"start":409,"enrollment":410,"conditions":2638,"interventions":2639},[88],[412],[257,116,368],{"nctId":784,"briefTitle":785,"status":786,"phases":2641,"primaryCompletion":788,"completion":789,"start":790,"enrollment":99,"conditions":2642,"interventions":2643},[88],[792],[794,795,796,797,716],{"nctId":1012,"briefTitle":1013,"status":107,"phases":2645,"primaryCompletion":1015,"completion":1016,"start":1017,"enrollment":1018,"conditions":2646,"interventions":2647},[88],[1020,351,1021,1022],[991,794,795],{"nctId":2649,"briefTitle":2650,"status":188,"phases":2651,"primaryCompletion":1894,"start":213,"enrollment":2256,"conditions":2652,"interventions":2653},"NCT00003642","Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer",[88],[255],[257,270],{"nctId":959,"briefTitle":960,"status":188,"phases":2655,"primaryCompletion":863,"completion":962,"start":963,"enrollment":740,"conditions":2656,"interventions":2657},[88],[965,966],[955,257,217,270,968],{"nctId":2659,"briefTitle":2660,"status":107,"phases":2661,"primaryCompletion":2662,"completion":2663,"start":2664,"enrollment":2665,"conditions":2666,"interventions":2670},"NCT02205047","Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma",[88],"2022-12-22","2024-12-31","2015-07-15",172,[2667,2668,2669],"Malignant Neoplasm of Stomach","Malignant Neoplasm of Cardio-esophageal Junction of Stomach","Epidermal Growth Factor Receptor (EGFR) Protein Overexpression",[794,2671,2672,2673],"5-fluorouracil or Capecitabine","Trastuzumab","Pertuzumab",{"nctId":2675,"briefTitle":2676,"status":107,"phases":2677,"primaryCompletion":976,"start":2678,"enrollment":2679,"conditions":2680,"interventions":2682},"NCT00004884","Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer",[88],"1999-07",96,[2681],"Pancreatic Cancer",[257,980,117],{"nctId":1938,"briefTitle":1939,"status":107,"phases":2684,"primaryCompletion":165,"start":1941,"enrollment":1588,"conditions":2685,"interventions":2686},[88],[826],[1647,227,257,173],{"nctId":2688,"briefTitle":2689,"status":107,"phases":2690,"primaryCompletion":2691,"start":865,"enrollment":2692,"conditions":2693,"interventions":2694},"NCT00227630","Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma",[88],"2007-08",59,[2567],[257,2625],{"nctId":1891,"briefTitle":1892,"status":188,"phases":2696,"primaryCompletion":507,"start":1894,"enrollment":875,"conditions":2697,"interventions":2698},[88],[1896,1897,1898,1899],[1901,289,257,368],{"trials":2700,"activeCount":99},[2701,2709,2721,2728,2732,2736,2744,2752,2760,2768,2772,2781,2789,2797,2805,2809,2818,2822,2826,2830,2837,2844],{"nctId":2702,"briefTitle":2703,"status":188,"phases":2704,"primaryCompletion":2705,"start":2678,"enrollment":2706,"conditions":2707,"interventions":2708},"NCT00004099","Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer",[89],"2004-02",144,[966],[257,270,154],{"nctId":2710,"briefTitle":2711,"status":361,"phases":2712,"primaryCompletion":2713,"completion":2714,"start":2715,"enrollment":2716,"conditions":2717,"interventions":2719},"NCT01880359","AF CRT +\u002F- Nimorazole in HNSCC",[89],"2019-09-06","2023-01-09","2014-07-25",640,[2718],"Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers",[794,2720],"Nimorazole",{"nctId":2722,"briefTitle":2723,"status":107,"phases":2724,"primaryCompletion":1701,"start":2725,"enrollment":2716,"conditions":2726,"interventions":2727},"NCT00002623","Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer",[89],"1994-12",[24],[289,257],{"nctId":261,"briefTitle":262,"status":107,"phases":2729,"primaryCompletion":264,"start":265,"enrollment":266,"conditions":2730,"interventions":2731},[89],[268],[41,257,270,271,156,272,176,273],{"nctId":1905,"briefTitle":1906,"status":107,"phases":2733,"primaryCompletion":1908,"start":1909,"enrollment":1910,"conditions":2734,"interventions":2735},[89],[255,286,287],[257,117,368],{"nctId":2737,"briefTitle":2738,"status":188,"phases":2739,"primaryCompletion":507,"start":2740,"enrollment":2741,"conditions":2742,"interventions":2743},"NCT00006356","Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer",[89],"2000-08",38,[401],[289,257],{"nctId":2745,"briefTitle":2746,"status":107,"phases":2747,"primaryCompletion":49,"start":2748,"enrollment":2749,"conditions":2750,"interventions":2751},"NCT00002839","Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx",[89],"1996-07",564,[1897],[257,270],{"nctId":2753,"briefTitle":2754,"status":361,"phases":2755,"primaryCompletion":2756,"start":124,"enrollment":2757,"conditions":2758,"interventions":2759},"NCT00039338","Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer",[89],"2019-07",686,[268],[257],{"nctId":2761,"briefTitle":2762,"status":107,"phases":2763,"primaryCompletion":124,"completion":2764,"start":347,"enrollment":2765,"conditions":2766,"interventions":2767},"NCT00003888","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer",[89],"2015-03",359,[1897],[257,980,270],{"nctId":343,"briefTitle":344,"status":107,"phases":2769,"primaryCompletion":346,"start":347,"enrollment":348,"conditions":2770,"interventions":2771},[89],[350,351,352],[41,169,257,174,271],{"nctId":2773,"briefTitle":2774,"status":107,"phases":2775,"primaryCompletion":2776,"start":2777,"enrollment":2778,"conditions":2779,"interventions":2780},"NCT00002555","High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer",[89],"2000-10","1994-02",338,[1897],[257],{"nctId":2782,"briefTitle":2783,"status":188,"phases":2784,"primaryCompletion":767,"start":2785,"enrollment":1826,"conditions":2786,"interventions":2788},"NCT00068744","Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer",[88,89],"2003-07",[2787],"Anal Cancer",[257,270,272],{"nctId":2790,"briefTitle":2791,"status":107,"phases":2792,"primaryCompletion":2793,"start":252,"enrollment":2794,"conditions":2795,"interventions":2796},"NCT00003636","Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer",[89],"2009-01",704,[1828,401,1829],[289,257],{"nctId":2798,"briefTitle":2799,"status":786,"phases":2800,"primaryCompletion":788,"completion":1978,"start":2801,"enrollment":99,"conditions":2802,"interventions":2804},"NCT03673735","Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC",[89],"2021-06",[2803],"Squamous Cell Head and Neck Carcinoma",[2016,794],{"nctId":299,"briefTitle":300,"status":107,"phases":2806,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":2807,"interventions":2808},[89],[307,308,309],[116,117,176,156,257,169],{"nctId":2810,"briefTitle":2811,"status":107,"phases":2812,"primaryCompletion":2813,"start":222,"enrollment":2814,"conditions":2815,"interventions":2816},"NCT00004920","Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura",[89],"2003-01",256,[2567],[257,2817],"raltitrexed",{"nctId":359,"briefTitle":360,"status":361,"phases":2819,"start":213,"enrollment":363,"conditions":2820,"interventions":2821},[88,89],[365,366,352],[41,169,257,174,368],{"nctId":1918,"briefTitle":1919,"status":107,"phases":2823,"primaryCompletion":815,"start":1921,"enrollment":1922,"conditions":2824,"interventions":2825},[89],[24],[257,117,368],{"nctId":504,"briefTitle":505,"status":107,"phases":2827,"primaryCompletion":507,"start":508,"enrollment":509,"conditions":2828,"interventions":2829},[89],[32],[169,257,116],{"nctId":2831,"briefTitle":2832,"status":107,"phases":2833,"primaryCompletion":2785,"start":2834,"enrollment":1033,"conditions":2835,"interventions":2836},"NCT00003029","Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas",[89],"1997-05",[2681],[257,270],{"nctId":2838,"briefTitle":2839,"status":786,"phases":2840,"enrollment":99,"conditions":2841,"interventions":2842},"NCT01142414","Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence",[89],[1897],[2843,257,270],"panitumumab",{"nctId":2845,"briefTitle":2846,"status":188,"phases":2847,"primaryCompletion":191,"start":2848,"enrollment":2145,"conditions":2849,"interventions":2850},"NCT00003803","Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed",[89],"1999-02",[24],[257,117],{"trials":2852,"activeCount":99},[],{"trials":2854,"activeCount":99},[],{"intervention":151,"totalTrials":2856,"cells":2857},16,{"EARLY_PHASE1":2858,"PHASE1":2860,"PHASE2":2862,"PHASE3":2901,"PHASE4":2949,"NA":2951},{"trials":2859,"activeCount":99},[],{"trials":2861,"activeCount":99},[],{"trials":2863,"activeCount":99},[2864,2871,2878,2882,2886,2895],{"nctId":2865,"briefTitle":2866,"status":361,"phases":2867,"start":517,"enrollment":2868,"conditions":2869,"interventions":2870},"NCT00003758","Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia",[88],60,[18],[151,1581],{"nctId":2872,"briefTitle":2873,"status":188,"phases":2874,"primaryCompletion":2875,"start":517,"enrollment":1798,"conditions":2876,"interventions":2877},"NCT00003729","Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia",[88],"2002-04",[18],[151,1676,1581],{"nctId":1711,"briefTitle":1712,"status":107,"phases":2879,"primaryCompletion":759,"start":1714,"enrollment":1715,"conditions":2880,"interventions":2881},[88],[18],[151,174,1580,1581,157],{"nctId":1571,"briefTitle":1572,"status":107,"phases":2883,"primaryCompletion":975,"start":1574,"enrollment":1575,"conditions":2884,"interventions":2885},[88],[18,1577],[1579,115,151,1580,1581],{"nctId":2887,"briefTitle":2888,"status":361,"phases":2889,"primaryCompletion":2890,"start":699,"enrollment":2891,"conditions":2892,"interventions":2893},"NCT00838240","Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia",[87,88],"2012-12",114,[18,1577],[2894,151,1581],"clofarabine",{"nctId":2896,"briefTitle":2897,"status":107,"phases":2898,"primaryCompletion":124,"start":438,"enrollment":1018,"conditions":2899,"interventions":2900},"NCT00003061","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma",[88],[21],[151,156],{"trials":2902,"activeCount":99},[2903,2907,2911,2915,2919,2923,2927,2931,2935,2945],{"nctId":142,"briefTitle":143,"status":107,"phases":2904,"primaryCompletion":145,"start":146,"enrollment":147,"conditions":2905,"interventions":2906},[89],[18,21],[150,115,151,152,153,116,154,155,156,157,158,94,159,118],{"nctId":1621,"briefTitle":1622,"status":361,"phases":2908,"start":1624,"enrollment":1625,"conditions":2909,"interventions":2910},[89],[18],[1579,115,151,174,1581,155,156,157,522,1628],{"nctId":1639,"briefTitle":1640,"status":361,"phases":2912,"primaryCompletion":1642,"start":1643,"enrollment":1644,"conditions":2913,"interventions":2914},[89],[18],[1647,169,1579,115,151,152,174],{"nctId":1657,"briefTitle":1658,"status":361,"phases":2916,"start":1660,"enrollment":1661,"conditions":2917,"interventions":2918},[89],[18],[169,1579,115,151,152,174,1581,1664,157],{"nctId":1745,"briefTitle":1746,"status":361,"phases":2920,"start":1748,"enrollment":1749,"conditions":2921,"interventions":2922},[89],[18,1577],[151,174,1581],{"nctId":1761,"briefTitle":1762,"status":107,"phases":2924,"primaryCompletion":1642,"completion":1764,"start":409,"enrollment":1765,"conditions":2925,"interventions":2926},[89],[18],[151,174,1580,1581,157],{"nctId":1769,"briefTitle":1770,"status":107,"phases":2928,"primaryCompletion":428,"start":1772,"enrollment":1773,"conditions":2929,"interventions":2930},[89],[18,1775],[169,1777,807,151,174,1581,157],{"nctId":1779,"briefTitle":1780,"status":107,"phases":2932,"primaryCompletion":489,"start":1782,"conditions":2933,"interventions":2934},[89],[18,1577],[151,152,153,174,1581,157,522],{"nctId":2936,"briefTitle":2937,"status":107,"phases":2938,"primaryCompletion":2939,"start":2940,"enrollment":2941,"conditions":2942,"interventions":2943},"NCT01324063","A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)",[89],"1994-06","1986-11",160,[18],[2944,1777,151,152],"sargramostim",{"nctId":513,"briefTitle":514,"status":361,"phases":2946,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":2947,"interventions":2948},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":2950,"activeCount":99},[],{"trials":2952,"activeCount":99},[],{"intervention":154,"totalTrials":203,"cells":2954},{"EARLY_PHASE1":2955,"PHASE1":2957,"PHASE2":2968,"PHASE3":2997,"PHASE4":3057,"NA":3059},{"trials":2956,"activeCount":99},[],{"trials":2958,"activeCount":99},[2959],{"nctId":2960,"briefTitle":2961,"status":107,"phases":2962,"primaryCompletion":2963,"start":2964,"enrollment":2856,"conditions":2965,"interventions":2966},"NCT00098982","Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer",[87],"2007-01","2004-09",[29],[2569,270,154,2967],"oxaliplatin",{"trials":2969,"activeCount":99},[2970,2979,2986,2990],{"nctId":2971,"briefTitle":2972,"status":188,"phases":2973,"primaryCompletion":346,"start":2974,"enrollment":2975,"conditions":2976,"interventions":2977},"NCT00043004","Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer",[88],"2002-05",119,[29,351],[935,2978,270,154,2967],"FOLFOX regimen",{"nctId":2980,"briefTitle":2981,"status":361,"phases":2982,"start":2963,"enrollment":2983,"conditions":2984,"interventions":2985},"NCT00438737","Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer",[88],100,[29,351],[935,2555,270,154,2967],{"nctId":2588,"briefTitle":2589,"status":107,"phases":2987,"primaryCompletion":2591,"start":2592,"enrollment":2593,"conditions":2988,"interventions":2989},[88],[966],[257,270,154],{"nctId":2991,"briefTitle":2992,"status":107,"phases":2993,"primaryCompletion":2994,"start":1587,"conditions":2995,"interventions":2996},"NCT00039208","Combination Chemotherapy in Treating Patients With Colorectal Cancer",[88],"2005-08",[29],[270,2635,154,2967],{"trials":2998,"activeCount":99},[2999,3003,3007,3015,3024,3031,3039,3047,3053],{"nctId":2702,"briefTitle":2703,"status":188,"phases":3000,"primaryCompletion":2705,"start":2678,"enrollment":2706,"conditions":3001,"interventions":3002},[89],[966],[257,270,154],{"nctId":142,"briefTitle":143,"status":107,"phases":3004,"primaryCompletion":145,"start":146,"enrollment":147,"conditions":3005,"interventions":3006},[89],[18,21],[150,115,151,152,153,116,154,155,156,157,158,94,159,118],{"nctId":3008,"briefTitle":3009,"status":107,"phases":3010,"primaryCompletion":1894,"start":2678,"enrollment":3011,"conditions":3012,"interventions":3013},"NCT00004885","Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer",[89],430,[29],[3014,270,2635,154],"FOLFIRI regimen",{"nctId":3016,"briefTitle":3017,"status":107,"phases":3018,"primaryCompletion":191,"completion":3019,"start":3020,"enrollment":3021,"conditions":3022,"interventions":3023},"NCT00002523","Radiation Therapy, Surgery, and Chemotherapy in Treating Patients With Rectal Cancer That Can Be Surgically Removed",[89],"2016-01","1993-04",1011,[29],[270,154],{"nctId":3025,"briefTitle":3026,"status":361,"phases":3027,"start":3028,"conditions":3029,"interventions":3030},"NCT00006479","Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer",[89],"2000-09",[29,351],[2978,270,154,2967],{"nctId":3032,"briefTitle":3033,"status":107,"phases":3034,"primaryCompletion":123,"start":823,"enrollment":3035,"conditions":3036,"interventions":3037},"NCT00064181","Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer",[89],86,[29],[3014,955,3038,270,2635,154],"celecoxib",{"nctId":3040,"briefTitle":3041,"status":107,"phases":3042,"primaryCompletion":124,"start":3043,"enrollment":3044,"conditions":3045,"interventions":3046},"NCT00003287","Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer",[89],"1998-03",554,[29],[2978,270,154,2967],{"nctId":3048,"briefTitle":3049,"status":107,"phases":3050,"primaryCompletion":2600,"start":145,"conditions":3051,"interventions":3052},"NCT00085163","Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon",[89],[29],[3038,270,154],{"nctId":513,"briefTitle":514,"status":361,"phases":3054,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":3055,"interventions":3056},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":3058,"activeCount":99},[],{"trials":3060,"activeCount":99},[],{"intervention":169,"totalTrials":1798,"cells":3062},{"EARLY_PHASE1":3063,"PHASE1":3065,"PHASE2":3067,"PHASE3":3073,"PHASE4":3123,"NA":3125},{"trials":3064,"activeCount":99},[],{"trials":3066,"activeCount":99},[],{"trials":3068,"activeCount":99},[3069],{"nctId":248,"briefTitle":249,"status":188,"phases":3070,"primaryCompletion":251,"start":252,"enrollment":253,"conditions":3071,"interventions":3072},[88],[255],[169,257,116,156,176],{"trials":3074,"activeCount":99},[3075,3079,3083,3087,3091,3095,3099,3103,3107,3111,3115,3119],{"nctId":1639,"briefTitle":1640,"status":361,"phases":3076,"primaryCompletion":1642,"start":1643,"enrollment":1644,"conditions":3077,"interventions":3078},[89],[18],[1647,169,1579,115,151,152,174],{"nctId":972,"briefTitle":973,"status":107,"phases":3080,"primaryCompletion":975,"start":976,"enrollment":977,"conditions":3081,"interventions":3082},[89],[15],[169,115,980,217,270,981],{"nctId":161,"briefTitle":162,"status":107,"phases":3084,"primaryCompletion":164,"start":165,"enrollment":166,"conditions":3085,"interventions":3086},[89],[21],[41,169,170,171,172,115,173,116,174,94,175,176,118],{"nctId":1657,"briefTitle":1658,"status":361,"phases":3088,"start":1660,"enrollment":1661,"conditions":3089,"interventions":3090},[89],[18],[169,1579,115,151,152,174,1581,1664,157],{"nctId":447,"briefTitle":448,"status":107,"phases":3092,"primaryCompletion":251,"start":450,"enrollment":439,"conditions":3093,"interventions":3094},[89],[412,452,351,401,453,32],[169,116,271],{"nctId":343,"briefTitle":344,"status":107,"phases":3096,"primaryCompletion":346,"start":347,"enrollment":348,"conditions":3097,"interventions":3098},[89],[350,351,352],[41,169,257,174,271],{"nctId":1769,"briefTitle":1770,"status":107,"phases":3100,"primaryCompletion":428,"start":1772,"enrollment":1773,"conditions":3101,"interventions":3102},[89],[18,1775],[169,1777,807,151,174,1581,157],{"nctId":475,"briefTitle":476,"status":107,"phases":3104,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":3105,"interventions":3106},[89],[412,452,401,453,32],[169,116,271,484],{"nctId":299,"briefTitle":300,"status":107,"phases":3108,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":3109,"interventions":3110},[89],[307,308,309],[116,117,176,156,257,169],{"nctId":219,"briefTitle":220,"status":188,"phases":3112,"primaryCompletion":222,"start":223,"enrollment":224,"conditions":3113,"interventions":3114},[89],[21],[169,227,115,94,118],{"nctId":359,"briefTitle":360,"status":361,"phases":3116,"start":213,"enrollment":363,"conditions":3117,"interventions":3118},[88,89],[365,366,352],[41,169,257,174,368],{"nctId":504,"briefTitle":505,"status":107,"phases":3120,"primaryCompletion":507,"start":508,"enrollment":509,"conditions":3121,"interventions":3122},[89],[32],[169,257,116],{"trials":3124,"activeCount":99},[],{"trials":3126,"activeCount":99},[],{"intervention":117,"totalTrials":3128,"cells":3129},12,{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3138,"PHASE3":3167,"PHASE4":3196,"NA":3198},{"trials":3131,"activeCount":99},[],{"trials":3133,"activeCount":99},[3134],{"nctId":2534,"briefTitle":2535,"status":107,"phases":3135,"primaryCompletion":479,"completion":2537,"start":767,"enrollment":1554,"conditions":3136,"interventions":3137},[87],[255,286],[257,117,968],{"trials":3139,"activeCount":99},[3140,3144,3148,3152,3159],{"nctId":2597,"briefTitle":2598,"status":107,"phases":3141,"primaryCompletion":2600,"start":2601,"conditions":3142,"interventions":3143},[88],[24],[257,2604,117],{"nctId":105,"briefTitle":106,"status":107,"phases":3145,"primaryCompletion":109,"start":110,"enrollment":19,"conditions":3146,"interventions":3147},[88],[21,112],[114,115,116,117,94,118],{"nctId":2675,"briefTitle":2676,"status":107,"phases":3149,"primaryCompletion":976,"start":2678,"enrollment":2679,"conditions":3150,"interventions":3151},[88],[2681],[257,980,117],{"nctId":3153,"briefTitle":3154,"status":107,"phases":3155,"primaryCompletion":491,"start":1861,"enrollment":3156,"conditions":3157,"interventions":3158},"NCT00017498","Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck",[88],21,[1897],[117],{"nctId":3160,"briefTitle":3161,"status":107,"phases":3162,"primaryCompletion":3163,"start":1714,"enrollment":3164,"conditions":3165,"interventions":3166},"NCT00006351","SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract",[88],"2001-12",34,[255,286,287],[117,725],{"trials":3168,"activeCount":99},[3169,3176,3180,3184,3188,3192],{"nctId":3170,"briefTitle":3171,"status":107,"phases":3172,"primaryCompletion":2963,"start":823,"enrollment":3173,"conditions":3174,"interventions":3175},"NCT00064207","Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer",[88,89],97,[2681],[117],{"nctId":1905,"briefTitle":1906,"status":107,"phases":3177,"primaryCompletion":1908,"start":1909,"enrollment":1910,"conditions":3178,"interventions":3179},[89],[255,286,287],[257,117,368],{"nctId":279,"briefTitle":280,"status":107,"phases":3181,"primaryCompletion":282,"start":283,"enrollment":284,"conditions":3182,"interventions":3183},[88,89],[255,286,287],[289,117,156,176],{"nctId":299,"briefTitle":300,"status":107,"phases":3185,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":3186,"interventions":3187},[89],[307,308,309],[116,117,176,156,257,169],{"nctId":1918,"briefTitle":1919,"status":107,"phases":3189,"primaryCompletion":815,"start":1921,"enrollment":1922,"conditions":3190,"interventions":3191},[89],[24],[257,117,368],{"nctId":2845,"briefTitle":2846,"status":188,"phases":3193,"primaryCompletion":191,"start":2848,"enrollment":2145,"conditions":3194,"interventions":3195},[89],[24],[257,117],{"trials":3197,"activeCount":99},[],{"trials":3199,"activeCount":99},[],{"intervention":1581,"totalTrials":3128,"cells":3201},{"EARLY_PHASE1":3202,"PHASE1":3204,"PHASE2":3206,"PHASE3":3228,"PHASE4":3258,"NA":3260},{"trials":3203,"activeCount":99},[],{"trials":3205,"activeCount":99},[],{"trials":3207,"activeCount":99},[3208,3212,3216,3220,3224],{"nctId":2865,"briefTitle":2866,"status":361,"phases":3209,"start":517,"enrollment":2868,"conditions":3210,"interventions":3211},[88],[18],[151,1581],{"nctId":2872,"briefTitle":2873,"status":188,"phases":3213,"primaryCompletion":2875,"start":517,"enrollment":1798,"conditions":3214,"interventions":3215},[88],[18],[151,1676,1581],{"nctId":1711,"briefTitle":1712,"status":107,"phases":3217,"primaryCompletion":759,"start":1714,"enrollment":1715,"conditions":3218,"interventions":3219},[88],[18],[151,174,1580,1581,157],{"nctId":1571,"briefTitle":1572,"status":107,"phases":3221,"primaryCompletion":975,"start":1574,"enrollment":1575,"conditions":3222,"interventions":3223},[88],[18,1577],[1579,115,151,1580,1581],{"nctId":2887,"briefTitle":2888,"status":361,"phases":3225,"primaryCompletion":2890,"start":699,"enrollment":2891,"conditions":3226,"interventions":3227},[87,88],[18,1577],[2894,151,1581],{"trials":3229,"activeCount":99},[3230,3234,3238,3242,3246,3250,3254],{"nctId":1621,"briefTitle":1622,"status":361,"phases":3231,"start":1624,"enrollment":1625,"conditions":3232,"interventions":3233},[89],[18],[1579,115,151,174,1581,155,156,157,522,1628],{"nctId":1630,"briefTitle":1631,"status":361,"phases":3235,"start":223,"enrollment":1633,"conditions":3236,"interventions":3237},[89],[18,21,1635,1577],[1579,115,1581,1637],{"nctId":1657,"briefTitle":1658,"status":361,"phases":3239,"start":1660,"enrollment":1661,"conditions":3240,"interventions":3241},[89],[18],[169,1579,115,151,152,174,1581,1664,157],{"nctId":1745,"briefTitle":1746,"status":361,"phases":3243,"start":1748,"enrollment":1749,"conditions":3244,"interventions":3245},[89],[18,1577],[151,174,1581],{"nctId":1761,"briefTitle":1762,"status":107,"phases":3247,"primaryCompletion":1642,"completion":1764,"start":409,"enrollment":1765,"conditions":3248,"interventions":3249},[89],[18],[151,174,1580,1581,157],{"nctId":1769,"briefTitle":1770,"status":107,"phases":3251,"primaryCompletion":428,"start":1772,"enrollment":1773,"conditions":3252,"interventions":3253},[89],[18,1775],[169,1777,807,151,174,1581,157],{"nctId":1779,"briefTitle":1780,"status":107,"phases":3255,"primaryCompletion":489,"start":1782,"conditions":3256,"interventions":3257},[89],[18,1577],[151,152,153,174,1581,157,522],{"trials":3259,"activeCount":99},[],{"trials":3261,"activeCount":99},[],{"intervention":2967,"totalTrials":95,"cells":3263},{"EARLY_PHASE1":3264,"PHASE1":3266,"PHASE2":3279,"PHASE3":3317,"PHASE4":3336,"NA":3338},{"trials":3265,"activeCount":99},[],{"trials":3267,"activeCount":99},[3268,3272],{"nctId":2960,"briefTitle":2961,"status":107,"phases":3269,"primaryCompletion":2963,"start":2964,"enrollment":2856,"conditions":3270,"interventions":3271},[87],[29],[2569,270,154,2967],{"nctId":3273,"briefTitle":3274,"status":107,"phases":3275,"primaryCompletion":2994,"start":2705,"enrollment":952,"conditions":3276,"interventions":3277},"NCT00081237","OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer",[87],[29],[3278,2967],"OSI-7904L",{"trials":3280,"activeCount":99},[3281,3285,3289,3295,3299,3313],{"nctId":2971,"briefTitle":2972,"status":188,"phases":3282,"primaryCompletion":346,"start":2974,"enrollment":2975,"conditions":3283,"interventions":3284},[88],[29,351],[935,2978,270,154,2967],{"nctId":2980,"briefTitle":2981,"status":361,"phases":3286,"start":2963,"enrollment":2983,"conditions":3287,"interventions":3288},[88],[29,351],[935,2555,270,154,2967],{"nctId":3290,"briefTitle":3291,"status":188,"phases":3292,"primaryCompletion":2974,"start":45,"enrollment":1554,"conditions":3293,"interventions":3294},"NCT00006121","Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy",[88],[15],[2967],{"nctId":2991,"briefTitle":2992,"status":107,"phases":3296,"primaryCompletion":2994,"start":1587,"conditions":3297,"interventions":3298},[88],[29],[270,2635,154,2967],{"nctId":3300,"briefTitle":3301,"status":786,"phases":3302,"primaryCompletion":3303,"start":3304,"enrollment":99,"conditions":3305,"interventions":3309},"NCT02856867","Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)",[88],"2019-06","2016-12",[3306,3307,3308],"Esophagogastric Adenocarcinoma","Metastatic Disease","No Previous Chemotherapy for Metastatic Esophagogastric Cancer",[3310,3311,3312,796],"Nintedanib","Fluorouracil","Leucovorin",{"nctId":784,"briefTitle":785,"status":786,"phases":3314,"primaryCompletion":788,"completion":789,"start":790,"enrollment":99,"conditions":3315,"interventions":3316},[88],[792],[794,795,796,797,716],{"trials":3318,"activeCount":99},[3319,3323,3332],{"nctId":3025,"briefTitle":3026,"status":361,"phases":3320,"start":3028,"conditions":3321,"interventions":3322},[89],[29,351],[2978,270,154,2967],{"nctId":3324,"briefTitle":3325,"status":107,"phases":3326,"primaryCompletion":3327,"start":3328,"enrollment":3329,"conditions":3330,"interventions":3331},"NCT00766155","Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer",[89],"2011-09","2008-08",1094,[29],[955,2967],{"nctId":3040,"briefTitle":3041,"status":107,"phases":3333,"primaryCompletion":124,"start":3043,"enrollment":3044,"conditions":3334,"interventions":3335},[89],[29],[2978,270,154,2967],{"trials":3337,"activeCount":99},[],{"trials":3339,"activeCount":99},[],{"intervention":980,"totalTrials":3341,"cells":3342},10,{"EARLY_PHASE1":3343,"PHASE1":3345,"PHASE2":3355,"PHASE3":3392,"PHASE4":3402,"NA":3404},{"trials":3344,"activeCount":99},[],{"trials":3346,"activeCount":99},[3347],{"nctId":3348,"briefTitle":3349,"status":107,"phases":3350,"primaryCompletion":1869,"start":264,"enrollment":722,"conditions":3351,"interventions":3353},"NCT00004886","MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors",[87],[3352],"Unspecified Adult Solid Tumor, Protocol Specific",[980,3354],"dofequidar fumarate",{"trials":3356,"activeCount":99},[3357,3361,3365,3369,3377,3381,3385],{"nctId":2547,"briefTitle":2548,"status":188,"phases":3358,"primaryCompletion":489,"completion":2550,"start":2551,"enrollment":2552,"conditions":3359,"interventions":3360},[88],[1897],[2555,289,257,980,270,2556,2557,2558],{"nctId":2571,"briefTitle":2572,"status":107,"phases":3362,"primaryCompletion":699,"completion":2574,"start":2575,"enrollment":320,"conditions":3363,"interventions":3364},[87,88],[1897],[289,257,980,270,968,2578,2556,2579,2580,2558],{"nctId":2582,"briefTitle":2583,"status":107,"phases":3366,"primaryCompletion":165,"start":738,"enrollment":2552,"conditions":3367,"interventions":3368},[88],[24],[257,980],{"nctId":3370,"briefTitle":3371,"status":107,"phases":3372,"primaryCompletion":2630,"start":134,"enrollment":3373,"conditions":3374,"interventions":3375},"NCT00085228","Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate",[88],116,[34],[3376,980],"oblimersen sodium",{"nctId":1866,"briefTitle":1867,"status":107,"phases":3378,"primaryCompletion":1869,"start":1870,"enrollment":1871,"conditions":3379,"interventions":3380},[88],[15],[980,1874,368],{"nctId":2675,"briefTitle":2676,"status":107,"phases":3382,"primaryCompletion":976,"start":2678,"enrollment":2679,"conditions":3383,"interventions":3384},[88],[2681],[257,980,117],{"nctId":3386,"briefTitle":3387,"status":107,"phases":3388,"start":3389,"enrollment":19,"conditions":3390,"interventions":3391},"NCT00002903","Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer",[88],"1995-07",[365,401,352],[980],{"trials":3393,"activeCount":99},[3394,3398],{"nctId":972,"briefTitle":973,"status":107,"phases":3395,"primaryCompletion":975,"start":976,"enrollment":977,"conditions":3396,"interventions":3397},[89],[15],[169,115,980,217,270,981],{"nctId":2761,"briefTitle":2762,"status":107,"phases":3399,"primaryCompletion":124,"completion":2764,"start":347,"enrollment":2765,"conditions":3400,"interventions":3401},[89],[1897],[257,980,270],{"trials":3403,"activeCount":99},[],{"trials":3405,"activeCount":99},[],{"intervention":156,"totalTrials":3407,"cells":3408},9,{"EARLY_PHASE1":3409,"PHASE1":3411,"PHASE2":3413,"PHASE3":3427,"PHASE4":3453,"NA":3455},{"trials":3410,"activeCount":99},[],{"trials":3412,"activeCount":99},[],{"trials":3414,"activeCount":99},[3415,3419,3423],{"nctId":248,"briefTitle":249,"status":188,"phases":3416,"primaryCompletion":251,"start":252,"enrollment":253,"conditions":3417,"interventions":3418},[88],[255],[169,257,116,156,176],{"nctId":1583,"briefTitle":1584,"status":107,"phases":3420,"primaryCompletion":721,"completion":1586,"start":1587,"enrollment":1588,"conditions":3421,"interventions":3422},[88],[15],[1591,1592,115,270,156],{"nctId":2896,"briefTitle":2897,"status":107,"phases":3424,"primaryCompletion":124,"start":438,"enrollment":1018,"conditions":3425,"interventions":3426},[88],[21],[151,156],{"trials":3428,"activeCount":99},[3429,3433,3437,3441,3445,3449],{"nctId":142,"briefTitle":143,"status":107,"phases":3430,"primaryCompletion":145,"start":146,"enrollment":147,"conditions":3431,"interventions":3432},[89],[18,21],[150,115,151,152,153,116,154,155,156,157,158,94,159,118],{"nctId":1621,"briefTitle":1622,"status":361,"phases":3434,"start":1624,"enrollment":1625,"conditions":3435,"interventions":3436},[89],[18],[1579,115,151,174,1581,155,156,157,522,1628],{"nctId":261,"briefTitle":262,"status":107,"phases":3438,"primaryCompletion":264,"start":265,"enrollment":266,"conditions":3439,"interventions":3440},[89],[268],[41,257,270,271,156,272,176,273],{"nctId":279,"briefTitle":280,"status":107,"phases":3442,"primaryCompletion":282,"start":283,"enrollment":284,"conditions":3443,"interventions":3444},[88,89],[255,286,287],[289,117,156,176],{"nctId":299,"briefTitle":300,"status":107,"phases":3446,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":3447,"interventions":3448},[89],[307,308,309],[116,117,176,156,257,169],{"nctId":513,"briefTitle":514,"status":361,"phases":3450,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":3451,"interventions":3452},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":3454,"activeCount":99},[],{"trials":3456,"activeCount":99},[],{"intervention":271,"totalTrials":3407,"cells":3458},{"EARLY_PHASE1":3459,"PHASE1":3461,"PHASE2":3471,"PHASE3":3484,"PHASE4":3514,"NA":3516},{"trials":3460,"activeCount":99},[],{"trials":3462,"activeCount":99},[3463],{"nctId":3464,"briefTitle":3465,"status":107,"phases":3466,"primaryCompletion":3467,"start":428,"enrollment":16,"conditions":3468,"interventions":3469},"NCT00030784","Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma",[87],"2005-03",[32],[271,3470],"pegylated liposomal doxorubicin hydrochloride",{"trials":3472,"activeCount":99},[3473],{"nctId":3474,"briefTitle":3475,"status":188,"phases":3476,"primaryCompletion":3477,"completion":3478,"start":3479,"enrollment":1749,"conditions":3480,"interventions":3482},"NCT02808247","Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma",[88],"2020-11-03","2021-04-14","2017-07-07",[3481],"Sarcoma, Soft Tissue",[3310,3483],"Ifosfamide",{"trials":3485,"activeCount":99},[3486,3490,3494,3498,3502,3506,3510],{"nctId":425,"briefTitle":426,"status":107,"phases":3487,"primaryCompletion":428,"start":429,"enrollment":430,"conditions":3488,"interventions":3489},[89],[32],[116,271],{"nctId":261,"briefTitle":262,"status":107,"phases":3491,"primaryCompletion":264,"start":265,"enrollment":266,"conditions":3492,"interventions":3493},[89],[268],[41,257,270,271,156,272,176,273],{"nctId":434,"briefTitle":435,"status":107,"phases":3495,"completion":437,"start":438,"enrollment":439,"conditions":3496,"interventions":3497},[89],[32],[116,174,271],{"nctId":447,"briefTitle":448,"status":107,"phases":3499,"primaryCompletion":251,"start":450,"enrollment":439,"conditions":3500,"interventions":3501},[89],[412,452,351,401,453,32],[169,116,271],{"nctId":343,"briefTitle":344,"status":107,"phases":3503,"primaryCompletion":346,"start":347,"enrollment":348,"conditions":3504,"interventions":3505},[89],[350,351,352],[41,169,257,174,271],{"nctId":475,"briefTitle":476,"status":107,"phases":3507,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":3508,"interventions":3509},[89],[412,452,401,453,32],[169,116,271,484],{"nctId":486,"briefTitle":487,"status":107,"phases":3511,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":3512,"interventions":3513},[89],[32],[170,116,271],{"trials":3515,"activeCount":99},[],{"trials":3517,"activeCount":99},[],{"intervention":289,"totalTrials":239,"cells":3519},{"EARLY_PHASE1":3520,"PHASE1":3522,"PHASE2":3524,"PHASE3":3542,"PHASE4":3560,"NA":3562},{"trials":3521,"activeCount":99},[],{"trials":3523,"activeCount":99},[],{"trials":3525,"activeCount":99},[3526,3530,3534,3538],{"nctId":1821,"briefTitle":1822,"status":107,"phases":3527,"primaryCompletion":1824,"completion":1825,"start":490,"enrollment":1826,"conditions":3528,"interventions":3529},[87,88],[1828,401,1829],[289,368,1831],{"nctId":2547,"briefTitle":2548,"status":188,"phases":3531,"primaryCompletion":489,"completion":2550,"start":2551,"enrollment":2552,"conditions":3532,"interventions":3533},[88],[1897],[2555,289,257,980,270,2556,2557,2558],{"nctId":2571,"briefTitle":2572,"status":107,"phases":3535,"primaryCompletion":699,"completion":2574,"start":2575,"enrollment":320,"conditions":3536,"interventions":3537},[87,88],[1897],[289,257,980,270,968,2578,2556,2579,2580,2558],{"nctId":1891,"briefTitle":1892,"status":188,"phases":3539,"primaryCompletion":507,"start":1894,"enrollment":875,"conditions":3540,"interventions":3541},[88],[1896,1897,1898,1899],[1901,289,257,368],{"trials":3543,"activeCount":99},[3544,3548,3552,3556],{"nctId":2722,"briefTitle":2723,"status":107,"phases":3545,"primaryCompletion":1701,"start":2725,"enrollment":2716,"conditions":3546,"interventions":3547},[89],[24],[289,257],{"nctId":2737,"briefTitle":2738,"status":188,"phases":3549,"primaryCompletion":507,"start":2740,"enrollment":2741,"conditions":3550,"interventions":3551},[89],[401],[289,257],{"nctId":279,"briefTitle":280,"status":107,"phases":3553,"primaryCompletion":282,"start":283,"enrollment":284,"conditions":3554,"interventions":3555},[88,89],[255,286,287],[289,117,156,176],{"nctId":2790,"briefTitle":2791,"status":107,"phases":3557,"primaryCompletion":2793,"start":252,"enrollment":2794,"conditions":3558,"interventions":3559},[89],[1828,401,1829],[289,257],{"trials":3561,"activeCount":99},[],{"trials":3563,"activeCount":99},[],{"intervention":157,"totalTrials":239,"cells":3565},{"EARLY_PHASE1":3566,"PHASE1":3568,"PHASE2":3570,"PHASE3":3576,"PHASE4":3606,"NA":3608},{"trials":3567,"activeCount":99},[],{"trials":3569,"activeCount":99},[],{"trials":3571,"activeCount":99},[3572],{"nctId":1711,"briefTitle":1712,"status":107,"phases":3573,"primaryCompletion":759,"start":1714,"enrollment":1715,"conditions":3574,"interventions":3575},[88],[18],[151,174,1580,1581,157],{"trials":3577,"activeCount":99},[3578,3582,3586,3590,3594,3598,3602],{"nctId":142,"briefTitle":143,"status":107,"phases":3579,"primaryCompletion":145,"start":146,"enrollment":147,"conditions":3580,"interventions":3581},[89],[18,21],[150,115,151,152,153,116,154,155,156,157,158,94,159,118],{"nctId":1621,"briefTitle":1622,"status":361,"phases":3583,"start":1624,"enrollment":1625,"conditions":3584,"interventions":3585},[89],[18],[1579,115,151,174,1581,155,156,157,522,1628],{"nctId":1657,"briefTitle":1658,"status":361,"phases":3587,"start":1660,"enrollment":1661,"conditions":3588,"interventions":3589},[89],[18],[169,1579,115,151,152,174,1581,1664,157],{"nctId":1761,"briefTitle":1762,"status":107,"phases":3591,"primaryCompletion":1642,"completion":1764,"start":409,"enrollment":1765,"conditions":3592,"interventions":3593},[89],[18],[151,174,1580,1581,157],{"nctId":1769,"briefTitle":1770,"status":107,"phases":3595,"primaryCompletion":428,"start":1772,"enrollment":1773,"conditions":3596,"interventions":3597},[89],[18,1775],[169,1777,807,151,174,1581,157],{"nctId":1779,"briefTitle":1780,"status":107,"phases":3599,"primaryCompletion":489,"start":1782,"conditions":3600,"interventions":3601},[89],[18,1577],[151,152,153,174,1581,157,522],{"nctId":513,"briefTitle":514,"status":361,"phases":3603,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":3604,"interventions":3605},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":3607,"activeCount":99},[],{"trials":3609,"activeCount":99},[],{"intervention":935,"totalTrials":320,"cells":3611},{"EARLY_PHASE1":3612,"PHASE1":3614,"PHASE2":3622,"PHASE3":3661,"PHASE4":3667,"NA":3669},{"trials":3613,"activeCount":99},[],{"trials":3615,"activeCount":99},[3616],{"nctId":3617,"briefTitle":3618,"status":107,"phases":3619,"primaryCompletion":1836,"start":264,"enrollment":30,"conditions":3620,"interventions":3621},"NCT00005061","Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors",[87],[3352],[935],{"trials":3623,"activeCount":99},[3624,3628,3632,3636,3649],{"nctId":2971,"briefTitle":2972,"status":188,"phases":3625,"primaryCompletion":346,"start":2974,"enrollment":2975,"conditions":3626,"interventions":3627},[88],[29,351],[935,2978,270,154,2967],{"nctId":2980,"briefTitle":2981,"status":361,"phases":3629,"start":2963,"enrollment":2983,"conditions":3630,"interventions":3631},[88],[29,351],[935,2555,270,154,2967],{"nctId":744,"briefTitle":745,"status":107,"phases":3633,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":3634,"interventions":3635},[88],[752],[754,716],{"nctId":3637,"briefTitle":3638,"status":188,"phases":3639,"primaryCompletion":3640,"completion":3640,"start":463,"enrollment":3641,"conditions":3642,"interventions":3646},"NCT01508000","Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases",[88],"2016-09",44,[3643,3644,3645],"Colorectal Cancer Metastatic","Liver Metastases","KRAS Wild Type Colorectal Cancer",[3647,754,3648],"FOLFOX6","Panitumumab",{"nctId":3650,"briefTitle":3651,"status":107,"phases":3652,"primaryCompletion":2801,"completion":3653,"start":3654,"enrollment":3655,"conditions":3656,"interventions":3658},"NCT02659384","Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer",[88],"2022-03","2016-12-23",122,[3657],"Ovarian Neoplasms",[754,3659,3660],"atezolizumab","acetylsalicylic acid",{"trials":3662,"activeCount":99},[3663],{"nctId":923,"briefTitle":924,"status":107,"phases":3664,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":3665,"interventions":3666},[89],[931,932,933],[935,581,858],{"trials":3668,"activeCount":99},[],{"trials":3670,"activeCount":99},[],{"intervention":152,"totalTrials":3672,"cells":3673},6,{"EARLY_PHASE1":3674,"PHASE1":3676,"PHASE2":3678,"PHASE3":3680,"PHASE4":3706,"NA":3708},{"trials":3675,"activeCount":99},[],{"trials":3677,"activeCount":99},[],{"trials":3679,"activeCount":99},[],{"trials":3681,"activeCount":99},[3682,3686,3690,3694,3698,3702],{"nctId":142,"briefTitle":143,"status":107,"phases":3683,"primaryCompletion":145,"start":146,"enrollment":147,"conditions":3684,"interventions":3685},[89],[18,21],[150,115,151,152,153,116,154,155,156,157,158,94,159,118],{"nctId":1639,"briefTitle":1640,"status":361,"phases":3687,"primaryCompletion":1642,"start":1643,"enrollment":1644,"conditions":3688,"interventions":3689},[89],[18],[1647,169,1579,115,151,152,174],{"nctId":1657,"briefTitle":1658,"status":361,"phases":3691,"start":1660,"enrollment":1661,"conditions":3692,"interventions":3693},[89],[18],[169,1579,115,151,152,174,1581,1664,157],{"nctId":1779,"briefTitle":1780,"status":107,"phases":3695,"primaryCompletion":489,"start":1782,"conditions":3696,"interventions":3697},[89],[18,1577],[151,152,153,174,1581,157,522],{"nctId":2936,"briefTitle":2937,"status":107,"phases":3699,"primaryCompletion":2939,"start":2940,"enrollment":2941,"conditions":3700,"interventions":3701},[89],[18],[2944,1777,151,152],{"nctId":513,"briefTitle":514,"status":361,"phases":3703,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":3704,"interventions":3705},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":3707,"activeCount":99},[],{"trials":3709,"activeCount":99},[],{"intervention":2604,"totalTrials":3672,"cells":3711},{"EARLY_PHASE1":3712,"PHASE1":3714,"PHASE2":3716,"PHASE3":3755,"PHASE4":3764,"NA":3766},{"trials":3713,"activeCount":99},[],{"trials":3715,"activeCount":99},[],{"trials":3717,"activeCount":99},[3718,3725,3732,3736,3742],{"nctId":3719,"briefTitle":3720,"status":107,"phases":3721,"primaryCompletion":3722,"start":507,"enrollment":2119,"conditions":3723,"interventions":3724},"NCT00052754","Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma",[88],"2005-10",[32],[2604],{"nctId":3726,"briefTitle":3727,"status":107,"phases":3728,"primaryCompletion":2691,"start":823,"enrollment":710,"conditions":3729,"interventions":3730},"NCT00066378","Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer",[88],[15],[3731,2604],"anastrozole",{"nctId":2597,"briefTitle":2598,"status":107,"phases":3733,"primaryCompletion":2600,"start":2601,"conditions":3734,"interventions":3735},[88],[24],[257,2604,117],{"nctId":3737,"briefTitle":3738,"status":107,"phases":3739,"primaryCompletion":110,"start":823,"enrollment":3641,"conditions":3740,"interventions":3741},"NCT00066339","Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy",[88],[15],[2604],{"nctId":3743,"briefTitle":3744,"status":107,"phases":3745,"primaryCompletion":3746,"completion":3747,"start":3748,"enrollment":3749,"conditions":3750,"interventions":3752},"NCT02856893","Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)",[88],"2022-09-20","2025-08-12","2017-10-10",156,[3751],"NSCLC",[3753,3754],"Osimertinib","Gefitinib",{"trials":3756,"activeCount":99},[3757],{"nctId":3758,"briefTitle":3759,"status":188,"phases":3760,"primaryCompletion":2621,"start":49,"enrollment":3761,"conditions":3762,"interventions":3763},"NCT00091156","Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[89],598,[24],[2604],{"trials":3765,"activeCount":99},[],{"trials":3767,"activeCount":99},[],{"intervention":3769,"totalTrials":3672,"cells":3770},"imatinib mesylate",{"EARLY_PHASE1":3771,"PHASE1":3773,"PHASE2":3775,"PHASE3":3799,"PHASE4":3824,"NA":3826},{"trials":3772,"activeCount":99},[],{"trials":3774,"activeCount":99},[],{"trials":3776,"activeCount":99},[3777,3784,3792],{"nctId":3778,"briefTitle":3779,"status":107,"phases":3780,"primaryCompletion":190,"start":124,"enrollment":3781,"conditions":3782,"interventions":3783},"NCT00039364","Imatinib Mesylate in Treating Patients With Gliomas",[88],112,[27],[3769],{"nctId":3785,"briefTitle":3786,"status":107,"phases":3787,"primaryCompletion":824,"start":2740,"enrollment":3788,"conditions":3789,"interventions":3791},"NCT00006357","STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma",[87,88],91,[412,3790,401,32,112],"Gastrointestinal Stromal Tumor",[3769],{"nctId":3793,"briefTitle":3794,"status":107,"phases":3795,"primaryCompletion":3796,"start":134,"enrollment":689,"conditions":3797,"interventions":3798},"NCT00085475","Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma",[88],"2007-04",[32],[3769],{"trials":3800,"activeCount":99},[3801,3810,3817],{"nctId":3802,"briefTitle":3803,"status":107,"phases":3804,"primaryCompletion":3805,"completion":3806,"start":2601,"enrollment":3807,"conditions":3808,"interventions":3809},"NCT00103168","Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor",[89],"2008-10","2017-09",908,[3790],[3769],{"nctId":3811,"briefTitle":3812,"status":361,"phases":3813,"primaryCompletion":1587,"start":283,"enrollment":3814,"conditions":3815,"interventions":3816},"NCT00685828","Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor",[89],946,[3790],[3769],{"nctId":3818,"briefTitle":3819,"status":188,"phases":3820,"primaryCompletion":803,"start":3821,"enrollment":3128,"conditions":3822,"interventions":3823},"NCT00956072","Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate",[89],"2009-05",[3790],[3769],{"trials":3825,"activeCount":99},[],{"trials":3827,"activeCount":99},[],{"intervention":469,"totalTrials":875,"cells":3829},{"EARLY_PHASE1":3830,"PHASE1":3832,"PHASE2":3841,"PHASE3":3861,"PHASE4":3875,"NA":3877},{"trials":3831,"activeCount":99},[],{"trials":3833,"activeCount":99},[3834],{"nctId":3835,"briefTitle":3836,"status":107,"phases":3837,"start":3838,"enrollment":8,"conditions":3839,"interventions":3840},"NCT00002904","Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors",[87],"1996-02",[3352],[469],{"trials":3842,"activeCount":99},[3843,3850],{"nctId":3844,"briefTitle":3845,"status":107,"phases":3846,"primaryCompletion":251,"enrollment":3847,"conditions":3848,"interventions":3849},"NCT00003939","Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma",[88],132,[27,412,3790,401,32,112],[469],{"nctId":3851,"briefTitle":3852,"status":107,"phases":3853,"primaryCompletion":3854,"completion":3855,"start":3856,"enrollment":1588,"conditions":3857,"interventions":3859},"NCT02234050","Trabectedin for Recurrent Grade II\u002FIII Meningioma",[88],"2017-07","2019-01-16","2015-07",[3858],"Recurrent High Grade Meningioma",[3860],"Trabectedin",{"trials":3862,"activeCount":99},[3863,3867],{"nctId":460,"briefTitle":461,"status":188,"phases":3864,"primaryCompletion":463,"completion":464,"start":465,"enrollment":466,"conditions":3865,"interventions":3866},[88,89],[32],[116,469],{"nctId":3868,"briefTitle":3869,"status":188,"phases":3870,"primaryCompletion":3871,"completion":3871,"start":3872,"enrollment":1798,"conditions":3873,"interventions":3874},"NCT02929394","Trabectedin Maintenance Post 1st-line in STS",[89],"2020-06-05","2017-11-07",[3481],[3860],{"trials":3876,"activeCount":99},[],{"trials":3878,"activeCount":99},[],{"intervention":2016,"totalTrials":875,"cells":3880},{"EARLY_PHASE1":3881,"PHASE1":3883,"PHASE2":3885,"PHASE3":3925,"PHASE4":3931,"NA":3933},{"trials":3882,"activeCount":99},[],{"trials":3884,"activeCount":99},[],{"trials":3886,"activeCount":99},[3887,3897,3908,3912],{"nctId":3888,"briefTitle":3889,"status":107,"phases":3890,"primaryCompletion":3891,"completion":3892,"start":3893,"enrollment":25,"conditions":3894,"interventions":3895},"NCT03101475","Synergism of Immunomodulation and Tumor Ablation",[88],"2021-03-03","2022-02-23","2018-11-23",[29,3644],[2016,3896],"Tremelimumab",{"nctId":3898,"briefTitle":3899,"status":786,"phases":3900,"primaryCompletion":3901,"completion":3902,"start":3903,"enrollment":99,"conditions":3904,"interventions":3907},"NCT03319316","Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)",[88],"2021-11","2022-11","2018-11-01",[3905,3906],"Squamous Non-small Cell Lung Cancer","Non-Squamous Non-small Cell Lung Cancer",[2016,3896],{"nctId":2004,"briefTitle":2005,"status":361,"phases":3909,"primaryCompletion":2007,"completion":2008,"start":2009,"enrollment":439,"conditions":3910,"interventions":3911},[88],[2011],[2013,1848,2014,2015,2016,2017,2018],{"nctId":3913,"briefTitle":3914,"status":786,"phases":3915,"primaryCompletion":3916,"completion":3917,"start":3918,"enrollment":99,"conditions":3919,"interventions":3923},"NCT05209529","Chemo-free BRCA-targeted Neoadjuvant Strategy",[88],"2028-09-06","2030-07-18","2024-02-01",[3920,3921,3922],"TNBC - Triple-Negative Breast Cancer","BRCA1 Mutation","BRCA2 Mutation",[3924,2016],"olaparib",{"trials":3926,"activeCount":99},[3927],{"nctId":2798,"briefTitle":2799,"status":786,"phases":3928,"primaryCompletion":788,"completion":1978,"start":2801,"enrollment":99,"conditions":3929,"interventions":3930},[89],[2803],[2016,794],{"trials":3932,"activeCount":99},[],{"trials":3934,"activeCount":99},[],{"intervention":1579,"totalTrials":875,"cells":3936},{"EARLY_PHASE1":3937,"PHASE1":3939,"PHASE2":3941,"PHASE3":3947,"PHASE4":3965,"NA":3967},{"trials":3938,"activeCount":99},[],{"trials":3940,"activeCount":99},[],{"trials":3942,"activeCount":99},[3943],{"nctId":1571,"briefTitle":1572,"status":107,"phases":3944,"primaryCompletion":975,"start":1574,"enrollment":1575,"conditions":3945,"interventions":3946},[88],[18,1577],[1579,115,151,1580,1581],{"trials":3948,"activeCount":99},[3949,3953,3957,3961],{"nctId":1621,"briefTitle":1622,"status":361,"phases":3950,"start":1624,"enrollment":1625,"conditions":3951,"interventions":3952},[89],[18],[1579,115,151,174,1581,155,156,157,522,1628],{"nctId":1630,"briefTitle":1631,"status":361,"phases":3954,"start":223,"enrollment":1633,"conditions":3955,"interventions":3956},[89],[18,21,1635,1577],[1579,115,1581,1637],{"nctId":1639,"briefTitle":1640,"status":361,"phases":3958,"primaryCompletion":1642,"start":1643,"enrollment":1644,"conditions":3959,"interventions":3960},[89],[18],[1647,169,1579,115,151,152,174],{"nctId":1657,"briefTitle":1658,"status":361,"phases":3962,"start":1660,"enrollment":1661,"conditions":3963,"interventions":3964},[89],[18],[169,1579,115,151,152,174,1581,1664,157],{"trials":3966,"activeCount":99},[],{"trials":3968,"activeCount":99},[],{"intervention":227,"totalTrials":875,"cells":3970},{"EARLY_PHASE1":3971,"PHASE1":3973,"PHASE2":3975,"PHASE3":3981,"PHASE4":4011,"NA":4013},{"trials":3972,"activeCount":99},[],{"trials":3974,"activeCount":99},[],{"trials":3976,"activeCount":99},[3977],{"nctId":1938,"briefTitle":1939,"status":107,"phases":3978,"primaryCompletion":165,"start":1941,"enrollment":1588,"conditions":3979,"interventions":3980},[88],[826],[1647,227,257,173],{"trials":3982,"activeCount":99},[3983,3993,4000,4007],{"nctId":3984,"briefTitle":3985,"status":107,"phases":3986,"primaryCompletion":283,"start":3987,"enrollment":3988,"conditions":3989,"interventions":3990},"NCT00002737","Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer",[89],"1996-03",320,[452],[227,3991,3992],"chemotherapy","isotretinoin",{"nctId":3994,"briefTitle":3995,"status":107,"phases":3996,"primaryCompletion":110,"start":3997,"enrollment":2679,"conditions":3998,"interventions":3999},"NCT00053807","Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer",[89],"1998-02",[452],[1647,227,270],{"nctId":4001,"briefTitle":4002,"status":361,"phases":4003,"start":450,"enrollment":4004,"conditions":4005,"interventions":4006},"NCT00002763","High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma",[89],1000,[826],[227],{"nctId":219,"briefTitle":220,"status":188,"phases":4008,"primaryCompletion":222,"start":223,"enrollment":224,"conditions":4009,"interventions":4010},[89],[21],[169,227,115,94,118],{"trials":4012,"activeCount":99},[],{"trials":4014,"activeCount":99},[],{"intervention":955,"totalTrials":875,"cells":4016},{"EARLY_PHASE1":4017,"PHASE1":4019,"PHASE2":4025,"PHASE3":4031,"PHASE4":4048,"NA":4050},{"trials":4018,"activeCount":99},[],{"trials":4020,"activeCount":99},[4021],{"nctId":947,"briefTitle":948,"status":107,"phases":4022,"primaryCompletion":950,"start":951,"enrollment":952,"conditions":4023,"interventions":4024},[87],[15],[955,115,217],{"trials":4026,"activeCount":99},[4027],{"nctId":959,"briefTitle":960,"status":188,"phases":4028,"primaryCompletion":863,"completion":962,"start":963,"enrollment":740,"conditions":4029,"interventions":4030},[88],[965,966],[955,257,217,270,968],{"trials":4032,"activeCount":99},[4033,4037,4044],{"nctId":3032,"briefTitle":3033,"status":107,"phases":4034,"primaryCompletion":123,"start":823,"enrollment":3035,"conditions":4035,"interventions":4036},[89],[29],[3014,955,3038,270,2635,154],{"nctId":4038,"briefTitle":4039,"status":188,"phases":4040,"primaryCompletion":2601,"start":409,"enrollment":2552,"conditions":4041,"interventions":4042},"NCT00049660","Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer",[88,89],[15],[955,4043],"vinorelbine tartrate",{"nctId":3324,"briefTitle":3325,"status":107,"phases":4045,"primaryCompletion":3327,"start":3328,"enrollment":3329,"conditions":4046,"interventions":4047},[89],[29],[955,2967],{"trials":4049,"activeCount":99},[],{"trials":4051,"activeCount":99},[],{"intervention":4053,"totalTrials":591,"cells":4054},"BCG vaccine",{"EARLY_PHASE1":4055,"PHASE1":4057,"PHASE2":4059,"PHASE3":4067,"PHASE4":4092,"NA":4094},{"trials":4056,"activeCount":99},[],{"trials":4058,"activeCount":99},[],{"trials":4060,"activeCount":99},[4061],{"nctId":4062,"briefTitle":4063,"status":107,"phases":4064,"primaryCompletion":1860,"start":1836,"enrollment":3173,"conditions":4065,"interventions":4066},"NCT00023842","BCG With or Without Mitomycin in Treating Patients With Bladder Cancer",[88],[255],[4053,272],{"trials":4068,"activeCount":99},[4069,4077,4084],{"nctId":4070,"briefTitle":4071,"status":107,"phases":4072,"primaryCompletion":507,"start":1643,"enrollment":4073,"conditions":4074,"interventions":4075},"NCT00006352","Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer",[89],453,[24],[4053,4076],"monoclonal antibody BEC2",{"nctId":4078,"briefTitle":4079,"status":107,"phases":4080,"primaryCompletion":4081,"start":3043,"enrollment":1773,"conditions":4082,"interventions":4083},"NCT00003279","Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer",[89],"2000-01",[24],[4053,4076],{"nctId":4085,"briefTitle":4086,"status":107,"phases":4087,"primaryCompletion":4088,"start":223,"enrollment":4089,"conditions":4090,"interventions":4091},"NCT00002990","Surgery and BCG in Treating Patients With Bladder Cancer",[89],"2005-04",1288,[255],[4053],{"trials":4093,"activeCount":99},[],{"trials":4095,"activeCount":99},[],{"intervention":272,"totalTrials":591,"cells":4097},{"EARLY_PHASE1":4098,"PHASE1":4100,"PHASE2":4102,"PHASE3":4108,"PHASE4":4125,"NA":4127},{"trials":4099,"activeCount":99},[],{"trials":4101,"activeCount":99},[],{"trials":4103,"activeCount":99},[4104],{"nctId":4062,"briefTitle":4063,"status":107,"phases":4105,"primaryCompletion":1860,"start":1836,"enrollment":3173,"conditions":4106,"interventions":4107},[88],[255],[4053,272],{"trials":4109,"activeCount":99},[4110,4114,4118],{"nctId":261,"briefTitle":262,"status":107,"phases":4111,"primaryCompletion":264,"start":265,"enrollment":266,"conditions":4112,"interventions":4113},[89],[268],[41,257,270,271,156,272,176,273],{"nctId":2782,"briefTitle":2783,"status":188,"phases":4115,"primaryCompletion":767,"start":2785,"enrollment":1826,"conditions":4116,"interventions":4117},[88,89],[2787],[257,270,272],{"nctId":4119,"briefTitle":4120,"status":188,"phases":4121,"primaryCompletion":49,"start":2974,"enrollment":4122,"conditions":4123,"interventions":4124},"NCT00042887","Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer",[89],58,[255],[272],{"trials":4126,"activeCount":99},[],{"trials":4128,"activeCount":99},[],{"intervention":1647,"totalTrials":591,"cells":4130},{"EARLY_PHASE1":4131,"PHASE1":4133,"PHASE2":4135,"PHASE3":4148,"PHASE4":4158,"NA":4160},{"trials":4132,"activeCount":99},[],{"trials":4134,"activeCount":99},[],{"trials":4136,"activeCount":99},[4137,4144],{"nctId":4138,"briefTitle":4139,"status":107,"phases":4140,"primaryCompletion":824,"start":4141,"enrollment":3035,"conditions":4142,"interventions":4143},"NCT00003148","Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia",[88],"1997-10",[18],[1647],{"nctId":1938,"briefTitle":1939,"status":107,"phases":4145,"primaryCompletion":165,"start":1941,"enrollment":1588,"conditions":4146,"interventions":4147},[88],[826],[1647,227,257,173],{"trials":4149,"activeCount":99},[4150,4154],{"nctId":1639,"briefTitle":1640,"status":361,"phases":4151,"primaryCompletion":1642,"start":1643,"enrollment":1644,"conditions":4152,"interventions":4153},[89],[18],[1647,169,1579,115,151,152,174],{"nctId":3994,"briefTitle":3995,"status":107,"phases":4155,"primaryCompletion":110,"start":3997,"enrollment":2679,"conditions":4156,"interventions":4157},[89],[452],[1647,227,270],{"trials":4159,"activeCount":99},[],{"trials":4161,"activeCount":99},[],{"intervention":4163,"totalTrials":591,"cells":4164},"bicalutamide",{"EARLY_PHASE1":4165,"PHASE1":4167,"PHASE2":4169,"PHASE3":4180,"PHASE4":4208,"NA":4210},{"trials":4166,"activeCount":99},[],{"trials":4168,"activeCount":99},[],{"trials":4170,"activeCount":99},[4171],{"nctId":4172,"briefTitle":4173,"status":786,"phases":4174,"primaryCompletion":3019,"completion":4175,"start":302,"enrollment":99,"conditions":4176,"interventions":4177},"NCT01658527","TAK-700 in Castration Resistant Prostate Cancer",[88],"2017-01",[34],[4178,4179],"Orteronel","Bicalutamide",{"trials":4181,"activeCount":99},[4182,4192,4200],{"nctId":4183,"briefTitle":4184,"status":107,"phases":4185,"primaryCompletion":1870,"start":4186,"enrollment":4187,"conditions":4188,"interventions":4189},"NCT00003026","Hormone Therapy in Treating Patients With Advanced Prostate Cancer",[89],"1997-04",966,[34],[4163,4190,4191],"flutamide","triptorelin",{"nctId":4193,"briefTitle":4194,"status":188,"phases":4195,"primaryCompletion":4196,"start":283,"enrollment":804,"conditions":4197,"interventions":4198},"NCT00014586","Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer",[89],"2003-02",[34],[4163,4199],"goserelin acetate",{"nctId":4201,"briefTitle":4202,"status":107,"phases":4203,"primaryCompletion":4204,"completion":3019,"start":824,"enrollment":4205,"conditions":4206,"interventions":4207},"NCT00021450","Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer",[89],"2008-04",819,[34],[4163,4199],{"trials":4209,"activeCount":99},[],{"trials":4211,"activeCount":99},[],{"intervention":2635,"totalTrials":591,"cells":4213},{"EARLY_PHASE1":4214,"PHASE1":4216,"PHASE2":4218,"PHASE3":4228,"PHASE4":4238,"NA":4240},{"trials":4215,"activeCount":99},[],{"trials":4217,"activeCount":99},[],{"trials":4219,"activeCount":99},[4220,4224],{"nctId":2991,"briefTitle":2992,"status":107,"phases":4221,"primaryCompletion":2994,"start":1587,"conditions":4222,"interventions":4223},[88],[29],[270,2635,154,2967],{"nctId":2627,"briefTitle":2628,"status":107,"phases":4225,"primaryCompletion":2630,"start":2631,"conditions":4226,"interventions":4227},[88],[2633],[257,2635],{"trials":4229,"activeCount":99},[4230,4234],{"nctId":3008,"briefTitle":3009,"status":107,"phases":4231,"primaryCompletion":1894,"start":2678,"enrollment":3011,"conditions":4232,"interventions":4233},[89],[29],[3014,270,2635,154],{"nctId":3032,"briefTitle":3033,"status":107,"phases":4235,"primaryCompletion":123,"start":823,"enrollment":3035,"conditions":4236,"interventions":4237},[89],[29],[3014,955,3038,270,2635,154],{"trials":4239,"activeCount":99},[],{"trials":4241,"activeCount":99},[],{"intervention":1580,"totalTrials":591,"cells":4243},{"EARLY_PHASE1":4244,"PHASE1":4246,"PHASE2":4248,"PHASE3":4258,"PHASE4":4271,"NA":4273},{"trials":4245,"activeCount":99},[],{"trials":4247,"activeCount":99},[],{"trials":4249,"activeCount":99},[4250,4254],{"nctId":1711,"briefTitle":1712,"status":107,"phases":4251,"primaryCompletion":759,"start":1714,"enrollment":1715,"conditions":4252,"interventions":4253},[88],[18],[151,174,1580,1581,157],{"nctId":1571,"briefTitle":1572,"status":107,"phases":4255,"primaryCompletion":975,"start":1574,"enrollment":1575,"conditions":4256,"interventions":4257},[88],[18,1577],[1579,115,151,1580,1581],{"trials":4259,"activeCount":99},[4260,4264],{"nctId":1761,"briefTitle":1762,"status":107,"phases":4261,"primaryCompletion":1642,"completion":1764,"start":409,"enrollment":1765,"conditions":4262,"interventions":4263},[89],[18],[151,174,1580,1581,157],{"nctId":4265,"briefTitle":4266,"status":361,"phases":4267,"primaryCompletion":776,"start":1908,"enrollment":4268,"conditions":4269,"interventions":4270},"NCT00091234","Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia",[88,89],279,[18],[1580],{"trials":4272,"activeCount":99},[],{"trials":4274,"activeCount":99},[],{"intervention":114,"totalTrials":192,"cells":4276},{"EARLY_PHASE1":4277,"PHASE1":4279,"PHASE2":4281,"PHASE3":4287,"PHASE4":4297,"NA":4299},{"trials":4278,"activeCount":99},[],{"trials":4280,"activeCount":99},[],{"trials":4282,"activeCount":99},[4283],{"nctId":105,"briefTitle":106,"status":107,"phases":4284,"primaryCompletion":109,"start":110,"enrollment":19,"conditions":4285,"interventions":4286},[88],[21,112],[114,115,116,117,94,118],{"trials":4288,"activeCount":99},[4289,4293],{"nctId":131,"briefTitle":132,"status":107,"phases":4290,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":4291,"interventions":4292},[89],[21],[140,114,115,116,94,118],{"nctId":186,"briefTitle":187,"status":188,"phases":4294,"primaryCompletion":190,"start":191,"enrollment":192,"conditions":4295,"interventions":4296},[88,89],[21],[114,195,115,116,174,94,118],{"trials":4298,"activeCount":99},[],{"trials":4300,"activeCount":99},[],{"intervention":153,"totalTrials":192,"cells":4302},{"EARLY_PHASE1":4303,"PHASE1":4305,"PHASE2":4307,"PHASE3":4309,"PHASE4":4323,"NA":4325},{"trials":4304,"activeCount":99},[],{"trials":4306,"activeCount":99},[],{"trials":4308,"activeCount":99},[],{"trials":4310,"activeCount":99},[4311,4315,4319],{"nctId":142,"briefTitle":143,"status":107,"phases":4312,"primaryCompletion":145,"start":146,"enrollment":147,"conditions":4313,"interventions":4314},[89],[18,21],[150,115,151,152,153,116,154,155,156,157,158,94,159,118],{"nctId":1779,"briefTitle":1780,"status":107,"phases":4316,"primaryCompletion":489,"start":1782,"conditions":4317,"interventions":4318},[89],[18,1577],[151,152,153,174,1581,157,522],{"nctId":513,"briefTitle":514,"status":361,"phases":4320,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":4321,"interventions":4322},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":4324,"activeCount":99},[],{"trials":4326,"activeCount":99},[],{"intervention":155,"totalTrials":192,"cells":4328},{"EARLY_PHASE1":4329,"PHASE1":4331,"PHASE2":4333,"PHASE3":4335,"PHASE4":4349,"NA":4351},{"trials":4330,"activeCount":99},[],{"trials":4332,"activeCount":99},[],{"trials":4334,"activeCount":99},[],{"trials":4336,"activeCount":99},[4337,4341,4345],{"nctId":142,"briefTitle":143,"status":107,"phases":4338,"primaryCompletion":145,"start":146,"enrollment":147,"conditions":4339,"interventions":4340},[89],[18,21],[150,115,151,152,153,116,154,155,156,157,158,94,159,118],{"nctId":1621,"briefTitle":1622,"status":361,"phases":4342,"start":1624,"enrollment":1625,"conditions":4343,"interventions":4344},[89],[18],[1579,115,151,174,1581,155,156,157,522,1628],{"nctId":513,"briefTitle":514,"status":361,"phases":4346,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":4347,"interventions":4348},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":4350,"activeCount":99},[],{"trials":4352,"activeCount":99},[],{"intervention":158,"totalTrials":192,"cells":4354},{"EARLY_PHASE1":4355,"PHASE1":4357,"PHASE2":4359,"PHASE3":4361,"PHASE4":4375,"NA":4377},{"trials":4356,"activeCount":99},[],{"trials":4358,"activeCount":99},[],{"trials":4360,"activeCount":99},[],{"trials":4362,"activeCount":99},[4363,4367,4371],{"nctId":142,"briefTitle":143,"status":107,"phases":4364,"primaryCompletion":145,"start":146,"enrollment":147,"conditions":4365,"interventions":4366},[89],[18,21],[150,115,151,152,153,116,154,155,156,157,158,94,159,118],{"nctId":197,"briefTitle":198,"status":188,"phases":4368,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":4369,"interventions":4370},[89],[205],[207,207,208,209,210],{"nctId":513,"briefTitle":514,"status":361,"phases":4372,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":4373,"interventions":4374},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":4376,"activeCount":99},[],{"trials":4378,"activeCount":99},[],{"intervention":2569,"totalTrials":192,"cells":4380},{"EARLY_PHASE1":4381,"PHASE1":4383,"PHASE2":4389,"PHASE3":4395,"PHASE4":4404,"NA":4406},{"trials":4382,"activeCount":99},[],{"trials":4384,"activeCount":99},[4385],{"nctId":2960,"briefTitle":2961,"status":107,"phases":4386,"primaryCompletion":2963,"start":2964,"enrollment":2856,"conditions":4387,"interventions":4388},[87],[29],[2569,270,154,2967],{"trials":4390,"activeCount":99},[4391],{"nctId":2560,"briefTitle":2561,"status":107,"phases":4392,"primaryCompletion":2563,"completion":2564,"start":1057,"enrollment":2565,"conditions":4393,"interventions":4394},[88],[2567],[2569,257],{"trials":4396,"activeCount":99},[4397],{"nctId":4398,"briefTitle":4399,"status":786,"phases":4400,"enrollment":99,"conditions":4401,"interventions":4402},"NCT01386398","Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma",[89],[21],[2569,4403],"vorinostat",{"trials":4405,"activeCount":99},[],{"trials":4407,"activeCount":99},[],{"intervention":522,"totalTrials":192,"cells":4409},{"EARLY_PHASE1":4410,"PHASE1":4412,"PHASE2":4414,"PHASE3":4416,"PHASE4":4430,"NA":4432},{"trials":4411,"activeCount":99},[],{"trials":4413,"activeCount":99},[],{"trials":4415,"activeCount":99},[],{"trials":4417,"activeCount":99},[4418,4422,4426],{"nctId":1621,"briefTitle":1622,"status":361,"phases":4419,"start":1624,"enrollment":1625,"conditions":4420,"interventions":4421},[89],[18],[1579,115,151,174,1581,155,156,157,522,1628],{"nctId":1779,"briefTitle":1780,"status":107,"phases":4423,"primaryCompletion":489,"start":1782,"conditions":4424,"interventions":4425},[89],[18,1577],[151,152,153,174,1581,157,522],{"nctId":513,"briefTitle":514,"status":361,"phases":4427,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":4428,"interventions":4429},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":4431,"activeCount":99},[],{"trials":4433,"activeCount":99},[],{"intervention":2978,"totalTrials":192,"cells":4435},{"EARLY_PHASE1":4436,"PHASE1":4438,"PHASE2":4440,"PHASE3":4446,"PHASE4":4456,"NA":4458},{"trials":4437,"activeCount":99},[],{"trials":4439,"activeCount":99},[],{"trials":4441,"activeCount":99},[4442],{"nctId":2971,"briefTitle":2972,"status":188,"phases":4443,"primaryCompletion":346,"start":2974,"enrollment":2975,"conditions":4444,"interventions":4445},[88],[29,351],[935,2978,270,154,2967],{"trials":4447,"activeCount":99},[4448,4452],{"nctId":3025,"briefTitle":3026,"status":361,"phases":4449,"start":3028,"conditions":4450,"interventions":4451},[89],[29,351],[2978,270,154,2967],{"nctId":3040,"briefTitle":3041,"status":107,"phases":4453,"primaryCompletion":124,"start":3043,"enrollment":3044,"conditions":4454,"interventions":4455},[89],[29],[2978,270,154,2967],{"trials":4457,"activeCount":99},[],{"trials":4459,"activeCount":99},[],{"intervention":807,"totalTrials":192,"cells":4461},{"EARLY_PHASE1":4462,"PHASE1":4464,"PHASE2":4466,"PHASE3":4472,"PHASE4":4487,"NA":4489},{"trials":4463,"activeCount":99},[],{"trials":4465,"activeCount":99},[],{"trials":4467,"activeCount":99},[4468],{"nctId":799,"briefTitle":800,"status":107,"phases":4469,"primaryCompletion":802,"completion":803,"start":49,"enrollment":804,"conditions":4470,"interventions":4471},[88],[27],[807,808,54],{"trials":4473,"activeCount":99},[4474,4483],{"nctId":4475,"briefTitle":4476,"status":107,"phases":4477,"primaryCompletion":1714,"start":4478,"enrollment":4479,"conditions":4480,"interventions":4481},"NCT00002620","Radiation Therapy in Treating Patients With Brain Cancer",[89],"1994-11",212,[27],[807,3991,4482],"mitolactol",{"nctId":1769,"briefTitle":1770,"status":107,"phases":4484,"primaryCompletion":428,"start":1772,"enrollment":1773,"conditions":4485,"interventions":4486},[89],[18,1775],[169,1777,807,151,174,1581,157],{"trials":4488,"activeCount":99},[],{"trials":4490,"activeCount":99},[],{"intervention":4199,"totalTrials":192,"cells":4492},{"EARLY_PHASE1":4493,"PHASE1":4495,"PHASE2":4497,"PHASE3":4499,"PHASE4":4518,"NA":4520},{"trials":4494,"activeCount":99},[],{"trials":4496,"activeCount":99},[],{"trials":4498,"activeCount":99},[],{"trials":4500,"activeCount":99},[4501,4505,4509],{"nctId":4193,"briefTitle":4194,"status":188,"phases":4502,"primaryCompletion":4196,"start":283,"enrollment":804,"conditions":4503,"interventions":4504},[89],[34],[4163,4199],{"nctId":4201,"briefTitle":4202,"status":107,"phases":4506,"primaryCompletion":4204,"completion":3019,"start":824,"enrollment":4205,"conditions":4507,"interventions":4508},[89],[34],[4163,4199],{"nctId":4510,"briefTitle":4511,"status":107,"phases":4512,"primaryCompletion":4513,"start":4514,"conditions":4515,"interventions":4516},"NCT00849082","Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate Cancer",[89],"1995-11","1987-05",[34],[4517,4199],"cyproterone acetate",{"trials":4519,"activeCount":99},[],{"trials":4521,"activeCount":99},[],{"intervention":4523,"totalTrials":523,"cells":4524},"epoetin alfa",{"EARLY_PHASE1":4525,"PHASE1":4527,"PHASE2":4529,"PHASE3":4538,"PHASE4":4546,"NA":4548},{"trials":4526,"activeCount":99},[],{"trials":4528,"activeCount":99},[],{"trials":4530,"activeCount":99},[4531],{"nctId":4532,"briefTitle":4533,"status":361,"phases":4534,"start":1921,"enrollment":1018,"conditions":4535,"interventions":4537},"NCT00003681","Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome",[88],[4536,1577],"Anemia",[4523,1901],{"trials":4539,"activeCount":99},[4540],{"nctId":4541,"briefTitle":4542,"status":188,"phases":4543,"primaryCompletion":491,"start":976,"enrollment":2552,"conditions":4544,"interventions":4545},"NCT00017277","Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer",[89],[1897],[4523],{"trials":4547,"activeCount":99},[],{"trials":4549,"activeCount":99},[],{"intervention":4076,"totalTrials":523,"cells":4551},{"EARLY_PHASE1":4552,"PHASE1":4554,"PHASE2":4556,"PHASE3":4558,"PHASE4":4568,"NA":4570},{"trials":4553,"activeCount":99},[],{"trials":4555,"activeCount":99},[],{"trials":4557,"activeCount":99},[],{"trials":4559,"activeCount":99},[4560,4564],{"nctId":4070,"briefTitle":4071,"status":107,"phases":4561,"primaryCompletion":507,"start":1643,"enrollment":4073,"conditions":4562,"interventions":4563},[89],[24],[4053,4076],{"nctId":4078,"briefTitle":4079,"status":107,"phases":4565,"primaryCompletion":4081,"start":3043,"enrollment":1773,"conditions":4566,"interventions":4567},[89],[24],[4053,4076],{"trials":4569,"activeCount":99},[],{"trials":4571,"activeCount":99},[],{"intervention":1831,"totalTrials":523,"cells":4573},{"EARLY_PHASE1":4574,"PHASE1":4576,"PHASE2":4578,"PHASE3":4584,"PHASE4":4594,"NA":4596},{"trials":4575,"activeCount":99},[],{"trials":4577,"activeCount":99},[],{"trials":4579,"activeCount":99},[4580],{"nctId":1821,"briefTitle":1822,"status":107,"phases":4581,"primaryCompletion":1824,"completion":1825,"start":490,"enrollment":1826,"conditions":4582,"interventions":4583},[87,88],[1828,401,1829],[289,368,1831],{"trials":4585,"activeCount":99},[4586],{"nctId":4587,"briefTitle":4588,"status":188,"phases":4589,"primaryCompletion":464,"completion":464,"start":4590,"enrollment":4591,"conditions":4592,"interventions":4593},"NCT01208064","Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy",[88,89],"2011-07",102,[24],[1831],{"trials":4595,"activeCount":99},[],{"trials":4597,"activeCount":99},[],{"intervention":150,"totalTrials":523,"cells":4599},{"EARLY_PHASE1":4600,"PHASE1":4602,"PHASE2":4604,"PHASE3":4606,"PHASE4":4616,"NA":4618},{"trials":4601,"activeCount":99},[],{"trials":4603,"activeCount":99},[],{"trials":4605,"activeCount":99},[],{"trials":4607,"activeCount":99},[4608,4612],{"nctId":142,"briefTitle":143,"status":107,"phases":4609,"primaryCompletion":145,"start":146,"enrollment":147,"conditions":4610,"interventions":4611},[89],[18,21],[150,115,151,152,153,116,154,155,156,157,158,94,159,118],{"nctId":513,"briefTitle":514,"status":361,"phases":4613,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":4614,"interventions":4615},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":4617,"activeCount":99},[],{"trials":4619,"activeCount":99},[],{"intervention":159,"totalTrials":523,"cells":4621},{"EARLY_PHASE1":4622,"PHASE1":4624,"PHASE2":4626,"PHASE3":4628,"PHASE4":4638,"NA":4640},{"trials":4623,"activeCount":99},[],{"trials":4625,"activeCount":99},[],{"trials":4627,"activeCount":99},[],{"trials":4629,"activeCount":99},[4630,4634],{"nctId":142,"briefTitle":143,"status":107,"phases":4631,"primaryCompletion":145,"start":146,"enrollment":147,"conditions":4632,"interventions":4633},[89],[18,21],[150,115,151,152,153,116,154,155,156,157,158,94,159,118],{"nctId":513,"briefTitle":514,"status":361,"phases":4635,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":4636,"interventions":4637},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":4639,"activeCount":99},[],{"trials":4641,"activeCount":99},[],{"intervention":808,"totalTrials":523,"cells":4643},{"EARLY_PHASE1":4644,"PHASE1":4646,"PHASE2":4648,"PHASE3":4654,"PHASE4":4664,"NA":4666},{"trials":4645,"activeCount":99},[],{"trials":4647,"activeCount":99},[],{"trials":4649,"activeCount":99},[4650],{"nctId":799,"briefTitle":800,"status":107,"phases":4651,"primaryCompletion":802,"completion":803,"start":49,"enrollment":804,"conditions":4652,"interventions":4653},[88],[27],[807,808,54],{"trials":4655,"activeCount":99},[4656],{"nctId":4657,"briefTitle":4658,"status":107,"phases":4659,"primaryCompletion":2551,"start":4660,"enrollment":4661,"conditions":4662,"interventions":4663},"NCT00263822","Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer",[89],"2005-09",835,[1828,401,1829],[808],{"trials":4665,"activeCount":99},[],{"trials":4667,"activeCount":99},[],{"intervention":4669,"totalTrials":523,"cells":4670},"tamoxifen citrate",{"EARLY_PHASE1":4671,"PHASE1":4673,"PHASE2":4682,"PHASE3":4684,"PHASE4":4695,"NA":4697},{"trials":4672,"activeCount":99},[],{"trials":4674,"activeCount":99},[4675],{"nctId":4676,"briefTitle":4677,"status":107,"phases":4678,"primaryCompletion":721,"completion":4679,"start":975,"enrollment":30,"conditions":4680,"interventions":4681},"NCT00424164","Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer",[87],"2010-05-28",[15],[968,4669],{"trials":4683,"activeCount":99},[],{"trials":4685,"activeCount":99},[4686],{"nctId":4687,"briefTitle":4688,"status":107,"phases":4689,"primaryCompletion":1701,"start":4690,"enrollment":4691,"conditions":4692,"interventions":4693},"NCT00002777","Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer",[89],"1996-05",342,[15],[4694,4669],"exemestane",{"trials":4696,"activeCount":99},[],{"trials":4698,"activeCount":99},[],{"intervention":273,"totalTrials":523,"cells":4700},{"EARLY_PHASE1":4701,"PHASE1":4703,"PHASE2":4705,"PHASE3":4707,"PHASE4":4717,"NA":4719},{"trials":4702,"activeCount":99},[],{"trials":4704,"activeCount":99},[],{"trials":4706,"activeCount":99},[],{"trials":4708,"activeCount":99},[4709,4713],{"nctId":261,"briefTitle":262,"status":107,"phases":4710,"primaryCompletion":264,"start":265,"enrollment":266,"conditions":4711,"interventions":4712},[89],[268],[41,257,270,271,156,272,176,273],{"nctId":513,"briefTitle":514,"status":361,"phases":4714,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":4715,"interventions":4716},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":4718,"activeCount":99},[],{"trials":4720,"activeCount":99},[],{"intervention":3991,"totalTrials":523,"cells":4722},{"EARLY_PHASE1":4723,"PHASE1":4725,"PHASE2":4727,"PHASE3":4729,"PHASE4":4739,"NA":4741},{"trials":4724,"activeCount":99},[],{"trials":4726,"activeCount":99},[],{"trials":4728,"activeCount":99},[],{"trials":4730,"activeCount":99},[4731,4735],{"nctId":4475,"briefTitle":4476,"status":107,"phases":4732,"primaryCompletion":1714,"start":4478,"enrollment":4479,"conditions":4733,"interventions":4734},[89],[27],[807,3991,4482],{"nctId":3984,"briefTitle":3985,"status":107,"phases":4736,"primaryCompletion":283,"start":3987,"enrollment":3988,"conditions":4737,"interventions":4738},[89],[452],[227,3991,3992],{"trials":4740,"activeCount":99},[],{"trials":4742,"activeCount":99},[],{"intervention":170,"totalTrials":523,"cells":4744},{"EARLY_PHASE1":4745,"PHASE1":4747,"PHASE2":4749,"PHASE3":4751,"PHASE4":4761,"NA":4763},{"trials":4746,"activeCount":99},[],{"trials":4748,"activeCount":99},[],{"trials":4750,"activeCount":99},[],{"trials":4752,"activeCount":99},[4753,4757],{"nctId":161,"briefTitle":162,"status":107,"phases":4754,"primaryCompletion":164,"start":165,"enrollment":166,"conditions":4755,"interventions":4756},[89],[21],[41,169,170,171,172,115,173,116,174,94,175,176,118],{"nctId":486,"briefTitle":487,"status":107,"phases":4758,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":4759,"interventions":4760},[89],[32],[170,116,271],{"trials":4762,"activeCount":99},[],{"trials":4764,"activeCount":99},[],{"intervention":3014,"totalTrials":523,"cells":4766},{"EARLY_PHASE1":4767,"PHASE1":4769,"PHASE2":4771,"PHASE3":4773,"PHASE4":4783,"NA":4785},{"trials":4768,"activeCount":99},[],{"trials":4770,"activeCount":99},[],{"trials":4772,"activeCount":99},[],{"trials":4774,"activeCount":99},[4775,4779],{"nctId":3008,"briefTitle":3009,"status":107,"phases":4776,"primaryCompletion":1894,"start":2678,"enrollment":3011,"conditions":4777,"interventions":4778},[89],[29],[3014,270,2635,154],{"nctId":3032,"briefTitle":3033,"status":107,"phases":4780,"primaryCompletion":123,"start":823,"enrollment":3035,"conditions":4781,"interventions":4782},[89],[29],[3014,955,3038,270,2635,154],{"trials":4784,"activeCount":99},[],{"trials":4786,"activeCount":99},[],{"intervention":1676,"totalTrials":523,"cells":4788},{"EARLY_PHASE1":4789,"PHASE1":4791,"PHASE2":4793,"PHASE3":4799,"PHASE4":4805,"NA":4807},{"trials":4790,"activeCount":99},[],{"trials":4792,"activeCount":99},[],{"trials":4794,"activeCount":99},[4795],{"nctId":2872,"briefTitle":2873,"status":188,"phases":4796,"primaryCompletion":2875,"start":517,"enrollment":1798,"conditions":4797,"interventions":4798},[88],[18],[151,1676,1581],{"trials":4800,"activeCount":99},[4801],{"nctId":1670,"briefTitle":1671,"status":361,"phases":4802,"start":976,"conditions":4803,"interventions":4804},[89],[18],[1675,115,1676],{"trials":4806,"activeCount":99},[],{"trials":4808,"activeCount":99},[],{"intervention":4810,"totalTrials":523,"cells":4811},"decitabine",{"EARLY_PHASE1":4812,"PHASE1":4814,"PHASE2":4816,"PHASE3":4818,"PHASE4":4839,"NA":4841},{"trials":4813,"activeCount":99},[],{"trials":4815,"activeCount":99},[],{"trials":4817,"activeCount":99},[],{"trials":4819,"activeCount":99},[4820,4832],{"nctId":4821,"briefTitle":4822,"status":361,"phases":4823,"primaryCompletion":4824,"completion":4825,"start":4826,"enrollment":4827,"conditions":4828,"interventions":4830},"NCT02172872","\"InDACtion\" vs \"3+7\" Induction in AML",[89],"2022-03-07","2023-12","2014-11-28",606,[4829],"Acute Myeloid Leukemia (AML)",[4831,4810],"standard combination chemotherapy",{"nctId":4833,"briefTitle":4834,"status":361,"phases":4835,"primaryCompletion":516,"start":2974,"enrollment":1071,"conditions":4836,"interventions":4838},"NCT00043134","Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome",[89],[18,1577,4837],"Myelodysplastic\u002FMyeloproliferative Neoplasms",[4810],{"trials":4840,"activeCount":99},[],{"trials":4842,"activeCount":99},[],{"intervention":207,"totalTrials":523,"cells":4844},{"EARLY_PHASE1":4845,"PHASE1":4847,"PHASE2":4849,"PHASE3":4860,"PHASE4":4866,"NA":4868},{"trials":4846,"activeCount":99},[],{"trials":4848,"activeCount":99},[],{"trials":4850,"activeCount":99},[4851],{"nctId":4852,"briefTitle":4853,"status":786,"phases":4854,"primaryCompletion":4855,"start":4175,"enrollment":99,"conditions":4856,"interventions":4858},"NCT03005015","Lenvatinib in Second Line Endometrial Carcinoma",[88],"2020-07",[4857],"Endometrial Neoplasms",[4859,207],"Lenvatinib",{"trials":4861,"activeCount":99},[4862],{"nctId":197,"briefTitle":198,"status":188,"phases":4863,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":4864,"interventions":4865},[89],[205],[207,207,208,209,210],{"trials":4867,"activeCount":99},[],{"trials":4869,"activeCount":99},[],{"intervention":3648,"totalTrials":523,"cells":4871},{"EARLY_PHASE1":4872,"PHASE1":4874,"PHASE2":4876,"PHASE3":4882,"PHASE4":4888,"NA":4890},{"trials":4873,"activeCount":99},[],{"trials":4875,"activeCount":99},[],{"trials":4877,"activeCount":99},[4878],{"nctId":3637,"briefTitle":3638,"status":188,"phases":4879,"primaryCompletion":3640,"completion":3640,"start":463,"enrollment":3641,"conditions":4880,"interventions":4881},[88],[3643,3644,3645],[3647,754,3648],{"trials":4883,"activeCount":99},[4884],{"nctId":2838,"briefTitle":2839,"status":786,"phases":4885,"enrollment":99,"conditions":4886,"interventions":4887},[89],[1897],[2843,257,270],{"trials":4889,"activeCount":99},[],{"trials":4891,"activeCount":99},[],{"intervention":3038,"totalTrials":523,"cells":4893},{"EARLY_PHASE1":4894,"PHASE1":4896,"PHASE2":4898,"PHASE3":4900,"PHASE4":4910,"NA":4912},{"trials":4895,"activeCount":99},[],{"trials":4897,"activeCount":99},[],{"trials":4899,"activeCount":99},[],{"trials":4901,"activeCount":99},[4902,4906],{"nctId":3032,"briefTitle":3033,"status":107,"phases":4903,"primaryCompletion":123,"start":823,"enrollment":3035,"conditions":4904,"interventions":4905},[89],[29],[3014,955,3038,270,2635,154],{"nctId":3048,"briefTitle":3049,"status":107,"phases":4907,"primaryCompletion":2600,"start":145,"conditions":4908,"interventions":4909},[89],[29],[3038,270,154],{"trials":4911,"activeCount":99},[],{"trials":4913,"activeCount":99},[],{"intervention":4915,"totalTrials":523,"cells":4916},"caspofungin acetate",{"EARLY_PHASE1":4917,"PHASE1":4919,"PHASE2":4921,"PHASE3":4931,"PHASE4":4942,"NA":4944},{"trials":4918,"activeCount":99},[],{"trials":4920,"activeCount":99},[],{"trials":4922,"activeCount":99},[4923],{"nctId":4924,"briefTitle":4925,"status":107,"phases":4926,"primaryCompletion":282,"start":1860,"enrollment":4927,"conditions":4928,"interventions":4930},"NCT00110045","Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant",[88],171,[4929],"Cancer",[4915],{"trials":4932,"activeCount":99},[4933],{"nctId":4934,"briefTitle":4935,"status":107,"phases":4936,"primaryCompletion":4937,"completion":4937,"start":2564,"enrollment":4938,"conditions":4939,"interventions":4941},"NCT01288378","Empirical Versus Preemptive Antifungal Therapy",[89],"2019-04-04",556,[4940,18,1577],"Fungal Infection",[4915],{"trials":4943,"activeCount":99},[],{"trials":4945,"activeCount":99},[],{"intervention":484,"totalTrials":523,"cells":4947},{"EARLY_PHASE1":4948,"PHASE1":4950,"PHASE2":4952,"PHASE3":4954,"PHASE4":4969,"NA":4971},{"trials":4949,"activeCount":99},[],{"trials":4951,"activeCount":99},[],{"trials":4953,"activeCount":99},[],{"trials":4955,"activeCount":99},[4956,4965],{"nctId":4957,"briefTitle":4958,"status":188,"phases":4959,"primaryCompletion":4960,"start":123,"enrollment":4927,"conditions":4961,"interventions":4963},"NCT00110123","Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma",[89],"2011-06",[4962,351],"Intraocular Melanoma",[4964,484],"fotemustine",{"nctId":475,"briefTitle":476,"status":107,"phases":4966,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":4967,"interventions":4968},[89],[412,452,401,453,32],[169,116,271,484],{"trials":4970,"activeCount":99},[],{"trials":4972,"activeCount":99},[],{"intervention":2817,"totalTrials":523,"cells":4974},{"EARLY_PHASE1":4975,"PHASE1":4977,"PHASE2":4979,"PHASE3":4987,"PHASE4":4993,"NA":4995},{"trials":4976,"activeCount":99},[],{"trials":4978,"activeCount":99},[],{"trials":4980,"activeCount":99},[4981],{"nctId":4982,"briefTitle":4983,"status":107,"phases":4984,"primaryCompletion":1836,"start":222,"enrollment":19,"conditions":4985,"interventions":4986},"NCT00004254","Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed",[88],[2567],[2817],{"trials":4988,"activeCount":99},[4989],{"nctId":2810,"briefTitle":2811,"status":107,"phases":4990,"primaryCompletion":2813,"start":222,"enrollment":2814,"conditions":4991,"interventions":4992},[89],[2567],[257,2817],{"trials":4994,"activeCount":99},[],{"trials":4996,"activeCount":99},[],{"intervention":1777,"totalTrials":523,"cells":4998},{"EARLY_PHASE1":4999,"PHASE1":5001,"PHASE2":5003,"PHASE3":5005,"PHASE4":5015,"NA":5017},{"trials":5000,"activeCount":99},[],{"trials":5002,"activeCount":99},[],{"trials":5004,"activeCount":99},[],{"trials":5006,"activeCount":99},[5007,5011],{"nctId":1769,"briefTitle":1770,"status":107,"phases":5008,"primaryCompletion":428,"start":1772,"enrollment":1773,"conditions":5009,"interventions":5010},[89],[18,1775],[169,1777,807,151,174,1581,157],{"nctId":2936,"briefTitle":2937,"status":107,"phases":5012,"primaryCompletion":2939,"start":2940,"enrollment":2941,"conditions":5013,"interventions":5014},[89],[18],[2944,1777,151,152],{"trials":5016,"activeCount":99},[],{"trials":5018,"activeCount":99},[],{"intervention":140,"totalTrials":665,"cells":5020},{"EARLY_PHASE1":5021,"PHASE1":5023,"PHASE2":5025,"PHASE3":5027,"PHASE4":5033,"NA":5035},{"trials":5022,"activeCount":99},[],{"trials":5024,"activeCount":99},[],{"trials":5026,"activeCount":99},[],{"trials":5028,"activeCount":99},[5029],{"nctId":131,"briefTitle":132,"status":107,"phases":5030,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":5031,"interventions":5032},[89],[21],[140,114,115,116,94,118],{"trials":5034,"activeCount":99},[],{"trials":5036,"activeCount":99},[],{"intervention":2720,"totalTrials":665,"cells":5038},{"EARLY_PHASE1":5039,"PHASE1":5041,"PHASE2":5043,"PHASE3":5045,"PHASE4":5051,"NA":5053},{"trials":5040,"activeCount":99},[],{"trials":5042,"activeCount":99},[],{"trials":5044,"activeCount":99},[],{"trials":5046,"activeCount":99},[5047],{"nctId":2710,"briefTitle":2711,"status":361,"phases":5048,"primaryCompletion":2713,"completion":2714,"start":2715,"enrollment":2716,"conditions":5049,"interventions":5050},[89],[2718],[794,2720],{"trials":5052,"activeCount":99},[],{"trials":5054,"activeCount":99},[],{"intervention":5056,"totalTrials":665,"cells":5057},"Apalutamide",{"EARLY_PHASE1":5058,"PHASE1":5060,"PHASE2":5062,"PHASE3":5064,"PHASE4":5076,"NA":5078},{"trials":5059,"activeCount":99},[],{"trials":5061,"activeCount":99},[],{"trials":5063,"activeCount":99},[],{"trials":5065,"activeCount":99},[5066],{"nctId":5067,"briefTitle":5068,"status":786,"phases":5069,"primaryCompletion":5070,"completion":5070,"start":5071,"enrollment":99,"conditions":5072,"interventions":5073},"NCT03488810","Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer",[89],"2026-06-15","2020-03-10",[34],[5056,5074,5075],"Luteinising Hormone Releasing Hormone analog agonist","Non-steroidal anti-androgen",{"trials":5077,"activeCount":99},[],{"trials":5079,"activeCount":99},[],{"intervention":5074,"totalTrials":665,"cells":5081},{"EARLY_PHASE1":5082,"PHASE1":5084,"PHASE2":5086,"PHASE3":5088,"PHASE4":5094,"NA":5096},{"trials":5083,"activeCount":99},[],{"trials":5085,"activeCount":99},[],{"trials":5087,"activeCount":99},[],{"trials":5089,"activeCount":99},[5090],{"nctId":5067,"briefTitle":5068,"status":786,"phases":5091,"primaryCompletion":5070,"completion":5070,"start":5071,"enrollment":99,"conditions":5092,"interventions":5093},[89],[34],[5056,5074,5075],{"trials":5095,"activeCount":99},[],{"trials":5097,"activeCount":99},[],{"intervention":5075,"totalTrials":665,"cells":5099},{"EARLY_PHASE1":5100,"PHASE1":5102,"PHASE2":5104,"PHASE3":5106,"PHASE4":5112,"NA":5114},{"trials":5101,"activeCount":99},[],{"trials":5103,"activeCount":99},[],{"trials":5105,"activeCount":99},[],{"trials":5107,"activeCount":99},[5108],{"nctId":5067,"briefTitle":5068,"status":786,"phases":5109,"primaryCompletion":5070,"completion":5070,"start":5071,"enrollment":99,"conditions":5110,"interventions":5111},[89],[34],[5056,5074,5075],{"trials":5113,"activeCount":99},[],{"trials":5115,"activeCount":99},[],{"intervention":5117,"totalTrials":665,"cells":5118},"Telotristat Ethyl",{"EARLY_PHASE1":5119,"PHASE1":5121,"PHASE2":5123,"PHASE3":5125,"PHASE4":5138,"NA":5140},{"trials":5120,"activeCount":99},[],{"trials":5122,"activeCount":99},[],{"trials":5124,"activeCount":99},[],{"trials":5126,"activeCount":99},[5127],{"nctId":5128,"briefTitle":5129,"status":786,"phases":5130,"primaryCompletion":5131,"completion":5132,"start":927,"enrollment":99,"conditions":5133,"interventions":5136},"NCT04065165","Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome",[89],"2023-07","2027-10",[5134,5135],"Small Intestinal NET","Carcinoid Heart Disease",[5117,5137],"Lanreotide",{"trials":5139,"activeCount":99},[],{"trials":5141,"activeCount":99},[],{"intervention":5137,"totalTrials":665,"cells":5143},{"EARLY_PHASE1":5144,"PHASE1":5146,"PHASE2":5148,"PHASE3":5150,"PHASE4":5156,"NA":5158},{"trials":5145,"activeCount":99},[],{"trials":5147,"activeCount":99},[],{"trials":5149,"activeCount":99},[],{"trials":5151,"activeCount":99},[5152],{"nctId":5128,"briefTitle":5129,"status":786,"phases":5153,"primaryCompletion":5131,"completion":5132,"start":927,"enrollment":99,"conditions":5154,"interventions":5155},[89],[5134,5135],[5117,5137],{"trials":5157,"activeCount":99},[],{"trials":5159,"activeCount":99},[],{"intervention":1628,"totalTrials":665,"cells":5161},{"EARLY_PHASE1":5162,"PHASE1":5164,"PHASE2":5166,"PHASE3":5168,"PHASE4":5174,"NA":5176},{"trials":5163,"activeCount":99},[],{"trials":5165,"activeCount":99},[],{"trials":5167,"activeCount":99},[],{"trials":5169,"activeCount":99},[5170],{"nctId":1621,"briefTitle":1622,"status":361,"phases":5171,"start":1624,"enrollment":1625,"conditions":5172,"interventions":5173},[89],[18],[1579,115,151,174,1581,155,156,157,522,1628],{"trials":5175,"activeCount":99},[],{"trials":5177,"activeCount":99},[],{"intervention":1637,"totalTrials":665,"cells":5179},{"EARLY_PHASE1":5180,"PHASE1":5182,"PHASE2":5184,"PHASE3":5186,"PHASE4":5192,"NA":5194},{"trials":5181,"activeCount":99},[],{"trials":5183,"activeCount":99},[],{"trials":5185,"activeCount":99},[],{"trials":5187,"activeCount":99},[5188],{"nctId":1630,"briefTitle":1631,"status":361,"phases":5189,"start":223,"enrollment":1633,"conditions":5190,"interventions":5191},[89],[18,21,1635,1577],[1579,115,1581,1637],{"trials":5193,"activeCount":99},[],{"trials":5195,"activeCount":99},[],{"intervention":4482,"totalTrials":665,"cells":5197},{"EARLY_PHASE1":5198,"PHASE1":5200,"PHASE2":5202,"PHASE3":5204,"PHASE4":5210,"NA":5212},{"trials":5199,"activeCount":99},[],{"trials":5201,"activeCount":99},[],{"trials":5203,"activeCount":99},[],{"trials":5205,"activeCount":99},[5206],{"nctId":4475,"briefTitle":4476,"status":107,"phases":5207,"primaryCompletion":1714,"start":4478,"enrollment":4479,"conditions":5208,"interventions":5209},[89],[27],[807,3991,4482],{"trials":5211,"activeCount":99},[],{"trials":5213,"activeCount":99},[],{"intervention":1061,"totalTrials":665,"cells":5215},{"EARLY_PHASE1":5216,"PHASE1":5218,"PHASE2":5220,"PHASE3":5222,"PHASE4":5228,"NA":5230},{"trials":5217,"activeCount":99},[],{"trials":5219,"activeCount":99},[],{"trials":5221,"activeCount":99},[],{"trials":5223,"activeCount":99},[5224],{"nctId":1053,"briefTitle":1054,"status":107,"phases":5225,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":1058,"conditions":5226,"interventions":5227},[89],[15],[1061,1062,1042,1063],{"trials":5229,"activeCount":99},[],{"trials":5231,"activeCount":99},[],{"intervention":1062,"totalTrials":665,"cells":5233},{"EARLY_PHASE1":5234,"PHASE1":5236,"PHASE2":5238,"PHASE3":5240,"PHASE4":5246,"NA":5248},{"trials":5235,"activeCount":99},[],{"trials":5237,"activeCount":99},[],{"trials":5239,"activeCount":99},[],{"trials":5241,"activeCount":99},[5242],{"nctId":1053,"briefTitle":1054,"status":107,"phases":5243,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":1058,"conditions":5244,"interventions":5245},[89],[15],[1061,1062,1042,1063],{"trials":5247,"activeCount":99},[],{"trials":5249,"activeCount":99},[],{"intervention":1063,"totalTrials":665,"cells":5251},{"EARLY_PHASE1":5252,"PHASE1":5254,"PHASE2":5256,"PHASE3":5258,"PHASE4":5264,"NA":5266},{"trials":5253,"activeCount":99},[],{"trials":5255,"activeCount":99},[],{"trials":5257,"activeCount":99},[],{"trials":5259,"activeCount":99},[5260],{"nctId":1053,"briefTitle":1054,"status":107,"phases":5261,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":1058,"conditions":5262,"interventions":5263},[89],[15],[1061,1062,1042,1063],{"trials":5265,"activeCount":99},[],{"trials":5267,"activeCount":99},[],{"intervention":3992,"totalTrials":665,"cells":5269},{"EARLY_PHASE1":5270,"PHASE1":5272,"PHASE2":5274,"PHASE3":5276,"PHASE4":5282,"NA":5284},{"trials":5271,"activeCount":99},[],{"trials":5273,"activeCount":99},[],{"trials":5275,"activeCount":99},[],{"trials":5277,"activeCount":99},[5278],{"nctId":3984,"briefTitle":3985,"status":107,"phases":5279,"primaryCompletion":283,"start":3987,"enrollment":3988,"conditions":5280,"interventions":5281},[89],[452],[227,3991,3992],{"trials":5283,"activeCount":99},[],{"trials":5285,"activeCount":99},[],{"intervention":5287,"totalTrials":665,"cells":5288},"piperacillin sodium",{"EARLY_PHASE1":5289,"PHASE1":5291,"PHASE2":5293,"PHASE3":5295,"PHASE4":5312,"NA":5314},{"trials":5290,"activeCount":99},[],{"trials":5292,"activeCount":99},[],{"trials":5294,"activeCount":99},[],{"trials":5296,"activeCount":99},[5297],{"nctId":5298,"briefTitle":5299,"status":107,"phases":5300,"primaryCompletion":1714,"start":5301,"enrollment":5302,"conditions":5303,"interventions":5308},"NCT00003805","Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count",[89],"1997-11",859,[5304,5305,5306,18,21,1635,1577,3352,5307],"Bone Marrow Suppression","Fever, Sweats, and Hot Flashes","Infection","Unspecified Childhood Solid Tumor, Protocol Specific",[5287,5309,5310,5311],"piperacillin-tazobactam","tazobactam sodium","vancomycin",{"trials":5313,"activeCount":99},[],{"trials":5315,"activeCount":99},[],{"intervention":5309,"totalTrials":665,"cells":5317},{"EARLY_PHASE1":5318,"PHASE1":5320,"PHASE2":5322,"PHASE3":5324,"PHASE4":5330,"NA":5332},{"trials":5319,"activeCount":99},[],{"trials":5321,"activeCount":99},[],{"trials":5323,"activeCount":99},[],{"trials":5325,"activeCount":99},[5326],{"nctId":5298,"briefTitle":5299,"status":107,"phases":5327,"primaryCompletion":1714,"start":5301,"enrollment":5302,"conditions":5328,"interventions":5329},[89],[5304,5305,5306,18,21,1635,1577,3352,5307],[5287,5309,5310,5311],{"trials":5331,"activeCount":99},[],{"trials":5333,"activeCount":99},[],{"intervention":5310,"totalTrials":665,"cells":5335},{"EARLY_PHASE1":5336,"PHASE1":5338,"PHASE2":5340,"PHASE3":5342,"PHASE4":5348,"NA":5350},{"trials":5337,"activeCount":99},[],{"trials":5339,"activeCount":99},[],{"trials":5341,"activeCount":99},[],{"trials":5343,"activeCount":99},[5344],{"nctId":5298,"briefTitle":5299,"status":107,"phases":5345,"primaryCompletion":1714,"start":5301,"enrollment":5302,"conditions":5346,"interventions":5347},[89],[5304,5305,5306,18,21,1635,1577,3352,5307],[5287,5309,5310,5311],{"trials":5349,"activeCount":99},[],{"trials":5351,"activeCount":99},[],{"intervention":5311,"totalTrials":665,"cells":5353},{"EARLY_PHASE1":5354,"PHASE1":5356,"PHASE2":5358,"PHASE3":5360,"PHASE4":5366,"NA":5368},{"trials":5355,"activeCount":99},[],{"trials":5357,"activeCount":99},[],{"trials":5359,"activeCount":99},[],{"trials":5361,"activeCount":99},[5362],{"nctId":5298,"briefTitle":5299,"status":107,"phases":5363,"primaryCompletion":1714,"start":5301,"enrollment":5302,"conditions":5364,"interventions":5365},[89],[5304,5305,5306,18,21,1635,1577,3352,5307],[5287,5309,5310,5311],{"trials":5367,"activeCount":99},[],{"trials":5369,"activeCount":99},[],{"intervention":981,"totalTrials":665,"cells":5371},{"EARLY_PHASE1":5372,"PHASE1":5374,"PHASE2":5376,"PHASE3":5378,"PHASE4":5384,"NA":5386},{"trials":5373,"activeCount":99},[],{"trials":5375,"activeCount":99},[],{"trials":5377,"activeCount":99},[],{"trials":5379,"activeCount":99},[5380],{"nctId":972,"briefTitle":973,"status":107,"phases":5381,"primaryCompletion":975,"start":976,"enrollment":977,"conditions":5382,"interventions":5383},[89],[15],[169,115,980,217,270,981],{"trials":5385,"activeCount":99},[],{"trials":5387,"activeCount":99},[],{"intervention":4190,"totalTrials":665,"cells":5389},{"EARLY_PHASE1":5390,"PHASE1":5392,"PHASE2":5394,"PHASE3":5396,"PHASE4":5402,"NA":5404},{"trials":5391,"activeCount":99},[],{"trials":5393,"activeCount":99},[],{"trials":5395,"activeCount":99},[],{"trials":5397,"activeCount":99},[5398],{"nctId":4183,"briefTitle":4184,"status":107,"phases":5399,"primaryCompletion":1870,"start":4186,"enrollment":4187,"conditions":5400,"interventions":5401},[89],[34],[4163,4190,4191],{"trials":5403,"activeCount":99},[],{"trials":5405,"activeCount":99},[],{"intervention":4191,"totalTrials":665,"cells":5407},{"EARLY_PHASE1":5408,"PHASE1":5410,"PHASE2":5412,"PHASE3":5414,"PHASE4":5420,"NA":5422},{"trials":5409,"activeCount":99},[],{"trials":5411,"activeCount":99},[],{"trials":5413,"activeCount":99},[],{"trials":5415,"activeCount":99},[5416],{"nctId":4183,"briefTitle":4184,"status":107,"phases":5417,"primaryCompletion":1870,"start":4186,"enrollment":4187,"conditions":5418,"interventions":5419},[89],[34],[4163,4190,4191],{"trials":5421,"activeCount":99},[],{"trials":5423,"activeCount":99},[],{"intervention":1664,"totalTrials":665,"cells":5425},{"EARLY_PHASE1":5426,"PHASE1":5428,"PHASE2":5430,"PHASE3":5432,"PHASE4":5438,"NA":5440},{"trials":5427,"activeCount":99},[],{"trials":5429,"activeCount":99},[],{"trials":5431,"activeCount":99},[],{"trials":5433,"activeCount":99},[5434],{"nctId":1657,"briefTitle":1658,"status":361,"phases":5435,"start":1660,"enrollment":1661,"conditions":5436,"interventions":5437},[89],[18],[169,1579,115,151,152,174,1581,1664,157],{"trials":5439,"activeCount":99},[],{"trials":5441,"activeCount":99},[],{"intervention":5443,"totalTrials":665,"cells":5444},"lenalidomide",{"EARLY_PHASE1":5445,"PHASE1":5447,"PHASE2":5449,"PHASE3":5451,"PHASE4":5461,"NA":5463},{"trials":5446,"activeCount":99},[],{"trials":5448,"activeCount":99},[],{"trials":5450,"activeCount":99},[],{"trials":5452,"activeCount":99},[5453],{"nctId":5454,"briefTitle":5455,"status":188,"phases":5456,"primaryCompletion":5457,"completion":5457,"start":5458,"enrollment":3156,"conditions":5459,"interventions":5460},"NCT01098656","Lenalidomide Maintenance Post-debulking in Advanced CTCL",[89],"2013-09","2010-07",[21],[5443],{"trials":5462,"activeCount":99},[],{"trials":5464,"activeCount":99},[],{"intervention":5466,"totalTrials":665,"cells":5467},"liposomal amphotericin B",{"EARLY_PHASE1":5468,"PHASE1":5470,"PHASE2":5472,"PHASE3":5474,"PHASE4":5484,"NA":5486},{"trials":5469,"activeCount":99},[],{"trials":5471,"activeCount":99},[],{"trials":5473,"activeCount":99},[],{"trials":5475,"activeCount":99},[5476],{"nctId":5477,"briefTitle":5478,"status":107,"phases":5479,"primaryCompletion":823,"start":5480,"enrollment":5481,"conditions":5482,"interventions":5483},"NCT00003938","Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients",[89],"1999-06",115,[4929],[5466],{"trials":5485,"activeCount":99},[],{"trials":5487,"activeCount":99},[],{"intervention":4403,"totalTrials":665,"cells":5489},{"EARLY_PHASE1":5490,"PHASE1":5492,"PHASE2":5494,"PHASE3":5496,"PHASE4":5502,"NA":5504},{"trials":5491,"activeCount":99},[],{"trials":5493,"activeCount":99},[],{"trials":5495,"activeCount":99},[],{"trials":5497,"activeCount":99},[5498],{"nctId":4398,"briefTitle":4399,"status":786,"phases":5499,"enrollment":99,"conditions":5500,"interventions":5501},[89],[21],[2569,4403],{"trials":5503,"activeCount":99},[],{"trials":5505,"activeCount":99},[],{"intervention":4831,"totalTrials":665,"cells":5507},{"EARLY_PHASE1":5508,"PHASE1":5510,"PHASE2":5512,"PHASE3":5514,"PHASE4":5520,"NA":5522},{"trials":5509,"activeCount":99},[],{"trials":5511,"activeCount":99},[],{"trials":5513,"activeCount":99},[],{"trials":5515,"activeCount":99},[5516],{"nctId":4821,"briefTitle":4822,"status":361,"phases":5517,"primaryCompletion":4824,"completion":4825,"start":4826,"enrollment":4827,"conditions":5518,"interventions":5519},[89],[4829],[4831,4810],{"trials":5521,"activeCount":99},[],{"trials":5523,"activeCount":99},[],{"intervention":5525,"totalTrials":665,"cells":5526},"Modified FOLFOX6",{"EARLY_PHASE1":5527,"PHASE1":5529,"PHASE2":5531,"PHASE3":5533,"PHASE4":5544,"NA":5546},{"trials":5528,"activeCount":99},[],{"trials":5530,"activeCount":99},[],{"trials":5532,"activeCount":99},[],{"trials":5534,"activeCount":99},[5535],{"nctId":5536,"briefTitle":5537,"status":786,"phases":5538,"primaryCompletion":5539,"completion":3304,"start":2890,"enrollment":99,"conditions":5540,"interventions":5542},"NCT01646554","Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases",[88,89],"2015-12",[3643,3644,5541],"KRAS Mutated Colorectal Cancer",[5525,5543],"Aflibercept",{"trials":5545,"activeCount":99},[],{"trials":5547,"activeCount":99},[],{"intervention":5543,"totalTrials":665,"cells":5549},{"EARLY_PHASE1":5550,"PHASE1":5552,"PHASE2":5554,"PHASE3":5556,"PHASE4":5562,"NA":5564},{"trials":5551,"activeCount":99},[],{"trials":5553,"activeCount":99},[],{"trials":5555,"activeCount":99},[],{"trials":5557,"activeCount":99},[5558],{"nctId":5536,"briefTitle":5537,"status":786,"phases":5559,"primaryCompletion":5539,"completion":3304,"start":2890,"enrollment":99,"conditions":5560,"interventions":5561},[88,89],[3643,3644,5541],[5525,5543],{"trials":5563,"activeCount":99},[],{"trials":5565,"activeCount":99},[],{"intervention":4517,"totalTrials":665,"cells":5567},{"EARLY_PHASE1":5568,"PHASE1":5570,"PHASE2":5572,"PHASE3":5574,"PHASE4":5580,"NA":5582},{"trials":5569,"activeCount":99},[],{"trials":5571,"activeCount":99},[],{"trials":5573,"activeCount":99},[],{"trials":5575,"activeCount":99},[5576],{"nctId":4510,"briefTitle":4511,"status":107,"phases":5577,"primaryCompletion":4513,"start":4514,"conditions":5578,"interventions":5579},[89],[34],[4517,4199],{"trials":5581,"activeCount":99},[],{"trials":5583,"activeCount":99},[],{"intervention":5585,"totalTrials":665,"cells":5586},"fulvestrant",{"EARLY_PHASE1":5587,"PHASE1":5589,"PHASE2":5591,"PHASE3":5593,"PHASE4":5601,"NA":5603},{"trials":5588,"activeCount":99},[],{"trials":5590,"activeCount":99},[],{"trials":5592,"activeCount":99},[],{"trials":5594,"activeCount":99},[5595],{"nctId":5596,"briefTitle":5597,"status":188,"phases":5598,"primaryCompletion":304,"start":251,"conditions":5599,"interventions":5600},"NCT00010153","ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer",[89],[15],[5585],{"trials":5602,"activeCount":99},[],{"trials":5604,"activeCount":99},[],{"intervention":839,"totalTrials":665,"cells":5606},{"EARLY_PHASE1":5607,"PHASE1":5609,"PHASE2":5611,"PHASE3":5613,"PHASE4":5619,"NA":5621},{"trials":5608,"activeCount":99},[],{"trials":5610,"activeCount":99},[],{"trials":5612,"activeCount":99},[],{"trials":5614,"activeCount":99},[5615],{"nctId":829,"briefTitle":830,"status":107,"phases":5616,"primaryCompletion":832,"completion":833,"start":834,"enrollment":835,"conditions":5617,"interventions":5618},[89],[837],[839,716],{"trials":5620,"activeCount":99},[],{"trials":5622,"activeCount":99},[],{"intervention":5624,"totalTrials":665,"cells":5625},"antiandrogen therapy",{"EARLY_PHASE1":5626,"PHASE1":5628,"PHASE2":5630,"PHASE3":5632,"PHASE4":5643,"NA":5645},{"trials":5627,"activeCount":99},[],{"trials":5629,"activeCount":99},[],{"trials":5631,"activeCount":99},[],{"trials":5633,"activeCount":99},[5634],{"nctId":5635,"briefTitle":5636,"status":188,"phases":5637,"primaryCompletion":5539,"completion":5638,"start":778,"enrollment":5639,"conditions":5640,"interventions":5641},"NCT00949962","Post-operative or Early Salvage XRT and ADT for High Risk PCa",[89],"2016-06",87,[34],[5624,5642],"leuprolide acetate",{"trials":5644,"activeCount":99},[],{"trials":5646,"activeCount":99},[],{"intervention":5642,"totalTrials":665,"cells":5648},{"EARLY_PHASE1":5649,"PHASE1":5651,"PHASE2":5653,"PHASE3":5655,"PHASE4":5661,"NA":5663},{"trials":5650,"activeCount":99},[],{"trials":5652,"activeCount":99},[],{"trials":5654,"activeCount":99},[],{"trials":5656,"activeCount":99},[5657],{"nctId":5635,"briefTitle":5636,"status":188,"phases":5658,"primaryCompletion":5539,"completion":5638,"start":778,"enrollment":5639,"conditions":5659,"interventions":5660},[89],[34],[5624,5642],{"trials":5662,"activeCount":99},[],{"trials":5664,"activeCount":99},[],{"intervention":4964,"totalTrials":665,"cells":5666},{"EARLY_PHASE1":5667,"PHASE1":5669,"PHASE2":5671,"PHASE3":5673,"PHASE4":5679,"NA":5681},{"trials":5668,"activeCount":99},[],{"trials":5670,"activeCount":99},[],{"trials":5672,"activeCount":99},[],{"trials":5674,"activeCount":99},[5675],{"nctId":4957,"briefTitle":4958,"status":188,"phases":5676,"primaryCompletion":4960,"start":123,"enrollment":4927,"conditions":5677,"interventions":5678},[89],[4962,351],[4964,484],{"trials":5680,"activeCount":99},[],{"trials":5682,"activeCount":99},[],{"intervention":5684,"totalTrials":665,"cells":5685},"amphotericin B deoxycholate",{"EARLY_PHASE1":5686,"PHASE1":5688,"PHASE2":5690,"PHASE3":5692,"PHASE4":5703,"NA":5705},{"trials":5687,"activeCount":99},[],{"trials":5689,"activeCount":99},[],{"trials":5691,"activeCount":99},[],{"trials":5693,"activeCount":99},[5694],{"nctId":5695,"briefTitle":5696,"status":107,"phases":5697,"primaryCompletion":2776,"start":5698,"enrollment":4479,"conditions":5699,"interventions":5701},"NCT00003031","Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis",[89],"1997-06",[5306,5700],"Pulmonary Complications",[5684,5702],"voriconazole",{"trials":5704,"activeCount":99},[],{"trials":5706,"activeCount":99},[],{"intervention":5702,"totalTrials":665,"cells":5708},{"EARLY_PHASE1":5709,"PHASE1":5711,"PHASE2":5713,"PHASE3":5715,"PHASE4":5721,"NA":5723},{"trials":5710,"activeCount":99},[],{"trials":5712,"activeCount":99},[],{"trials":5714,"activeCount":99},[],{"trials":5716,"activeCount":99},[5717],{"nctId":5695,"briefTitle":5696,"status":107,"phases":5718,"primaryCompletion":2776,"start":5698,"enrollment":4479,"conditions":5719,"interventions":5720},[89],[5306,5700],[5684,5702],{"trials":5722,"activeCount":99},[],{"trials":5724,"activeCount":99},[],{"intervention":195,"totalTrials":665,"cells":5726},{"EARLY_PHASE1":5727,"PHASE1":5729,"PHASE2":5731,"PHASE3":5733,"PHASE4":5739,"NA":5741},{"trials":5728,"activeCount":99},[],{"trials":5730,"activeCount":99},[],{"trials":5732,"activeCount":99},[],{"trials":5734,"activeCount":99},[5735],{"nctId":186,"briefTitle":187,"status":188,"phases":5736,"primaryCompletion":190,"start":191,"enrollment":192,"conditions":5737,"interventions":5738},[88,89],[21],[114,195,115,116,174,94,118],{"trials":5740,"activeCount":99},[],{"trials":5742,"activeCount":99},[],{"intervention":5744,"totalTrials":665,"cells":5745},"bexarotene",{"EARLY_PHASE1":5746,"PHASE1":5748,"PHASE2":5750,"PHASE3":5752,"PHASE4":5762,"NA":5764},{"trials":5747,"activeCount":99},[],{"trials":5749,"activeCount":99},[],{"trials":5751,"activeCount":99},[],{"trials":5753,"activeCount":99},[5754],{"nctId":5755,"briefTitle":5756,"status":188,"phases":5757,"primaryCompletion":489,"completion":4960,"start":2813,"enrollment":5758,"conditions":5759,"interventions":5760},"NCT00056056","Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides",[89],93,[21],[5744,5761],"methoxypsoralen",{"trials":5763,"activeCount":99},[],{"trials":5765,"activeCount":99},[],{"intervention":5761,"totalTrials":665,"cells":5767},{"EARLY_PHASE1":5768,"PHASE1":5770,"PHASE2":5772,"PHASE3":5774,"PHASE4":5780,"NA":5782},{"trials":5769,"activeCount":99},[],{"trials":5771,"activeCount":99},[],{"trials":5773,"activeCount":99},[],{"trials":5775,"activeCount":99},[5776],{"nctId":5755,"briefTitle":5756,"status":188,"phases":5777,"primaryCompletion":489,"completion":4960,"start":2813,"enrollment":5758,"conditions":5778,"interventions":5779},[89],[21],[5744,5761],{"trials":5781,"activeCount":99},[],{"trials":5783,"activeCount":99},[],{"intervention":5785,"totalTrials":665,"cells":5786},"ABVD + FDG-PET\u002FCT Scan treatment adaptation",{"EARLY_PHASE1":5787,"PHASE1":5789,"PHASE2":5791,"PHASE3":5793,"PHASE4":5805,"NA":5807},{"trials":5788,"activeCount":99},[],{"trials":5790,"activeCount":99},[],{"trials":5792,"activeCount":99},[],{"trials":5794,"activeCount":99},[5795],{"nctId":5796,"briefTitle":5797,"status":786,"phases":5798,"primaryCompletion":5799,"completion":5799,"start":5800,"enrollment":99,"conditions":5801,"interventions":5803},"NCT01652261","Very Early FDG-PET\u002FCT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)",[89],"2014-10","2013-05",[5802],"Hodgkin Lymphoma",[5785,5804],"BEACOPPesc",{"trials":5806,"activeCount":99},[],{"trials":5808,"activeCount":99},[],{"intervention":5804,"totalTrials":665,"cells":5810},{"EARLY_PHASE1":5811,"PHASE1":5813,"PHASE2":5815,"PHASE3":5817,"PHASE4":5823,"NA":5825},{"trials":5812,"activeCount":99},[],{"trials":5814,"activeCount":99},[],{"trials":5816,"activeCount":99},[],{"trials":5818,"activeCount":99},[5819],{"nctId":5796,"briefTitle":5797,"status":786,"phases":5820,"primaryCompletion":5799,"completion":5799,"start":5800,"enrollment":99,"conditions":5821,"interventions":5822},[89],[5802],[5785,5804],{"trials":5824,"activeCount":99},[],{"trials":5826,"activeCount":99},[],{"intervention":5828,"totalTrials":665,"cells":5829},"GM2-KLH vaccine",{"EARLY_PHASE1":5830,"PHASE1":5832,"PHASE2":5834,"PHASE3":5836,"PHASE4":5845,"NA":5847},{"trials":5831,"activeCount":99},[],{"trials":5833,"activeCount":99},[],{"trials":5835,"activeCount":99},[],{"trials":5837,"activeCount":99},[5838],{"nctId":5839,"briefTitle":5840,"status":361,"phases":5841,"start":264,"conditions":5842,"interventions":5843},"NCT00005052","Vaccine Therapy in Treating Patients With Primary Stage II Melanoma",[89],[826],[5828,5844],"QS21",{"trials":5846,"activeCount":99},[],{"trials":5848,"activeCount":99},[],{"intervention":5844,"totalTrials":665,"cells":5850},{"EARLY_PHASE1":5851,"PHASE1":5853,"PHASE2":5855,"PHASE3":5857,"PHASE4":5863,"NA":5865},{"trials":5852,"activeCount":99},[],{"trials":5854,"activeCount":99},[],{"trials":5856,"activeCount":99},[],{"trials":5858,"activeCount":99},[5859],{"nctId":5839,"briefTitle":5840,"status":361,"phases":5860,"start":264,"conditions":5861,"interventions":5862},[89],[826],[5828,5844],{"trials":5864,"activeCount":99},[],{"trials":5866,"activeCount":99},[],{"intervention":2944,"totalTrials":665,"cells":5868},{"EARLY_PHASE1":5869,"PHASE1":5871,"PHASE2":5873,"PHASE3":5875,"PHASE4":5881,"NA":5883},{"trials":5870,"activeCount":99},[],{"trials":5872,"activeCount":99},[],{"trials":5874,"activeCount":99},[],{"trials":5876,"activeCount":99},[5877],{"nctId":2936,"briefTitle":2937,"status":107,"phases":5878,"primaryCompletion":2939,"start":2940,"enrollment":2941,"conditions":5879,"interventions":5880},[89],[18],[2944,1777,151,152],{"trials":5882,"activeCount":99},[],{"trials":5884,"activeCount":99},[],{"intervention":208,"totalTrials":665,"cells":5886},{"EARLY_PHASE1":5887,"PHASE1":5889,"PHASE2":5891,"PHASE3":5893,"PHASE4":5899,"NA":5901},{"trials":5888,"activeCount":99},[],{"trials":5890,"activeCount":99},[],{"trials":5892,"activeCount":99},[],{"trials":5894,"activeCount":99},[5895],{"nctId":197,"briefTitle":198,"status":188,"phases":5896,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":5897,"interventions":5898},[89],[205],[207,207,208,209,210],{"trials":5900,"activeCount":99},[],{"trials":5902,"activeCount":99},[],{"intervention":1675,"totalTrials":665,"cells":5904},{"EARLY_PHASE1":5905,"PHASE1":5907,"PHASE2":5909,"PHASE3":5911,"PHASE4":5917,"NA":5919},{"trials":5906,"activeCount":99},[],{"trials":5908,"activeCount":99},[],{"trials":5910,"activeCount":99},[],{"trials":5912,"activeCount":99},[5913],{"nctId":1670,"briefTitle":1671,"status":361,"phases":5914,"start":976,"conditions":5915,"interventions":5916},[89],[18],[1675,115,1676],{"trials":5918,"activeCount":99},[],{"trials":5920,"activeCount":99},[],{"intervention":5922,"totalTrials":665,"cells":5923},"MART-1 antigen",{"EARLY_PHASE1":5924,"PHASE1":5926,"PHASE2":5928,"PHASE3":5930,"PHASE4":5941,"NA":5943},{"trials":5925,"activeCount":99},[],{"trials":5927,"activeCount":99},[],{"trials":5929,"activeCount":99},[],{"trials":5931,"activeCount":99},[5932],{"nctId":5933,"briefTitle":5934,"status":188,"phases":5935,"primaryCompletion":4196,"start":1587,"enrollment":1798,"conditions":5936,"interventions":5937},"NCT00036816","Vaccine Therapy in Treating Patients With Melanoma of the Eye",[89],[4962],[5922,5938,5939,5940],"NA17-A antigen","gp100 antigen","tyrosinase peptide",{"trials":5942,"activeCount":99},[],{"trials":5944,"activeCount":99},[],{"intervention":5938,"totalTrials":665,"cells":5946},{"EARLY_PHASE1":5947,"PHASE1":5949,"PHASE2":5951,"PHASE3":5953,"PHASE4":5959,"NA":5961},{"trials":5948,"activeCount":99},[],{"trials":5950,"activeCount":99},[],{"trials":5952,"activeCount":99},[],{"trials":5954,"activeCount":99},[5955],{"nctId":5933,"briefTitle":5934,"status":188,"phases":5956,"primaryCompletion":4196,"start":1587,"enrollment":1798,"conditions":5957,"interventions":5958},[89],[4962],[5922,5938,5939,5940],{"trials":5960,"activeCount":99},[],{"trials":5962,"activeCount":99},[],{"intervention":5939,"totalTrials":665,"cells":5964},{"EARLY_PHASE1":5965,"PHASE1":5967,"PHASE2":5969,"PHASE3":5971,"PHASE4":5977,"NA":5979},{"trials":5966,"activeCount":99},[],{"trials":5968,"activeCount":99},[],{"trials":5970,"activeCount":99},[],{"trials":5972,"activeCount":99},[5973],{"nctId":5933,"briefTitle":5934,"status":188,"phases":5974,"primaryCompletion":4196,"start":1587,"enrollment":1798,"conditions":5975,"interventions":5976},[89],[4962],[5922,5938,5939,5940],{"trials":5978,"activeCount":99},[],{"trials":5980,"activeCount":99},[],{"intervention":5940,"totalTrials":665,"cells":5982},{"EARLY_PHASE1":5983,"PHASE1":5985,"PHASE2":5987,"PHASE3":5989,"PHASE4":5995,"NA":5997},{"trials":5984,"activeCount":99},[],{"trials":5986,"activeCount":99},[],{"trials":5988,"activeCount":99},[],{"trials":5990,"activeCount":99},[5991],{"nctId":5933,"briefTitle":5934,"status":188,"phases":5992,"primaryCompletion":4196,"start":1587,"enrollment":1798,"conditions":5993,"interventions":5994},[89],[4962],[5922,5938,5939,5940],{"trials":5996,"activeCount":99},[],{"trials":5998,"activeCount":99},[],{"intervention":6000,"totalTrials":665,"cells":6001},"PEG IFN alfa-2b",{"EARLY_PHASE1":6002,"PHASE1":6004,"PHASE2":6006,"PHASE3":6008,"PHASE4":6020,"NA":6022},{"trials":6003,"activeCount":99},[],{"trials":6005,"activeCount":99},[],{"trials":6007,"activeCount":99},[],{"trials":6009,"activeCount":99},[6010],{"nctId":6011,"briefTitle":6012,"status":361,"phases":6013,"primaryCompletion":6014,"completion":6014,"start":6015,"enrollment":6016,"conditions":6017,"interventions":6019},"NCT01502696","Adjuvant PEG Intron in Ulcerated Melanoma",[89],"2019-04","2012-10",1200,[6018],"Ulcerated Melanomas",[6000],{"trials":6021,"activeCount":99},[],{"trials":6023,"activeCount":99},[],{"intervention":6025,"totalTrials":665,"cells":6026},"pegylated interferon alfa",{"EARLY_PHASE1":6027,"PHASE1":6029,"PHASE2":6031,"PHASE3":6033,"PHASE4":6042,"NA":6044},{"trials":6028,"activeCount":99},[],{"trials":6030,"activeCount":99},[],{"trials":6032,"activeCount":99},[],{"trials":6034,"activeCount":99},[6035],{"nctId":6036,"briefTitle":6037,"status":361,"phases":6038,"primaryCompletion":1808,"start":1714,"enrollment":6039,"conditions":6040,"interventions":6041},"NCT00006249","Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma",[89],1258,[826],[6025],{"trials":6043,"activeCount":99},[],{"trials":6045,"activeCount":99},[],{"intervention":6047,"totalTrials":665,"cells":6048},"ABVD q4 weeks",{"EARLY_PHASE1":6049,"PHASE1":6051,"PHASE2":6053,"PHASE3":6055,"PHASE4":6066,"NA":6068},{"trials":6050,"activeCount":99},[],{"trials":6052,"activeCount":99},[],{"trials":6054,"activeCount":99},[],{"trials":6056,"activeCount":99},[6057],{"nctId":6058,"briefTitle":6059,"status":361,"phases":6060,"primaryCompletion":6061,"start":398,"enrollment":6062,"conditions":6063,"interventions":6064},"NCT00433433","Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma",[89],"2011-12",1952,[21],[6047,6065],"BEACOPP escalated q3 weeks",{"trials":6067,"activeCount":99},[],{"trials":6069,"activeCount":99},[],{"intervention":6065,"totalTrials":665,"cells":6071},{"EARLY_PHASE1":6072,"PHASE1":6074,"PHASE2":6076,"PHASE3":6078,"PHASE4":6084,"NA":6086},{"trials":6073,"activeCount":99},[],{"trials":6075,"activeCount":99},[],{"trials":6077,"activeCount":99},[],{"trials":6079,"activeCount":99},[6080],{"nctId":6058,"briefTitle":6059,"status":361,"phases":6081,"primaryCompletion":6061,"start":398,"enrollment":6062,"conditions":6082,"interventions":6083},[89],[21],[6047,6065],{"trials":6085,"activeCount":99},[],{"trials":6087,"activeCount":99},[],{"intervention":4694,"totalTrials":665,"cells":6089},{"EARLY_PHASE1":6090,"PHASE1":6092,"PHASE2":6094,"PHASE3":6096,"PHASE4":6102,"NA":6104},{"trials":6091,"activeCount":99},[],{"trials":6093,"activeCount":99},[],{"trials":6095,"activeCount":99},[],{"trials":6097,"activeCount":99},[6098],{"nctId":4687,"briefTitle":4688,"status":107,"phases":6099,"primaryCompletion":1701,"start":4690,"enrollment":4691,"conditions":6100,"interventions":6101},[89],[15],[4694,4669],{"trials":6103,"activeCount":99},[],{"trials":6105,"activeCount":99},[],{"intervention":521,"totalTrials":665,"cells":6107},{"EARLY_PHASE1":6108,"PHASE1":6110,"PHASE2":6112,"PHASE3":6114,"PHASE4":6120,"NA":6122},{"trials":6109,"activeCount":99},[],{"trials":6111,"activeCount":99},[],{"trials":6113,"activeCount":99},[],{"trials":6115,"activeCount":99},[6116],{"nctId":513,"briefTitle":514,"status":361,"phases":6117,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":6118,"interventions":6119},[89],[18,21],[150,115,151,152,153,116,174,154,155,156,521,157,158,159,522,118,273],{"trials":6121,"activeCount":99},[],{"trials":6123,"activeCount":99},[],{"intervention":968,"totalTrials":591,"cells":6125},{"EARLY_PHASE1":6126,"PHASE1":6128,"PHASE2":6138,"PHASE3":6148,"PHASE4":6150,"NA":6152},{"trials":6127,"activeCount":99},[],{"trials":6129,"activeCount":99},[6130,6134],{"nctId":4676,"briefTitle":4677,"status":107,"phases":6131,"primaryCompletion":721,"completion":4679,"start":975,"enrollment":30,"conditions":6132,"interventions":6133},[87],[15],[968,4669],{"nctId":2534,"briefTitle":2535,"status":107,"phases":6135,"primaryCompletion":479,"completion":2537,"start":767,"enrollment":1554,"conditions":6136,"interventions":6137},[87],[255,286],[257,117,968],{"trials":6139,"activeCount":99},[6140,6144],{"nctId":2571,"briefTitle":2572,"status":107,"phases":6141,"primaryCompletion":699,"completion":2574,"start":2575,"enrollment":320,"conditions":6142,"interventions":6143},[87,88],[1897],[289,257,980,270,968,2578,2556,2579,2580,2558],{"nctId":959,"briefTitle":960,"status":188,"phases":6145,"primaryCompletion":863,"completion":962,"start":963,"enrollment":740,"conditions":6146,"interventions":6147},[88],[965,966],[955,257,217,270,968],{"trials":6149,"activeCount":99},[],{"trials":6151,"activeCount":99},[],{"trials":6153,"activeCount":99},[],{"intervention":6155,"totalTrials":591,"cells":6156},"rubitecan",{"EARLY_PHASE1":6157,"PHASE1":6159,"PHASE2":6161,"PHASE3":6188,"PHASE4":6190,"NA":6192},{"trials":6158,"activeCount":99},[],{"trials":6160,"activeCount":99},[],{"trials":6162,"activeCount":99},[6163,6170,6176,6182],{"nctId":6164,"briefTitle":6165,"status":107,"phases":6166,"primaryCompletion":491,"start":45,"enrollment":6167,"conditions":6168,"interventions":6169},"NCT00006230","Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer",[88],51,[401],[6155],{"nctId":6171,"briefTitle":6172,"status":107,"phases":6173,"primaryCompletion":3028,"start":738,"enrollment":689,"conditions":6174,"interventions":6175},"NCT00005826","Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme",[88],[27],[6155],{"nctId":6177,"briefTitle":6178,"status":107,"phases":6179,"primaryCompletion":165,"start":45,"enrollment":2741,"conditions":6180,"interventions":6181},"NCT00006082","Nitrocamptothecin in Treating Patients With Advanced Small Cell Lung Cancer",[88],[24],[6155],{"nctId":6183,"briefTitle":6184,"status":107,"phases":6185,"primaryCompletion":304,"start":45,"enrollment":3156,"conditions":6186,"interventions":6187},"NCT00006026","Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract",[88],[255,286,287],[6155],{"trials":6189,"activeCount":99},[],{"trials":6191,"activeCount":99},[],{"trials":6193,"activeCount":99},[],{"intervention":3310,"totalTrials":591,"cells":6195},{"EARLY_PHASE1":6196,"PHASE1":6198,"PHASE2":6200,"PHASE3":6230,"PHASE4":6232,"NA":6234},{"trials":6197,"activeCount":99},[],{"trials":6199,"activeCount":99},[],{"trials":6201,"activeCount":99},[6202,6211,6215,6219],{"nctId":6203,"briefTitle":6204,"status":107,"phases":6205,"primaryCompletion":6206,"completion":6206,"start":864,"enrollment":2983,"conditions":6207,"interventions":6210},"NCT01788982","Nintedanib(BIBF1120) in Thyroid Cancer",[88],"2019-08-28",[6208,6209],"Medullary Thyroid Cancer (MTC)","Differentiated Thyroid Cancer (DTC)",[3310],{"nctId":3300,"briefTitle":3301,"status":786,"phases":6212,"primaryCompletion":3303,"start":3304,"enrollment":99,"conditions":6213,"interventions":6214},[88],[3306,3307,3308],[3310,3311,3312,796],{"nctId":3474,"briefTitle":3475,"status":188,"phases":6216,"primaryCompletion":3477,"completion":3478,"start":3479,"enrollment":1749,"conditions":6217,"interventions":6218},[88],[3481],[3310,3483],{"nctId":6220,"briefTitle":6221,"status":188,"phases":6222,"primaryCompletion":6223,"completion":6224,"start":6225,"enrollment":6226,"conditions":6227,"interventions":6229},"NCT02863055","Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma",[88],"2023-10-12","2024-01-10","2018-02-04",37,[6228],"Malignant Pleural Mesothelioma",[3310],{"trials":6231,"activeCount":99},[],{"trials":6233,"activeCount":99},[],{"trials":6235,"activeCount":99},[],{"intervention":1591,"totalTrials":591,"cells":6237},{"EARLY_PHASE1":6238,"PHASE1":6240,"PHASE2":6246,"PHASE3":6267,"PHASE4":6269,"NA":6271},{"trials":6239,"activeCount":99},[],{"trials":6241,"activeCount":99},[6242],{"nctId":1805,"briefTitle":1806,"status":107,"phases":6243,"primaryCompletion":767,"start":1808,"enrollment":22,"conditions":6244,"interventions":6245},[87],[15],[1591,725,368],{"trials":6247,"activeCount":99},[6248,6252,6263],{"nctId":2659,"briefTitle":2660,"status":107,"phases":6249,"primaryCompletion":2662,"completion":2663,"start":2664,"enrollment":2665,"conditions":6250,"interventions":6251},[88],[2667,2668,2669],[794,2671,2672,2673],{"nctId":6253,"briefTitle":6254,"status":107,"phases":6255,"primaryCompletion":6256,"completion":6256,"start":6257,"enrollment":6258,"conditions":6259,"interventions":6262},"NCT01548677","Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer",[88],"2017-03","2013-04",1317,[15,6260,6261],"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Circulating Tumor Cells",[1591],{"nctId":1583,"briefTitle":1584,"status":107,"phases":6264,"primaryCompletion":721,"completion":1586,"start":1587,"enrollment":1588,"conditions":6265,"interventions":6266},[88],[15],[1591,1592,115,270,156],{"trials":6268,"activeCount":99},[],{"trials":6270,"activeCount":99},[],{"trials":6272,"activeCount":99},[],{"intervention":2555,"totalTrials":192,"cells":6274},{"EARLY_PHASE1":6275,"PHASE1":6277,"PHASE2":6279,"PHASE3":6299,"PHASE4":6301,"NA":6303},{"trials":6276,"activeCount":99},[],{"trials":6278,"activeCount":99},[],{"trials":6280,"activeCount":99},[6281,6291,6295],{"nctId":6282,"briefTitle":6283,"status":188,"phases":6284,"primaryCompletion":6285,"completion":6285,"start":6257,"enrollment":875,"conditions":6286,"interventions":6287},"NCT01522612","Colorectal Cancer (CRC) Cetuximab Elderly Frail",[88],"2015-01",[3643],[6288,6289,6290],"Cetuximab","5-fluorouracil","leucovorin",{"nctId":2547,"briefTitle":2548,"status":188,"phases":6292,"primaryCompletion":489,"completion":2550,"start":2551,"enrollment":2552,"conditions":6293,"interventions":6294},[88],[1897],[2555,289,257,980,270,2556,2557,2558],{"nctId":2980,"briefTitle":2981,"status":361,"phases":6296,"start":2963,"enrollment":2983,"conditions":6297,"interventions":6298},[88],[29,351],[935,2555,270,154,2967],{"trials":6300,"activeCount":99},[],{"trials":6302,"activeCount":99},[],{"trials":6304,"activeCount":99},[],{"intervention":6306,"totalTrials":192,"cells":6307},"glufosfamide",{"EARLY_PHASE1":6308,"PHASE1":6310,"PHASE2":6312,"PHASE3":6332,"PHASE4":6334,"NA":6336},{"trials":6309,"activeCount":99},[],{"trials":6311,"activeCount":99},[],{"trials":6313,"activeCount":99},[6314,6320,6326],{"nctId":6315,"briefTitle":6316,"status":107,"phases":6317,"primaryCompletion":976,"start":264,"enrollment":1871,"conditions":6318,"interventions":6319},"NCT00005053","Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer",[88],[2681],[6306],{"nctId":6321,"briefTitle":6322,"status":107,"phases":6323,"primaryCompletion":1870,"start":283,"enrollment":125,"conditions":6324,"interventions":6325},"NCT00014300","Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme",[88],[27],[6306],{"nctId":6327,"briefTitle":6328,"status":107,"phases":6329,"primaryCompletion":976,"start":4081,"enrollment":732,"conditions":6330,"interventions":6331},"NCT00005055","Glufosfamide With of Without Hydration in Treating Patients With Advanced Non-small Cell Lung Cancer",[88],[24],[6306],{"trials":6333,"activeCount":99},[],{"trials":6335,"activeCount":99},[],{"trials":6337,"activeCount":99},[],{"intervention":6339,"totalTrials":192,"cells":6340},"indisulam",{"EARLY_PHASE1":6341,"PHASE1":6343,"PHASE2":6356,"PHASE3":6364,"PHASE4":6366,"NA":6368},{"trials":6342,"activeCount":99},[],{"trials":6344,"activeCount":99},[6345,6351],{"nctId":6346,"briefTitle":6347,"status":107,"phases":6348,"start":3043,"enrollment":722,"conditions":6349,"interventions":6350},"NCT00003976","E7070 in Treating Patients With Solid Tumors",[87],[3352],[6339],{"nctId":6352,"briefTitle":6347,"status":107,"phases":6353,"start":739,"enrollment":722,"conditions":6354,"interventions":6355},"NCT00003981",[87],[3352],[6339],{"trials":6357,"activeCount":99},[6358],{"nctId":6359,"briefTitle":6360,"status":107,"phases":6361,"primaryCompletion":428,"start":1861,"enrollment":16,"conditions":6362,"interventions":6363},"NCT00014625","E7070 in Treating Patients With Stage IV Melanoma",[88],[826],[6339],{"trials":6365,"activeCount":99},[],{"trials":6367,"activeCount":99},[],{"trials":6369,"activeCount":99},[],{"intervention":2556,"totalTrials":192,"cells":6371},{"EARLY_PHASE1":6372,"PHASE1":6374,"PHASE2":6376,"PHASE3":6395,"PHASE4":6397,"NA":6399},{"trials":6373,"activeCount":99},[],{"trials":6375,"activeCount":99},[],{"trials":6377,"activeCount":99},[6378,6382,6386],{"nctId":2547,"briefTitle":2548,"status":188,"phases":6379,"primaryCompletion":489,"completion":2550,"start":2551,"enrollment":2552,"conditions":6380,"interventions":6381},[88],[1897],[2555,289,257,980,270,2556,2557,2558],{"nctId":2571,"briefTitle":2572,"status":107,"phases":6383,"primaryCompletion":699,"completion":2574,"start":2575,"enrollment":320,"conditions":6384,"interventions":6385},[87,88],[1897],[289,257,980,270,968,2578,2556,2579,2580,2558],{"nctId":6387,"briefTitle":6388,"status":107,"phases":6389,"primaryCompletion":2691,"start":6390,"enrollment":2741,"conditions":6391,"interventions":6392},"NCT00424060","Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma",[88],"2006-12",[27],[6393,2556,6394],"sagopilone","gene expression analysis",{"trials":6396,"activeCount":99},[],{"trials":6398,"activeCount":99},[],{"trials":6400,"activeCount":99},[],{"intervention":2013,"totalTrials":192,"cells":6402},{"EARLY_PHASE1":6403,"PHASE1":6405,"PHASE2":6407,"PHASE3":6429,"PHASE4":6431,"NA":6433},{"trials":6404,"activeCount":99},[],{"trials":6406,"activeCount":99},[],{"trials":6408,"activeCount":99},[6409,6418,6422],{"nctId":6410,"briefTitle":6411,"status":6412,"phases":6413,"primaryCompletion":6414,"completion":6415,"start":3019,"enrollment":2741,"conditions":6416,"interventions":6417},"NCT02470065","Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.","SUSPENDED",[88],"2018-09","2021-01",[2147],[2013],{"nctId":2004,"briefTitle":2005,"status":361,"phases":6419,"primaryCompletion":2007,"completion":2008,"start":2009,"enrollment":439,"conditions":6420,"interventions":6421},[88],[2011],[2013,1848,2014,2015,2016,2017,2018],{"nctId":6423,"briefTitle":6424,"status":107,"phases":6425,"primaryCompletion":6426,"completion":6426,"start":490,"enrollment":722,"conditions":6427,"interventions":6428},"NCT01538381","Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck",[88],"2015-08",[2011],[2013],{"trials":6430,"activeCount":99},[],{"trials":6432,"activeCount":99},[],{"trials":6434,"activeCount":99},[],{"intervention":3470,"totalTrials":192,"cells":6436},{"EARLY_PHASE1":6437,"PHASE1":6439,"PHASE2":6445,"PHASE3":6465,"PHASE4":6467,"NA":6469},{"trials":6438,"activeCount":99},[],{"trials":6440,"activeCount":99},[6441],{"nctId":3464,"briefTitle":3465,"status":107,"phases":6442,"primaryCompletion":3467,"start":428,"enrollment":16,"conditions":6443,"interventions":6444},[87],[32],[271,3470],{"trials":6446,"activeCount":99},[6447,6455],{"nctId":6448,"briefTitle":6449,"status":107,"phases":6450,"primaryCompletion":6451,"start":6452,"enrollment":3373,"conditions":6453,"interventions":6454},"NCT00005980","Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer",[88],"2002-07","2000-04",[15],[3470],{"nctId":6456,"briefTitle":6457,"status":107,"phases":6458,"primaryCompletion":6459,"completion":6460,"start":6461,"enrollment":6462,"conditions":6463,"interventions":6464},"NCT00074087","Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides",[88],"2009-07","2010-09","2003-10",49,[21],[3470],{"trials":6466,"activeCount":99},[],{"trials":6468,"activeCount":99},[],{"trials":6470,"activeCount":99},[],{"intervention":6472,"totalTrials":192,"cells":6473},"sabarubicin",{"EARLY_PHASE1":6474,"PHASE1":6476,"PHASE2":6490,"PHASE3":6499,"PHASE4":6501,"NA":6503},{"trials":6475,"activeCount":99},[],{"trials":6477,"activeCount":99},[6478,6484],{"nctId":6479,"briefTitle":6480,"status":107,"phases":6481,"start":5698,"enrollment":722,"conditions":6482,"interventions":6483},"NCT00003982","MEN-10755 in Treating Patients With Solid Tumors",[87],[352,3352],[6472],{"nctId":6485,"briefTitle":6486,"status":107,"phases":6487,"start":4186,"enrollment":875,"conditions":6488,"interventions":6489},"NCT00003028","MEN-10755 in Treating Adults With Recurrent or Refractory Solid Tumors",[87],[3352],[6472],{"trials":6491,"activeCount":99},[6492],{"nctId":6493,"briefTitle":6494,"status":107,"phases":6495,"primaryCompletion":191,"start":6496,"enrollment":6226,"conditions":6497,"interventions":6498},"NCT00027781","MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy",[88],"2001-08",[34],[6472],{"trials":6500,"activeCount":99},[],{"trials":6502,"activeCount":99},[],{"trials":6504,"activeCount":99},[],{"intervention":1888,"totalTrials":192,"cells":6506},{"EARLY_PHASE1":6507,"PHASE1":6509,"PHASE2":6511,"PHASE3":6533,"PHASE4":6535,"NA":6537},{"trials":6508,"activeCount":99},[],{"trials":6510,"activeCount":99},[],{"trials":6512,"activeCount":99},[6513,6517,6521],{"nctId":1876,"briefTitle":1877,"status":786,"phases":6514,"primaryCompletion":1879,"completion":1880,"start":1881,"enrollment":99,"conditions":6515,"interventions":6516},[88],[1883,1020,1884,1885],[1887,1888,1889],{"nctId":3650,"briefTitle":3651,"status":107,"phases":6518,"primaryCompletion":2801,"completion":3653,"start":3654,"enrollment":3655,"conditions":6519,"interventions":6520},[88],[3657],[754,3659,3660],{"nctId":6522,"briefTitle":6523,"status":188,"phases":6524,"primaryCompletion":6525,"completion":6526,"start":6527,"enrollment":6528,"conditions":6529,"interventions":6532},"NCT03357224","PARCT: Trial of Atezolizumab in Relapsed\u002FRefractory Cutaneous T Cell Lymphoma (CTCL)",[88],"2021-03-11","2022-08-18","2018-09-24",26,[6530,6531],"Lymphoma, T-Cell, Cutaneous","Mycosis Fungoides\u002FSezary Syndrome",[1888],{"trials":6534,"activeCount":99},[],{"trials":6536,"activeCount":99},[],{"trials":6538,"activeCount":99},[],{"intervention":725,"totalTrials":192,"cells":6540},{"EARLY_PHASE1":6541,"PHASE1":6543,"PHASE2":6553,"PHASE3":6559,"PHASE4":6561,"NA":6563},{"trials":6542,"activeCount":99},[],{"trials":6544,"activeCount":99},[6545,6549],{"nctId":1805,"briefTitle":1806,"status":107,"phases":6546,"primaryCompletion":767,"start":1808,"enrollment":22,"conditions":6547,"interventions":6548},[87],[15],[1591,725,368],{"nctId":718,"briefTitle":719,"status":361,"phases":6550,"primaryCompletion":721,"start":145,"enrollment":722,"conditions":6551,"interventions":6552},[87],[27],[725,54],{"trials":6554,"activeCount":99},[6555],{"nctId":3160,"briefTitle":3161,"status":107,"phases":6556,"primaryCompletion":3163,"start":1714,"enrollment":3164,"conditions":6557,"interventions":6558},[88],[255,286,287],[117,725],{"trials":6560,"activeCount":99},[],{"trials":6562,"activeCount":99},[],{"trials":6564,"activeCount":99},[],{"intervention":6290,"totalTrials":523,"cells":6566},{"EARLY_PHASE1":6567,"PHASE1":6569,"PHASE2":6571,"PHASE3":6581,"PHASE4":6583,"NA":6585},{"trials":6568,"activeCount":99},[],{"trials":6570,"activeCount":99},[],{"trials":6572,"activeCount":99},[6573,6577],{"nctId":6282,"briefTitle":6283,"status":188,"phases":6574,"primaryCompletion":6285,"completion":6285,"start":6257,"enrollment":875,"conditions":6575,"interventions":6576},[88],[3643],[6288,6289,6290],{"nctId":3300,"briefTitle":3301,"status":786,"phases":6578,"primaryCompletion":3303,"start":3304,"enrollment":99,"conditions":6579,"interventions":6580},[88],[3306,3307,3308],[3310,3311,3312,796],{"trials":6582,"activeCount":99},[],{"trials":6584,"activeCount":99},[],{"trials":6586,"activeCount":99},[],{"intervention":2558,"totalTrials":523,"cells":6588},{"EARLY_PHASE1":6589,"PHASE1":6591,"PHASE2":6593,"PHASE3":6603,"PHASE4":6605,"NA":6607},{"trials":6590,"activeCount":99},[],{"trials":6592,"activeCount":99},[],{"trials":6594,"activeCount":99},[6595,6599],{"nctId":2547,"briefTitle":2548,"status":188,"phases":6596,"primaryCompletion":489,"completion":2550,"start":2551,"enrollment":2552,"conditions":6597,"interventions":6598},[88],[1897],[2555,289,257,980,270,2556,2557,2558],{"nctId":2571,"briefTitle":2572,"status":107,"phases":6600,"primaryCompletion":699,"completion":2574,"start":2575,"enrollment":320,"conditions":6601,"interventions":6602},[87,88],[1897],[289,257,980,270,968,2578,2556,2579,2580,2558],{"trials":6604,"activeCount":99},[],{"trials":6606,"activeCount":99},[],{"trials":6608,"activeCount":99},[],{"intervention":3896,"totalTrials":523,"cells":6610},{"EARLY_PHASE1":6611,"PHASE1":6613,"PHASE2":6615,"PHASE3":6625,"PHASE4":6627,"NA":6629},{"trials":6612,"activeCount":99},[],{"trials":6614,"activeCount":99},[],{"trials":6616,"activeCount":99},[6617,6621],{"nctId":3888,"briefTitle":3889,"status":107,"phases":6618,"primaryCompletion":3891,"completion":3892,"start":3893,"enrollment":25,"conditions":6619,"interventions":6620},[88],[29,3644],[2016,3896],{"nctId":3898,"briefTitle":3899,"status":786,"phases":6622,"primaryCompletion":3901,"completion":3902,"start":3903,"enrollment":99,"conditions":6623,"interventions":6624},[88],[3905,3906],[2016,3896],{"trials":6626,"activeCount":99},[],{"trials":6628,"activeCount":99},[],{"trials":6630,"activeCount":99},[],{"intervention":6632,"totalTrials":523,"cells":6633},"acridine carboxamide",{"EARLY_PHASE1":6634,"PHASE1":6636,"PHASE2":6638,"PHASE3":6653,"PHASE4":6655,"NA":6657},{"trials":6635,"activeCount":99},[],{"trials":6637,"activeCount":99},[],{"trials":6639,"activeCount":99},[6640,6646],{"nctId":6641,"briefTitle":6642,"status":107,"phases":6643,"primaryCompletion":251,"start":1643,"enrollment":952,"conditions":6644,"interventions":6645},"NCT00004151","Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer",[88],[24],[6632],{"nctId":6647,"briefTitle":6648,"status":107,"phases":6649,"primaryCompletion":45,"start":6650,"conditions":6651,"interventions":6652},"NCT00004937","Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme",[88],"1999-10",[27],[6632],{"trials":6654,"activeCount":99},[],{"trials":6656,"activeCount":99},[],{"trials":6658,"activeCount":99},[],{"intervention":6660,"totalTrials":523,"cells":6661},"cabozantinib",{"EARLY_PHASE1":6662,"PHASE1":6664,"PHASE2":6666,"PHASE3":6689,"PHASE4":6691,"NA":6693},{"trials":6663,"activeCount":99},[],{"trials":6665,"activeCount":99},[],{"trials":6667,"activeCount":99},[6668,6678],{"nctId":6669,"briefTitle":6670,"status":107,"phases":6671,"primaryCompletion":6672,"completion":6673,"start":6674,"enrollment":6167,"conditions":6675,"interventions":6677},"NCT02216578","Ph II CABOGIST in GIST",[88],"2019-05-20","2021-02-23","2017-02-02",[6676],"Metastatic Gastrointestinal Stromal Tumor",[6660],{"nctId":6679,"briefTitle":6680,"status":107,"phases":6681,"primaryCompletion":6682,"completion":6683,"start":6684,"enrollment":4122,"conditions":6685,"interventions":6687},"NCT01979393","IRCI Gynae Sarcomas, High Grade Uterine Sarcoma",[88],"2022-05-18","2024-01-15","2015-02-02",[6686],"Uterine Sarcoma",[6688],"Cabozantinib",{"trials":6690,"activeCount":99},[],{"trials":6692,"activeCount":99},[],{"trials":6694,"activeCount":99},[],{"intervention":2625,"totalTrials":523,"cells":6696},{"EARLY_PHASE1":6697,"PHASE1":6699,"PHASE2":6701,"PHASE3":6711,"PHASE4":6713,"NA":6715},{"trials":6698,"activeCount":99},[],{"trials":6700,"activeCount":99},[],{"trials":6702,"activeCount":99},[6703,6707],{"nctId":2618,"briefTitle":2619,"status":188,"phases":6704,"primaryCompletion":2621,"start":2622,"enrollment":1798,"conditions":6705,"interventions":6706},[88],[24],[257,2625],{"nctId":2688,"briefTitle":2689,"status":107,"phases":6708,"primaryCompletion":2691,"start":865,"enrollment":2692,"conditions":6709,"interventions":6710},[88],[2567],[257,2625],{"trials":6712,"activeCount":99},[],{"trials":6714,"activeCount":99},[],{"trials":6716,"activeCount":99},[],{"intervention":403,"totalTrials":523,"cells":6718},{"EARLY_PHASE1":6719,"PHASE1":6721,"PHASE2":6723,"PHASE3":6736,"PHASE4":6738,"NA":6740},{"trials":6720,"activeCount":99},[],{"trials":6722,"activeCount":99},[],{"trials":6724,"activeCount":99},[6725,6729],{"nctId":394,"briefTitle":395,"status":361,"phases":6726,"primaryCompletion":397,"start":398,"enrollment":399,"conditions":6727,"interventions":6728},[88],[401,32,112],[403,116],{"nctId":6730,"briefTitle":6731,"status":107,"phases":6732,"primaryCompletion":110,"start":2974,"enrollment":6733,"conditions":6734,"interventions":6735},"NCT00041249","Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma",[88],64,[3790,32],[403],{"trials":6737,"activeCount":99},[],{"trials":6739,"activeCount":99},[],{"trials":6741,"activeCount":99},[],{"intervention":795,"totalTrials":523,"cells":6743},{"EARLY_PHASE1":6744,"PHASE1":6746,"PHASE2":6748,"PHASE3":6758,"PHASE4":6760,"NA":6762},{"trials":6745,"activeCount":99},[],{"trials":6747,"activeCount":99},[],{"trials":6749,"activeCount":99},[6750,6754],{"nctId":784,"briefTitle":785,"status":786,"phases":6751,"primaryCompletion":788,"completion":789,"start":790,"enrollment":99,"conditions":6752,"interventions":6753},[88],[792],[794,795,796,797,716],{"nctId":1012,"briefTitle":1013,"status":107,"phases":6755,"primaryCompletion":1015,"completion":1016,"start":1017,"enrollment":1018,"conditions":6756,"interventions":6757},[88],[1020,351,1021,1022],[991,794,795],{"trials":6759,"activeCount":99},[],{"trials":6761,"activeCount":99},[],{"trials":6763,"activeCount":99},[],{"intervention":1901,"totalTrials":523,"cells":6765},{"EARLY_PHASE1":6766,"PHASE1":6768,"PHASE2":6770,"PHASE3":6780,"PHASE4":6782,"NA":6784},{"trials":6767,"activeCount":99},[],{"trials":6769,"activeCount":99},[],{"trials":6771,"activeCount":99},[6772,6776],{"nctId":4532,"briefTitle":4533,"status":361,"phases":6773,"start":1921,"enrollment":1018,"conditions":6774,"interventions":6775},[88],[4536,1577],[4523,1901],{"nctId":1891,"briefTitle":1892,"status":188,"phases":6777,"primaryCompletion":507,"start":1894,"enrollment":875,"conditions":6778,"interventions":6779},[88],[1896,1897,1898,1899],[1901,289,257,368],{"trials":6781,"activeCount":99},[],{"trials":6783,"activeCount":99},[],{"trials":6785,"activeCount":99},[],{"intervention":6787,"totalTrials":523,"cells":6788},"boronophenylalanine-fructose complex",{"EARLY_PHASE1":6789,"PHASE1":6791,"PHASE2":6800,"PHASE3":6808,"PHASE4":6810,"NA":6812},{"trials":6790,"activeCount":99},[],{"trials":6792,"activeCount":99},[6793],{"nctId":6794,"briefTitle":6795,"status":107,"phases":6796,"primaryCompletion":854,"start":491,"enrollment":2399,"conditions":6797,"interventions":6798},"NCT00062348","Boronophenylalanine-Fructose Complex (BPA-F) and\u002For Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases",[87],[29,1897,351],[6787,6799],"sodium borocaptate",{"trials":6801,"activeCount":99},[6802],{"nctId":6803,"briefTitle":6804,"status":188,"phases":6805,"primaryCompletion":398,"start":134,"enrollment":591,"conditions":6806,"interventions":6807},"NCT00085059","Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma",[88],[826],[6787],{"trials":6809,"activeCount":99},[],{"trials":6811,"activeCount":99},[],{"trials":6813,"activeCount":99},[],{"intervention":6289,"totalTrials":665,"cells":6815},{"EARLY_PHASE1":6816,"PHASE1":6818,"PHASE2":6820,"PHASE3":6826,"PHASE4":6828,"NA":6830},{"trials":6817,"activeCount":99},[],{"trials":6819,"activeCount":99},[],{"trials":6821,"activeCount":99},[6822],{"nctId":6282,"briefTitle":6283,"status":188,"phases":6823,"primaryCompletion":6285,"completion":6285,"start":6257,"enrollment":875,"conditions":6824,"interventions":6825},[88],[3643],[6288,6289,6290],{"trials":6827,"activeCount":99},[],{"trials":6829,"activeCount":99},[],{"trials":6831,"activeCount":99},[],{"intervention":6833,"totalTrials":665,"cells":6834},"Pemetrexed\u002FCisplatin",{"EARLY_PHASE1":6835,"PHASE1":6837,"PHASE2":6839,"PHASE3":6849,"PHASE4":6851,"NA":6853},{"trials":6836,"activeCount":99},[],{"trials":6838,"activeCount":99},[],{"trials":6840,"activeCount":99},[6841],{"nctId":6842,"briefTitle":6843,"status":361,"phases":6844,"primaryCompletion":5131,"completion":6845,"start":6846,"enrollment":6733,"conditions":6847,"interventions":6848},"NCT02436733","Pleurectomy\u002F Decortication (P\u002FD) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM",[88],"2023-09","2016-09-20",[6228],[6833],{"trials":6850,"activeCount":99},[],{"trials":6852,"activeCount":99},[],{"trials":6854,"activeCount":99},[],{"intervention":6856,"totalTrials":665,"cells":6857},"Cabazitaxel",{"EARLY_PHASE1":6858,"PHASE1":6860,"PHASE2":6862,"PHASE3":6873,"PHASE4":6875,"NA":6877},{"trials":6859,"activeCount":99},[],{"trials":6861,"activeCount":99},[],{"trials":6863,"activeCount":99},[6864],{"nctId":6865,"briefTitle":6866,"status":107,"phases":6867,"primaryCompletion":6868,"completion":6868,"start":5799,"enrollment":6869,"conditions":6870,"interventions":6872},"NCT01913652","Ph II Cabazitaxel DD Liposarcoma",[88],"2020-12",42,[6871],"Dedifferentiated Liposarcoma",[6856],{"trials":6874,"activeCount":99},[],{"trials":6876,"activeCount":99},[],{"trials":6878,"activeCount":99},[],{"intervention":6880,"totalTrials":665,"cells":6881},"Methoxsalen",{"EARLY_PHASE1":6882,"PHASE1":6884,"PHASE2":6886,"PHASE3":6897,"PHASE4":6899,"NA":6901},{"trials":6883,"activeCount":99},[],{"trials":6885,"activeCount":99},[],{"trials":6887,"activeCount":99},[6888],{"nctId":6889,"briefTitle":6890,"status":786,"phases":6891,"primaryCompletion":6892,"completion":6893,"start":6894,"enrollment":99,"conditions":6895,"interventions":6896},"NCT03563040","Study of Photopheresis in the Treatment of Erythrodermic MF and SS",[88],"2022-09-01","2026-06-01","2020-12-01",[6530,6531],[6880],{"trials":6898,"activeCount":99},[],{"trials":6900,"activeCount":99},[],{"trials":6902,"activeCount":99},[],{"intervention":1975,"totalTrials":665,"cells":6904},{"EARLY_PHASE1":6905,"PHASE1":6907,"PHASE2":6909,"PHASE3":6915,"PHASE4":6917,"NA":6919},{"trials":6906,"activeCount":99},[],{"trials":6908,"activeCount":99},[],{"trials":6910,"activeCount":99},[6911],{"nctId":1967,"briefTitle":1968,"status":188,"phases":6912,"primaryCompletion":1970,"completion":1970,"start":1971,"enrollment":239,"conditions":6913,"interventions":6914},[88],[1973],[79,1975],{"trials":6916,"activeCount":99},[],{"trials":6918,"activeCount":99},[],{"trials":6920,"activeCount":99},[],{"intervention":6922,"totalTrials":665,"cells":6923},"bicalutamide + triptorelin",{"EARLY_PHASE1":6924,"PHASE1":6926,"PHASE2":6928,"PHASE3":6942,"PHASE4":6944,"NA":6946},{"trials":6925,"activeCount":99},[],{"trials":6927,"activeCount":99},[],{"trials":6929,"activeCount":99},[6930],{"nctId":6931,"briefTitle":6932,"status":107,"phases":6933,"primaryCompletion":68,"completion":6934,"start":6935,"enrollment":6936,"conditions":6937,"interventions":6939},"NCT01969578","Androgen Deprivation Therapy in Advanced Salivary Gland Cancer",[88],"2024-02-16","2015-09-24",149,[6938],"Salivary Gland Cancer",[6922,6940,6941],"Cisplatin + Doxorubicin","Carboplatin + Paclitaxel",{"trials":6943,"activeCount":99},[],{"trials":6945,"activeCount":99},[],{"trials":6947,"activeCount":99},[],{"intervention":6940,"totalTrials":665,"cells":6949},{"EARLY_PHASE1":6950,"PHASE1":6952,"PHASE2":6954,"PHASE3":6960,"PHASE4":6962,"NA":6964},{"trials":6951,"activeCount":99},[],{"trials":6953,"activeCount":99},[],{"trials":6955,"activeCount":99},[6956],{"nctId":6931,"briefTitle":6932,"status":107,"phases":6957,"primaryCompletion":68,"completion":6934,"start":6935,"enrollment":6936,"conditions":6958,"interventions":6959},[88],[6938],[6922,6940,6941],{"trials":6961,"activeCount":99},[],{"trials":6963,"activeCount":99},[],{"trials":6965,"activeCount":99},[],{"intervention":6941,"totalTrials":665,"cells":6967},{"EARLY_PHASE1":6968,"PHASE1":6970,"PHASE2":6972,"PHASE3":6978,"PHASE4":6980,"NA":6982},{"trials":6969,"activeCount":99},[],{"trials":6971,"activeCount":99},[],{"trials":6973,"activeCount":99},[6974],{"nctId":6931,"briefTitle":6932,"status":107,"phases":6975,"primaryCompletion":68,"completion":6934,"start":6935,"enrollment":6936,"conditions":6976,"interventions":6977},[88],[6938],[6922,6940,6941],{"trials":6979,"activeCount":99},[],{"trials":6981,"activeCount":99},[],{"trials":6983,"activeCount":99},[],{"intervention":893,"totalTrials":665,"cells":6985},{"EARLY_PHASE1":6986,"PHASE1":6988,"PHASE2":6990,"PHASE3":6996,"PHASE4":6998,"NA":7000},{"trials":6987,"activeCount":99},[],{"trials":6989,"activeCount":99},[],{"trials":6991,"activeCount":99},[6992],{"nctId":884,"briefTitle":885,"status":188,"phases":6993,"primaryCompletion":887,"completion":888,"start":889,"enrollment":30,"conditions":6994,"interventions":6995},[88],[891],[893,794,874,894],{"trials":6997,"activeCount":99},[],{"trials":6999,"activeCount":99},[],{"trials":7001,"activeCount":99},[],{"intervention":894,"totalTrials":665,"cells":7003},{"EARLY_PHASE1":7004,"PHASE1":7006,"PHASE2":7008,"PHASE3":7014,"PHASE4":7016,"NA":7018},{"trials":7005,"activeCount":99},[],{"trials":7007,"activeCount":99},[],{"trials":7009,"activeCount":99},[7010],{"nctId":884,"briefTitle":885,"status":188,"phases":7011,"primaryCompletion":887,"completion":888,"start":889,"enrollment":30,"conditions":7012,"interventions":7013},[88],[891],[893,794,874,894],{"trials":7015,"activeCount":99},[],{"trials":7017,"activeCount":99},[],{"trials":7019,"activeCount":99},[],{"intervention":1010,"totalTrials":665,"cells":7021},{"EARLY_PHASE1":7022,"PHASE1":7024,"PHASE2":7026,"PHASE3":7032,"PHASE4":7034,"NA":7036},{"trials":7023,"activeCount":99},[],{"trials":7025,"activeCount":99},[],{"trials":7027,"activeCount":99},[7028],{"nctId":1000,"briefTitle":1001,"status":107,"phases":7029,"primaryCompletion":1003,"completion":1004,"start":1005,"enrollment":1006,"conditions":7030,"interventions":7031},[88],[1008],[991,1010],{"trials":7033,"activeCount":99},[],{"trials":7035,"activeCount":99},[],{"trials":7037,"activeCount":99},[],{"intervention":2557,"totalTrials":665,"cells":7039},{"EARLY_PHASE1":7040,"PHASE1":7042,"PHASE2":7044,"PHASE3":7050,"PHASE4":7052,"NA":7054},{"trials":7041,"activeCount":99},[],{"trials":7043,"activeCount":99},[],{"trials":7045,"activeCount":99},[7046],{"nctId":2547,"briefTitle":2548,"status":188,"phases":7047,"primaryCompletion":489,"completion":2550,"start":2551,"enrollment":2552,"conditions":7048,"interventions":7049},[88],[1897],[2555,289,257,980,270,2556,2557,2558],{"trials":7051,"activeCount":99},[],{"trials":7053,"activeCount":99},[],{"trials":7055,"activeCount":99},[],{"intervention":7057,"totalTrials":665,"cells":7058},"D1\u002F3-MAGE-3-His fusion protein",{"EARLY_PHASE1":7059,"PHASE1":7061,"PHASE2":7063,"PHASE3":7074,"PHASE4":7076,"NA":7078},{"trials":7060,"activeCount":99},[],{"trials":7062,"activeCount":99},[],{"trials":7064,"activeCount":99},[7065],{"nctId":7066,"briefTitle":7067,"status":361,"phases":7068,"primaryCompletion":2963,"start":49,"enrollment":7069,"conditions":7070,"interventions":7071},"NCT00086866","Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery",[88],165,[826],[7057,7072,7073],"SB-AS02B adjuvant","SB-AS15 adjuvant",{"trials":7075,"activeCount":99},[],{"trials":7077,"activeCount":99},[],{"trials":7079,"activeCount":99},[],{"intervention":7072,"totalTrials":665,"cells":7081},{"EARLY_PHASE1":7082,"PHASE1":7084,"PHASE2":7086,"PHASE3":7092,"PHASE4":7094,"NA":7096},{"trials":7083,"activeCount":99},[],{"trials":7085,"activeCount":99},[],{"trials":7087,"activeCount":99},[7088],{"nctId":7066,"briefTitle":7067,"status":361,"phases":7089,"primaryCompletion":2963,"start":49,"enrollment":7069,"conditions":7090,"interventions":7091},[88],[826],[7057,7072,7073],{"trials":7093,"activeCount":99},[],{"trials":7095,"activeCount":99},[],{"trials":7097,"activeCount":99},[],{"intervention":7073,"totalTrials":665,"cells":7099},{"EARLY_PHASE1":7100,"PHASE1":7102,"PHASE2":7104,"PHASE3":7110,"PHASE4":7112,"NA":7114},{"trials":7101,"activeCount":99},[],{"trials":7103,"activeCount":99},[],{"trials":7105,"activeCount":99},[7106],{"nctId":7066,"briefTitle":7067,"status":361,"phases":7107,"primaryCompletion":2963,"start":49,"enrollment":7069,"conditions":7108,"interventions":7109},[88],[826],[7057,7072,7073],{"trials":7111,"activeCount":99},[],{"trials":7113,"activeCount":99},[],{"trials":7115,"activeCount":99},[],{"intervention":7117,"totalTrials":665,"cells":7118},"Pertuzumab + trastuzumab",{"EARLY_PHASE1":7119,"PHASE1":7121,"PHASE2":7123,"PHASE3":7133,"PHASE4":7135,"NA":7137},{"trials":7120,"activeCount":99},[],{"trials":7122,"activeCount":99},[],{"trials":7124,"activeCount":99},[7125],{"nctId":7126,"briefTitle":7127,"status":107,"phases":7128,"primaryCompletion":6256,"completion":3902,"start":463,"enrollment":1749,"conditions":7129,"interventions":7131},"NCT01597414","Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1",[88],[7130],"Elderly Metastatic Breast Cancer Population",[7117,7132],"Pertuzumab + trastuzumab + metronomic chemotherapy",{"trials":7134,"activeCount":99},[],{"trials":7136,"activeCount":99},[],{"trials":7138,"activeCount":99},[],{"intervention":7132,"totalTrials":665,"cells":7140},{"EARLY_PHASE1":7141,"PHASE1":7143,"PHASE2":7145,"PHASE3":7151,"PHASE4":7153,"NA":7155},{"trials":7142,"activeCount":99},[],{"trials":7144,"activeCount":99},[],{"trials":7146,"activeCount":99},[7147],{"nctId":7126,"briefTitle":7127,"status":107,"phases":7148,"primaryCompletion":6256,"completion":3902,"start":463,"enrollment":1749,"conditions":7149,"interventions":7150},[88],[7130],[7117,7132],{"trials":7152,"activeCount":99},[],{"trials":7154,"activeCount":99},[],{"trials":7156,"activeCount":99},[],{"intervention":2578,"totalTrials":665,"cells":7158},{"EARLY_PHASE1":7159,"PHASE1":7161,"PHASE2":7163,"PHASE3":7169,"PHASE4":7171,"NA":7173},{"trials":7160,"activeCount":99},[],{"trials":7162,"activeCount":99},[],{"trials":7164,"activeCount":99},[7165],{"nctId":2571,"briefTitle":2572,"status":107,"phases":7166,"primaryCompletion":699,"completion":2574,"start":2575,"enrollment":320,"conditions":7167,"interventions":7168},[87,88],[1897],[289,257,980,270,968,2578,2556,2579,2580,2558],{"trials":7170,"activeCount":99},[],{"trials":7172,"activeCount":99},[],{"trials":7174,"activeCount":99},[],{"intervention":2579,"totalTrials":665,"cells":7176},{"EARLY_PHASE1":7177,"PHASE1":7179,"PHASE2":7181,"PHASE3":7187,"PHASE4":7189,"NA":7191},{"trials":7178,"activeCount":99},[],{"trials":7180,"activeCount":99},[],{"trials":7182,"activeCount":99},[7183],{"nctId":2571,"briefTitle":2572,"status":107,"phases":7184,"primaryCompletion":699,"completion":2574,"start":2575,"enrollment":320,"conditions":7185,"interventions":7186},[87,88],[1897],[289,257,980,270,968,2578,2556,2579,2580,2558],{"trials":7188,"activeCount":99},[],{"trials":7190,"activeCount":99},[],{"trials":7192,"activeCount":99},[],{"intervention":2580,"totalTrials":665,"cells":7194},{"EARLY_PHASE1":7195,"PHASE1":7197,"PHASE2":7199,"PHASE3":7205,"PHASE4":7207,"NA":7209},{"trials":7196,"activeCount":99},[],{"trials":7198,"activeCount":99},[],{"trials":7200,"activeCount":99},[7201],{"nctId":2571,"briefTitle":2572,"status":107,"phases":7202,"primaryCompletion":699,"completion":2574,"start":2575,"enrollment":320,"conditions":7203,"interventions":7204},[87,88],[1897],[289,257,980,270,968,2578,2556,2579,2580,2558],{"trials":7206,"activeCount":99},[],{"trials":7208,"activeCount":99},[],{"trials":7210,"activeCount":99},[],{"intervention":7212,"totalTrials":665,"cells":7213},"docetaxel+lapatinib",{"EARLY_PHASE1":7214,"PHASE1":7216,"PHASE2":7218,"PHASE3":7230,"PHASE4":7232,"NA":7234},{"trials":7215,"activeCount":99},[],{"trials":7217,"activeCount":99},[],{"trials":7219,"activeCount":99},[7220],{"nctId":7221,"briefTitle":7222,"status":107,"phases":7223,"primaryCompletion":7224,"completion":7224,"start":1057,"enrollment":7225,"conditions":7226,"interventions":7227},"NCT00450892","Phase I\u002FII Study of Neoadjuvant Lapatinib in Breast Cancer",[87,88],"2013-07",129,[15],[7212,7228,7229],"docetaxel + trastuzumab","docetaxel + trastuzumab + lapatinib",{"trials":7231,"activeCount":99},[],{"trials":7233,"activeCount":99},[],{"trials":7235,"activeCount":99},[],{"intervention":7228,"totalTrials":665,"cells":7237},{"EARLY_PHASE1":7238,"PHASE1":7240,"PHASE2":7242,"PHASE3":7248,"PHASE4":7250,"NA":7252},{"trials":7239,"activeCount":99},[],{"trials":7241,"activeCount":99},[],{"trials":7243,"activeCount":99},[7244],{"nctId":7221,"briefTitle":7222,"status":107,"phases":7245,"primaryCompletion":7224,"completion":7224,"start":1057,"enrollment":7225,"conditions":7246,"interventions":7247},[87,88],[15],[7212,7228,7229],{"trials":7249,"activeCount":99},[],{"trials":7251,"activeCount":99},[],{"trials":7253,"activeCount":99},[],{"intervention":7229,"totalTrials":665,"cells":7255},{"EARLY_PHASE1":7256,"PHASE1":7258,"PHASE2":7260,"PHASE3":7266,"PHASE4":7268,"NA":7270},{"trials":7257,"activeCount":99},[],{"trials":7259,"activeCount":99},[],{"trials":7261,"activeCount":99},[7262],{"nctId":7221,"briefTitle":7222,"status":107,"phases":7263,"primaryCompletion":7224,"completion":7224,"start":1057,"enrollment":7225,"conditions":7264,"interventions":7265},[87,88],[15],[7212,7228,7229],{"trials":7267,"activeCount":99},[],{"trials":7269,"activeCount":99},[],{"trials":7271,"activeCount":99},[],{"intervention":7273,"totalTrials":665,"cells":7274},"amoxicillin",{"EARLY_PHASE1":7275,"PHASE1":7277,"PHASE2":7279,"PHASE3":7292,"PHASE4":7294,"NA":7296},{"trials":7276,"activeCount":99},[],{"trials":7278,"activeCount":99},[],{"trials":7280,"activeCount":99},[7281],{"nctId":7282,"briefTitle":7283,"status":107,"phases":7284,"primaryCompletion":213,"start":7285,"enrollment":2679,"conditions":7286,"interventions":7287},"NCT00003151","Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma",[88],"1997-09",[21],[7273,7288,7289,7290,7291],"clarithromycin","metronidazole hydrochloride","omeprazole","tetracycline hydrochloride",{"trials":7293,"activeCount":99},[],{"trials":7295,"activeCount":99},[],{"trials":7297,"activeCount":99},[],{"intervention":7288,"totalTrials":665,"cells":7299},{"EARLY_PHASE1":7300,"PHASE1":7302,"PHASE2":7304,"PHASE3":7310,"PHASE4":7312,"NA":7314},{"trials":7301,"activeCount":99},[],{"trials":7303,"activeCount":99},[],{"trials":7305,"activeCount":99},[7306],{"nctId":7282,"briefTitle":7283,"status":107,"phases":7307,"primaryCompletion":213,"start":7285,"enrollment":2679,"conditions":7308,"interventions":7309},[88],[21],[7273,7288,7289,7290,7291],{"trials":7311,"activeCount":99},[],{"trials":7313,"activeCount":99},[],{"trials":7315,"activeCount":99},[],{"intervention":7289,"totalTrials":665,"cells":7317},{"EARLY_PHASE1":7318,"PHASE1":7320,"PHASE2":7322,"PHASE3":7328,"PHASE4":7330,"NA":7332},{"trials":7319,"activeCount":99},[],{"trials":7321,"activeCount":99},[],{"trials":7323,"activeCount":99},[7324],{"nctId":7282,"briefTitle":7283,"status":107,"phases":7325,"primaryCompletion":213,"start":7285,"enrollment":2679,"conditions":7326,"interventions":7327},[88],[21],[7273,7288,7289,7290,7291],{"trials":7329,"activeCount":99},[],{"trials":7331,"activeCount":99},[],{"trials":7333,"activeCount":99},[],{"intervention":7290,"totalTrials":665,"cells":7335},{"EARLY_PHASE1":7336,"PHASE1":7338,"PHASE2":7340,"PHASE3":7346,"PHASE4":7348,"NA":7350},{"trials":7337,"activeCount":99},[],{"trials":7339,"activeCount":99},[],{"trials":7341,"activeCount":99},[7342],{"nctId":7282,"briefTitle":7283,"status":107,"phases":7343,"primaryCompletion":213,"start":7285,"enrollment":2679,"conditions":7344,"interventions":7345},[88],[21],[7273,7288,7289,7290,7291],{"trials":7347,"activeCount":99},[],{"trials":7349,"activeCount":99},[],{"trials":7351,"activeCount":99},[],{"intervention":7291,"totalTrials":665,"cells":7353},{"EARLY_PHASE1":7354,"PHASE1":7356,"PHASE2":7358,"PHASE3":7364,"PHASE4":7366,"NA":7368},{"trials":7355,"activeCount":99},[],{"trials":7357,"activeCount":99},[],{"trials":7359,"activeCount":99},[7360],{"nctId":7282,"briefTitle":7283,"status":107,"phases":7361,"primaryCompletion":213,"start":7285,"enrollment":2679,"conditions":7362,"interventions":7363},[88],[21],[7273,7288,7289,7290,7291],{"trials":7365,"activeCount":99},[],{"trials":7367,"activeCount":99},[],{"trials":7369,"activeCount":99},[],{"intervention":904,"totalTrials":665,"cells":7371},{"EARLY_PHASE1":7372,"PHASE1":7374,"PHASE2":7376,"PHASE3":7382,"PHASE4":7384,"NA":7386},{"trials":7373,"activeCount":99},[],{"trials":7375,"activeCount":99},[],{"trials":7377,"activeCount":99},[7378],{"nctId":896,"briefTitle":897,"status":786,"phases":7379,"primaryCompletion":899,"completion":899,"start":900,"enrollment":99,"conditions":7380,"interventions":7381},[88],[902],[874,904],{"trials":7383,"activeCount":99},[],{"trials":7385,"activeCount":99},[],{"trials":7387,"activeCount":99},[],{"intervention":7389,"totalTrials":665,"cells":7390},"exatecan mesylate",{"EARLY_PHASE1":7391,"PHASE1":7393,"PHASE2":7395,"PHASE3":7403,"PHASE4":7405,"NA":7407},{"trials":7392,"activeCount":99},[],{"trials":7394,"activeCount":99},[],{"trials":7396,"activeCount":99},[7397],{"nctId":7398,"briefTitle":7399,"status":107,"phases":7400,"primaryCompletion":2601,"start":2974,"enrollment":732,"conditions":7401,"interventions":7402},"NCT00041236","Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma",[88],[32],[7389],{"trials":7404,"activeCount":99},[],{"trials":7406,"activeCount":99},[],{"trials":7408,"activeCount":99},[],{"intervention":3376,"totalTrials":665,"cells":7410},{"EARLY_PHASE1":7411,"PHASE1":7413,"PHASE2":7415,"PHASE3":7421,"PHASE4":7423,"NA":7425},{"trials":7412,"activeCount":99},[],{"trials":7414,"activeCount":99},[],{"trials":7416,"activeCount":99},[7417],{"nctId":3370,"briefTitle":3371,"status":107,"phases":7418,"primaryCompletion":2630,"start":134,"enrollment":3373,"conditions":7419,"interventions":7420},[88],[34],[3376,980],{"trials":7422,"activeCount":99},[],{"trials":7424,"activeCount":99},[],{"trials":7426,"activeCount":99},[],{"intervention":3731,"totalTrials":665,"cells":7428},{"EARLY_PHASE1":7429,"PHASE1":7431,"PHASE2":7433,"PHASE3":7439,"PHASE4":7441,"NA":7443},{"trials":7430,"activeCount":99},[],{"trials":7432,"activeCount":99},[],{"trials":7434,"activeCount":99},[7435],{"nctId":3726,"briefTitle":3727,"status":107,"phases":7436,"primaryCompletion":2691,"start":823,"enrollment":710,"conditions":7437,"interventions":7438},[88],[15],[3731,2604],{"trials":7440,"activeCount":99},[],{"trials":7442,"activeCount":99},[],{"trials":7444,"activeCount":99},[],{"intervention":7446,"totalTrials":665,"cells":7447},"BI 2536",{"EARLY_PHASE1":7448,"PHASE1":7450,"PHASE2":7452,"PHASE3":7461,"PHASE4":7463,"NA":7465},{"trials":7449,"activeCount":99},[],{"trials":7451,"activeCount":99},[],{"trials":7453,"activeCount":99},[7454],{"nctId":7455,"briefTitle":7456,"status":107,"phases":7457,"primaryCompletion":397,"start":700,"enrollment":7458,"conditions":7459,"interventions":7460},"NCT00526149","BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors",[88],76,[15,412,1897,826,401,32],[7446],{"trials":7462,"activeCount":99},[],{"trials":7464,"activeCount":99},[],{"trials":7466,"activeCount":99},[],{"intervention":4859,"totalTrials":665,"cells":7468},{"EARLY_PHASE1":7469,"PHASE1":7471,"PHASE2":7473,"PHASE3":7479,"PHASE4":7481,"NA":7483},{"trials":7470,"activeCount":99},[],{"trials":7472,"activeCount":99},[],{"trials":7474,"activeCount":99},[7475],{"nctId":4852,"briefTitle":4853,"status":786,"phases":7476,"primaryCompletion":4855,"start":4175,"enrollment":99,"conditions":7477,"interventions":7478},[88],[4857],[4859,207],{"trials":7480,"activeCount":99},[],{"trials":7482,"activeCount":99},[],{"trials":7484,"activeCount":99},[],{"intervention":7486,"totalTrials":665,"cells":7487},"lintuzumab",{"EARLY_PHASE1":7488,"PHASE1":7490,"PHASE2":7492,"PHASE3":7500,"PHASE4":7502,"NA":7504},{"trials":7489,"activeCount":99},[],{"trials":7491,"activeCount":99},[],{"trials":7493,"activeCount":99},[7494],{"nctId":7495,"briefTitle":7496,"status":786,"phases":7497,"start":2848,"enrollment":99,"conditions":7498,"interventions":7499},"NCT00003984","Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome",[88],[1577],[7486],{"trials":7501,"activeCount":99},[],{"trials":7503,"activeCount":99},[],{"trials":7505,"activeCount":99},[],{"intervention":771,"totalTrials":665,"cells":7507},{"EARLY_PHASE1":7508,"PHASE1":7510,"PHASE2":7512,"PHASE3":7518,"PHASE4":7520,"NA":7522},{"trials":7509,"activeCount":99},[],{"trials":7511,"activeCount":99},[],{"trials":7513,"activeCount":99},[7514],{"nctId":764,"briefTitle":765,"status":107,"phases":7515,"primaryCompletion":767,"start":768,"enrollment":30,"conditions":7516,"interventions":7517},[87,88],[27],[54,771],{"trials":7519,"activeCount":99},[],{"trials":7521,"activeCount":99},[],{"trials":7523,"activeCount":99},[],{"intervention":3647,"totalTrials":665,"cells":7525},{"EARLY_PHASE1":7526,"PHASE1":7528,"PHASE2":7530,"PHASE3":7536,"PHASE4":7538,"NA":7540},{"trials":7527,"activeCount":99},[],{"trials":7529,"activeCount":99},[],{"trials":7531,"activeCount":99},[7532],{"nctId":3637,"briefTitle":3638,"status":188,"phases":7533,"primaryCompletion":3640,"completion":3640,"start":463,"enrollment":3641,"conditions":7534,"interventions":7535},[88],[3643,3644,3645],[3647,754,3648],{"trials":7537,"activeCount":99},[],{"trials":7539,"activeCount":99},[],{"trials":7541,"activeCount":99},[],{"intervention":7543,"totalTrials":665,"cells":7544},"chlormethine gel",{"EARLY_PHASE1":7545,"PHASE1":7547,"PHASE2":7549,"PHASE3":7560,"PHASE4":7562,"NA":7564},{"trials":7546,"activeCount":99},[],{"trials":7548,"activeCount":99},[],{"trials":7550,"activeCount":99},[7551],{"nctId":7552,"briefTitle":7553,"status":188,"phases":7554,"primaryCompletion":7555,"completion":7555,"start":7556,"enrollment":523,"conditions":7557,"interventions":7559},"NCT04218825","REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)",[88],"2023-04-04","2022-03-29",[7558],"Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (Stage IA-IB)",[7543],{"trials":7561,"activeCount":99},[],{"trials":7563,"activeCount":99},[],{"trials":7565,"activeCount":99},[],{"intervention":782,"totalTrials":665,"cells":7567},{"EARLY_PHASE1":7568,"PHASE1":7570,"PHASE2":7572,"PHASE3":7578,"PHASE4":7580,"NA":7582},{"trials":7569,"activeCount":99},[],{"trials":7571,"activeCount":99},[],{"trials":7573,"activeCount":99},[7574],{"nctId":773,"briefTitle":774,"status":107,"phases":7575,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":7576,"interventions":7577},[88],[27],[54,782],{"trials":7579,"activeCount":99},[],{"trials":7581,"activeCount":99},[],{"trials":7583,"activeCount":99},[],{"intervention":7585,"totalTrials":665,"cells":7586},"sunitinib malate",{"EARLY_PHASE1":7587,"PHASE1":7589,"PHASE2":7591,"PHASE3":7601,"PHASE4":7603,"NA":7605},{"trials":7588,"activeCount":99},[],{"trials":7590,"activeCount":99},[],{"trials":7592,"activeCount":99},[7593],{"nctId":7594,"briefTitle":7595,"status":188,"phases":7596,"primaryCompletion":5458,"completion":7597,"start":7598,"enrollment":3407,"conditions":7599,"interventions":7600},"NCT00953459","Sunitinib Malate in Treating Patients With Small Cell Lung Cancer",[88],"2012-09","2009-02",[24],[7585],{"trials":7602,"activeCount":99},[],{"trials":7604,"activeCount":99},[],{"trials":7606,"activeCount":99},[],{"intervention":797,"totalTrials":665,"cells":7608},{"EARLY_PHASE1":7609,"PHASE1":7611,"PHASE2":7613,"PHASE3":7619,"PHASE4":7621,"NA":7623},{"trials":7610,"activeCount":99},[],{"trials":7612,"activeCount":99},[],{"trials":7614,"activeCount":99},[7615],{"nctId":784,"briefTitle":785,"status":786,"phases":7616,"primaryCompletion":788,"completion":789,"start":790,"enrollment":99,"conditions":7617,"interventions":7618},[88],[792],[794,795,796,797,716],{"trials":7620,"activeCount":99},[],{"trials":7622,"activeCount":99},[],{"trials":7624,"activeCount":99},[],{"intervention":1874,"totalTrials":665,"cells":7626},{"EARLY_PHASE1":7627,"PHASE1":7629,"PHASE2":7631,"PHASE3":7637,"PHASE4":7639,"NA":7641},{"trials":7628,"activeCount":99},[],{"trials":7630,"activeCount":99},[],{"trials":7632,"activeCount":99},[7633],{"nctId":1866,"briefTitle":1867,"status":107,"phases":7634,"primaryCompletion":1869,"start":1870,"enrollment":1871,"conditions":7635,"interventions":7636},[88],[15],[980,1874,368],{"trials":7638,"activeCount":99},[],{"trials":7640,"activeCount":99},[],{"trials":7642,"activeCount":99},[],{"intervention":6393,"totalTrials":665,"cells":7644},{"EARLY_PHASE1":7645,"PHASE1":7647,"PHASE2":7649,"PHASE3":7655,"PHASE4":7657,"NA":7659},{"trials":7646,"activeCount":99},[],{"trials":7648,"activeCount":99},[],{"trials":7650,"activeCount":99},[7651],{"nctId":6387,"briefTitle":6388,"status":107,"phases":7652,"primaryCompletion":2691,"start":6390,"enrollment":2741,"conditions":7653,"interventions":7654},[88],[27],[6393,2556,6394],{"trials":7656,"activeCount":99},[],{"trials":7658,"activeCount":99},[],{"trials":7660,"activeCount":99},[],{"intervention":1887,"totalTrials":665,"cells":7662},{"EARLY_PHASE1":7663,"PHASE1":7665,"PHASE2":7667,"PHASE3":7673,"PHASE4":7675,"NA":7677},{"trials":7664,"activeCount":99},[],{"trials":7666,"activeCount":99},[],{"trials":7668,"activeCount":99},[7669],{"nctId":1876,"briefTitle":1877,"status":786,"phases":7670,"primaryCompletion":1879,"completion":1880,"start":1881,"enrollment":99,"conditions":7671,"interventions":7672},[88],[1883,1020,1884,1885],[1887,1888,1889],{"trials":7674,"activeCount":99},[],{"trials":7676,"activeCount":99},[],{"trials":7678,"activeCount":99},[],{"intervention":3660,"totalTrials":665,"cells":7680},{"EARLY_PHASE1":7681,"PHASE1":7683,"PHASE2":7685,"PHASE3":7691,"PHASE4":7693,"NA":7695},{"trials":7682,"activeCount":99},[],{"trials":7684,"activeCount":99},[],{"trials":7686,"activeCount":99},[7687],{"nctId":3650,"briefTitle":3651,"status":107,"phases":7688,"primaryCompletion":2801,"completion":3653,"start":3654,"enrollment":3655,"conditions":7689,"interventions":7690},[88],[3657],[754,3659,3660],{"trials":7692,"activeCount":99},[],{"trials":7694,"activeCount":99},[],{"trials":7696,"activeCount":99},[],{"intervention":2014,"totalTrials":665,"cells":7698},{"EARLY_PHASE1":7699,"PHASE1":7701,"PHASE2":7703,"PHASE3":7709,"PHASE4":7711,"NA":7713},{"trials":7700,"activeCount":99},[],{"trials":7702,"activeCount":99},[],{"trials":7704,"activeCount":99},[7705],{"nctId":2004,"briefTitle":2005,"status":361,"phases":7706,"primaryCompletion":2007,"completion":2008,"start":2009,"enrollment":439,"conditions":7707,"interventions":7708},[88],[2011],[2013,1848,2014,2015,2016,2017,2018],{"trials":7710,"activeCount":99},[],{"trials":7712,"activeCount":99},[],{"trials":7714,"activeCount":99},[],{"intervention":2015,"totalTrials":665,"cells":7716},{"EARLY_PHASE1":7717,"PHASE1":7719,"PHASE2":7721,"PHASE3":7727,"PHASE4":7729,"NA":7731},{"trials":7718,"activeCount":99},[],{"trials":7720,"activeCount":99},[],{"trials":7722,"activeCount":99},[7723],{"nctId":2004,"briefTitle":2005,"status":361,"phases":7724,"primaryCompletion":2007,"completion":2008,"start":2009,"enrollment":439,"conditions":7725,"interventions":7726},[88],[2011],[2013,1848,2014,2015,2016,2017,2018],{"trials":7728,"activeCount":99},[],{"trials":7730,"activeCount":99},[],{"trials":7732,"activeCount":99},[],{"intervention":2017,"totalTrials":665,"cells":7734},{"EARLY_PHASE1":7735,"PHASE1":7737,"PHASE2":7739,"PHASE3":7745,"PHASE4":7747,"NA":7749},{"trials":7736,"activeCount":99},[],{"trials":7738,"activeCount":99},[],{"trials":7740,"activeCount":99},[7741],{"nctId":2004,"briefTitle":2005,"status":361,"phases":7742,"primaryCompletion":2007,"completion":2008,"start":2009,"enrollment":439,"conditions":7743,"interventions":7744},[88],[2011],[2013,1848,2014,2015,2016,2017,2018],{"trials":7746,"activeCount":99},[],{"trials":7748,"activeCount":99},[],{"trials":7750,"activeCount":99},[],{"intervention":2018,"totalTrials":665,"cells":7752},{"EARLY_PHASE1":7753,"PHASE1":7755,"PHASE2":7757,"PHASE3":7763,"PHASE4":7765,"NA":7767},{"trials":7754,"activeCount":99},[],{"trials":7756,"activeCount":99},[],{"trials":7758,"activeCount":99},[7759],{"nctId":2004,"briefTitle":2005,"status":361,"phases":7760,"primaryCompletion":2007,"completion":2008,"start":2009,"enrollment":439,"conditions":7761,"interventions":7762},[88],[2011],[2013,1848,2014,2015,2016,2017,2018],{"trials":7764,"activeCount":99},[],{"trials":7766,"activeCount":99},[],{"trials":7768,"activeCount":99},[],{"intervention":7770,"totalTrials":665,"cells":7771},"infliximab",{"EARLY_PHASE1":7772,"PHASE1":7774,"PHASE2":7776,"PHASE3":7785,"PHASE4":7787,"NA":7789},{"trials":7773,"activeCount":99},[],{"trials":7775,"activeCount":99},[],{"trials":7777,"activeCount":99},[7778],{"nctId":7779,"briefTitle":7780,"status":107,"phases":7781,"primaryCompletion":6390,"start":6461,"enrollment":7782,"conditions":7783,"interventions":7784},"NCT00074074","Infliximab in Treating Patients With Myelodysplastic Syndrome",[88],46,[1577],[7770],{"trials":7786,"activeCount":99},[],{"trials":7788,"activeCount":99},[],{"trials":7790,"activeCount":99},[],{"intervention":2671,"totalTrials":665,"cells":7792},{"EARLY_PHASE1":7793,"PHASE1":7795,"PHASE2":7797,"PHASE3":7803,"PHASE4":7805,"NA":7807},{"trials":7794,"activeCount":99},[],{"trials":7796,"activeCount":99},[],{"trials":7798,"activeCount":99},[7799],{"nctId":2659,"briefTitle":2660,"status":107,"phases":7800,"primaryCompletion":2662,"completion":2663,"start":2664,"enrollment":2665,"conditions":7801,"interventions":7802},[88],[2667,2668,2669],[794,2671,2672,2673],{"trials":7804,"activeCount":99},[],{"trials":7806,"activeCount":99},[],{"trials":7808,"activeCount":99},[],{"intervention":2673,"totalTrials":665,"cells":7810},{"EARLY_PHASE1":7811,"PHASE1":7813,"PHASE2":7815,"PHASE3":7821,"PHASE4":7823,"NA":7825},{"trials":7812,"activeCount":99},[],{"trials":7814,"activeCount":99},[],{"trials":7816,"activeCount":99},[7817],{"nctId":2659,"briefTitle":2660,"status":107,"phases":7818,"primaryCompletion":2662,"completion":2663,"start":2664,"enrollment":2665,"conditions":7819,"interventions":7820},[88],[2667,2668,2669],[794,2671,2672,2673],{"trials":7822,"activeCount":99},[],{"trials":7824,"activeCount":99},[],{"trials":7826,"activeCount":99},[],{"intervention":7828,"totalTrials":665,"cells":7829},"ISIS 3521",{"EARLY_PHASE1":7830,"PHASE1":7832,"PHASE2":7834,"PHASE3":7843,"PHASE4":7845,"NA":7847},{"trials":7831,"activeCount":99},[],{"trials":7833,"activeCount":99},[],{"trials":7835,"activeCount":99},[7836],{"nctId":7837,"briefTitle":7838,"status":107,"phases":7839,"start":7840,"enrollment":1018,"conditions":7841,"interventions":7842},"NCT00003989","ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma",[88],"1998-06",[24,826],[7828],{"trials":7844,"activeCount":99},[],{"trials":7846,"activeCount":99},[],{"trials":7848,"activeCount":99},[],{"intervention":7850,"totalTrials":665,"cells":7851},"Crizotinib",{"EARLY_PHASE1":7852,"PHASE1":7854,"PHASE2":7856,"PHASE3":7873,"PHASE4":7875,"NA":7877},{"trials":7853,"activeCount":99},[],{"trials":7855,"activeCount":99},[],{"trials":7857,"activeCount":99},[7858],{"nctId":7859,"briefTitle":7860,"status":107,"phases":7861,"primaryCompletion":7862,"completion":7863,"start":7597,"enrollment":7864,"conditions":7865,"interventions":7872},"NCT01524926","CREATE: Cross-tumoral Phase 2 With Crizotinib",[88],"2017-12-06","2022-10-30",582,[7866,7867,7868,7869,7870,7871],"Locally Advanced and\u002For Metastatic Anaplastic Large Cell Lymphoma","Locally Advanced and\u002For Metastatic Inflammatory Myofibroblastic Tumor","Locally Advanced and\u002For Metastatic Papillary Renal Cell Carcinoma Type 1","Locally Advanced and\u002For Metastatic Alveolar Soft Part Sarcoma","Locally Advanced and\u002For Metastatic Clear Cell Sarcoma","Locally Advanced and\u002For Metastatic Alveolar Rhabdomyosarcoma",[7850],{"trials":7874,"activeCount":99},[],{"trials":7876,"activeCount":99},[],{"trials":7878,"activeCount":99},[],{"intervention":2894,"totalTrials":665,"cells":7880},{"EARLY_PHASE1":7881,"PHASE1":7883,"PHASE2":7885,"PHASE3":7891,"PHASE4":7893,"NA":7895},{"trials":7882,"activeCount":99},[],{"trials":7884,"activeCount":99},[],{"trials":7886,"activeCount":99},[7887],{"nctId":2887,"briefTitle":2888,"status":361,"phases":7888,"primaryCompletion":2890,"start":699,"enrollment":2891,"conditions":7889,"interventions":7890},[87,88],[18,1577],[2894,151,1581],{"trials":7892,"activeCount":99},[],{"trials":7894,"activeCount":99},[],{"trials":7896,"activeCount":99},[],{"intervention":7898,"totalTrials":665,"cells":7899},"Xevinapant",{"EARLY_PHASE1":7900,"PHASE1":7902,"PHASE2":7904,"PHASE3":7916,"PHASE4":7918,"NA":7920},{"trials":7901,"activeCount":99},[],{"trials":7903,"activeCount":99},[],{"trials":7905,"activeCount":99},[7906],{"nctId":7907,"briefTitle":7908,"status":6412,"phases":7909,"primaryCompletion":7910,"completion":7911,"start":7912,"enrollment":676,"conditions":7913,"interventions":7915},"NCT05724602","Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma",[88],"2029-07","2029-10","2023-11-15",[7914],"Locally Advanced Head and Neck Squamous Cell Carcinoma",[7898],{"trials":7917,"activeCount":99},[],{"trials":7919,"activeCount":99},[],{"trials":7921,"activeCount":99},[],{"intervention":3924,"totalTrials":665,"cells":7923},{"EARLY_PHASE1":7924,"PHASE1":7926,"PHASE2":7928,"PHASE3":7934,"PHASE4":7936,"NA":7938},{"trials":7925,"activeCount":99},[],{"trials":7927,"activeCount":99},[],{"trials":7929,"activeCount":99},[7930],{"nctId":3913,"briefTitle":3914,"status":786,"phases":7931,"primaryCompletion":3916,"completion":3917,"start":3918,"enrollment":99,"conditions":7932,"interventions":7933},[88],[3920,3921,3922],[3924,2016],{"trials":7935,"activeCount":99},[],{"trials":7937,"activeCount":99},[],{"trials":7939,"activeCount":99},[],{"intervention":1592,"totalTrials":665,"cells":7941},{"EARLY_PHASE1":7942,"PHASE1":7944,"PHASE2":7946,"PHASE3":7952,"PHASE4":7954,"NA":7956},{"trials":7943,"activeCount":99},[],{"trials":7945,"activeCount":99},[],{"trials":7947,"activeCount":99},[7948],{"nctId":1583,"briefTitle":1584,"status":107,"phases":7949,"primaryCompletion":721,"completion":1586,"start":1587,"enrollment":1588,"conditions":7950,"interventions":7951},[88],[15],[1591,1592,115,270,156],{"trials":7953,"activeCount":99},[],{"trials":7955,"activeCount":99},[],{"trials":7957,"activeCount":99},[],{"intervention":7959,"totalTrials":665,"cells":7960},"INO-3112 vaccine",{"EARLY_PHASE1":7961,"PHASE1":7963,"PHASE2":7965,"PHASE3":7978,"PHASE4":7980,"NA":7982},{"trials":7962,"activeCount":99},[],{"trials":7964,"activeCount":99},[],{"trials":7966,"activeCount":99},[7967],{"nctId":7968,"briefTitle":7969,"status":786,"phases":7970,"primaryCompletion":7971,"completion":7972,"start":7973,"enrollment":99,"conditions":7974,"interventions":7976},"NCT02501278","A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer",[88],"2019-05","2021-05","2016-05",[7975],"Uterine Cervical Neoplasms",[7959,7977],"Cisplatin chemotherapy",{"trials":7979,"activeCount":99},[],{"trials":7981,"activeCount":99},[],{"trials":7983,"activeCount":99},[],{"intervention":7977,"totalTrials":665,"cells":7985},{"EARLY_PHASE1":7986,"PHASE1":7988,"PHASE2":7990,"PHASE3":7996,"PHASE4":7998,"NA":8000},{"trials":7987,"activeCount":99},[],{"trials":7989,"activeCount":99},[],{"trials":7991,"activeCount":99},[7992],{"nctId":7968,"briefTitle":7969,"status":786,"phases":7993,"primaryCompletion":7971,"completion":7972,"start":7973,"enrollment":99,"conditions":7994,"interventions":7995},[88],[7975],[7959,7977],{"trials":7997,"activeCount":99},[],{"trials":7999,"activeCount":99},[],{"trials":8001,"activeCount":99},[],{"intervention":8003,"totalTrials":665,"cells":8004},"Denosumab 120 MG\u002F1.7 ML Subcutaneous Solution [XGEVA]",{"EARLY_PHASE1":8005,"PHASE1":8007,"PHASE2":8009,"PHASE3":8020,"PHASE4":8022,"NA":8024},{"trials":8006,"activeCount":99},[],{"trials":8008,"activeCount":99},[],{"trials":8010,"activeCount":99},[8011],{"nctId":8012,"briefTitle":8013,"status":188,"phases":8014,"primaryCompletion":8015,"completion":8015,"start":8016,"enrollment":523,"conditions":8017,"interventions":8019},"NCT03620149","Reduced Dose-density of Denosumab for Unresectable GCTB",[88],"2020-07-30","2019-09-26",[8018],"Bone Giant Cell Tumor",[8003],{"trials":8021,"activeCount":99},[],{"trials":8023,"activeCount":99},[],{"trials":8025,"activeCount":99},[],{"intervention":8027,"totalTrials":665,"cells":8028},"liposomal lurtotecan",{"EARLY_PHASE1":8029,"PHASE1":8031,"PHASE2":8033,"PHASE3":8041,"PHASE4":8043,"NA":8045},{"trials":8030,"activeCount":99},[],{"trials":8032,"activeCount":99},[],{"trials":8034,"activeCount":99},[8035],{"nctId":8036,"briefTitle":8037,"status":107,"phases":8038,"primaryCompletion":165,"start":1909,"enrollment":1018,"conditions":8039,"interventions":8040},"NCT00022594","Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer",[88],[1897],[8027],{"trials":8042,"activeCount":99},[],{"trials":8044,"activeCount":99},[],{"trials":8046,"activeCount":99},[],{"intervention":3753,"totalTrials":665,"cells":8048},{"EARLY_PHASE1":8049,"PHASE1":8051,"PHASE2":8053,"PHASE3":8059,"PHASE4":8061,"NA":8063},{"trials":8050,"activeCount":99},[],{"trials":8052,"activeCount":99},[],{"trials":8054,"activeCount":99},[8055],{"nctId":3743,"briefTitle":3744,"status":107,"phases":8056,"primaryCompletion":3746,"completion":3747,"start":3748,"enrollment":3749,"conditions":8057,"interventions":8058},[88],[3751],[3753,3754],{"trials":8060,"activeCount":99},[],{"trials":8062,"activeCount":99},[],{"trials":8064,"activeCount":99},[],{"intervention":8066,"totalTrials":665,"cells":8067},"human papillomavirus 16 E7 peptide",{"EARLY_PHASE1":8068,"PHASE1":8070,"PHASE2":8072,"PHASE3":8082,"PHASE4":8084,"NA":8086},{"trials":8069,"activeCount":99},[],{"trials":8071,"activeCount":99},[],{"trials":8073,"activeCount":99},[8074],{"nctId":8075,"briefTitle":8076,"status":107,"phases":8077,"start":8078,"enrollment":3641,"conditions":8079,"interventions":8080},"NCT00002916","Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer",[88],"1996-11",[268],[8066,8081],"synthetic human papillomavirus 16 E6 peptide",{"trials":8083,"activeCount":99},[],{"trials":8085,"activeCount":99},[],{"trials":8087,"activeCount":99},[],{"intervention":8081,"totalTrials":665,"cells":8089},{"EARLY_PHASE1":8090,"PHASE1":8092,"PHASE2":8094,"PHASE3":8100,"PHASE4":8102,"NA":8104},{"trials":8091,"activeCount":99},[],{"trials":8093,"activeCount":99},[],{"trials":8095,"activeCount":99},[8096],{"nctId":8075,"briefTitle":8076,"status":107,"phases":8097,"start":8078,"enrollment":3641,"conditions":8098,"interventions":8099},[88],[268],[8066,8081],{"trials":8101,"activeCount":99},[],{"trials":8103,"activeCount":99},[],{"trials":8105,"activeCount":99},[],{"intervention":4178,"totalTrials":665,"cells":8107},{"EARLY_PHASE1":8108,"PHASE1":8110,"PHASE2":8112,"PHASE3":8118,"PHASE4":8120,"NA":8122},{"trials":8109,"activeCount":99},[],{"trials":8111,"activeCount":99},[],{"trials":8113,"activeCount":99},[8114],{"nctId":4172,"briefTitle":4173,"status":786,"phases":8115,"primaryCompletion":3019,"completion":4175,"start":302,"enrollment":99,"conditions":8116,"interventions":8117},[88],[34],[4178,4179],{"trials":8119,"activeCount":99},[],{"trials":8121,"activeCount":99},[],{"trials":8123,"activeCount":99},[],{"intervention":6799,"totalTrials":523,"cells":8125},{"EARLY_PHASE1":8126,"PHASE1":8128,"PHASE2":8141,"PHASE3":8143,"PHASE4":8145,"NA":8147},{"trials":8127,"activeCount":99},[],{"trials":8129,"activeCount":99},[8130,8137],{"nctId":8131,"briefTitle":8132,"status":107,"phases":8133,"primaryCompletion":2785,"start":1869,"enrollment":8134,"conditions":8135,"interventions":8136},"NCT00004015","Boron Neutron Capture Therapy Following Surgery in Treating Patients With Glioblastoma Multiforme Removed During Surgery",[87],36,[27],[6799],{"nctId":6794,"briefTitle":6795,"status":107,"phases":8138,"primaryCompletion":854,"start":491,"enrollment":2399,"conditions":8139,"interventions":8140},[87],[29,1897,351],[6787,6799],{"trials":8142,"activeCount":99},[],{"trials":8144,"activeCount":99},[],{"trials":8146,"activeCount":99},[],{"trials":8148,"activeCount":99},[],{"intervention":3278,"totalTrials":665,"cells":8150},{"EARLY_PHASE1":8151,"PHASE1":8153,"PHASE2":8159,"PHASE3":8161,"PHASE4":8163,"NA":8165},{"trials":8152,"activeCount":99},[],{"trials":8154,"activeCount":99},[8155],{"nctId":3273,"briefTitle":3274,"status":107,"phases":8156,"primaryCompletion":2994,"start":2705,"enrollment":952,"conditions":8157,"interventions":8158},[87],[29],[3278,2967],{"trials":8160,"activeCount":99},[],{"trials":8162,"activeCount":99},[],{"trials":8164,"activeCount":99},[],{"trials":8166,"activeCount":99},[],{"intervention":8168,"totalTrials":665,"cells":8169},"halofuginone hydrobromide",{"EARLY_PHASE1":8170,"PHASE1":8172,"PHASE2":8180,"PHASE3":8182,"PHASE4":8184,"NA":8186},{"trials":8171,"activeCount":99},[],{"trials":8173,"activeCount":99},[8174],{"nctId":8175,"briefTitle":8176,"status":107,"phases":8177,"primaryCompletion":2705,"start":6496,"enrollment":19,"conditions":8178,"interventions":8179},"NCT00027677","Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors",[87],[3352],[8168],{"trials":8181,"activeCount":99},[],{"trials":8183,"activeCount":99},[],{"trials":8185,"activeCount":99},[],{"trials":8187,"activeCount":99},[],{"intervention":8189,"totalTrials":665,"cells":8190},"KRN7000",{"EARLY_PHASE1":8191,"PHASE1":8193,"PHASE2":8201,"PHASE3":8203,"PHASE4":8205,"NA":8207},{"trials":8192,"activeCount":99},[],{"trials":8194,"activeCount":99},[8195],{"nctId":8196,"briefTitle":8197,"status":786,"phases":8198,"start":252,"enrollment":99,"conditions":8199,"interventions":8200},"NCT00003985","KRN7000 in Treating Patients With Solid Tumors",[87],[24,3352],[8189],{"trials":8202,"activeCount":99},[],{"trials":8204,"activeCount":99},[],{"trials":8206,"activeCount":99},[],{"trials":8208,"activeCount":99},[],{"intervention":703,"totalTrials":665,"cells":8210},{"EARLY_PHASE1":8211,"PHASE1":8213,"PHASE2":8219,"PHASE3":8221,"PHASE4":8223,"NA":8225},{"trials":8212,"activeCount":99},[],{"trials":8214,"activeCount":99},[8215],{"nctId":696,"briefTitle":697,"status":361,"phases":8216,"primaryCompletion":699,"start":700,"enrollment":16,"conditions":8217,"interventions":8218},[87],[27],[703,54],{"trials":8220,"activeCount":99},[],{"trials":8222,"activeCount":99},[],{"trials":8224,"activeCount":99},[],{"trials":8226,"activeCount":99},[],{"intervention":8228,"totalTrials":665,"cells":8229},"CNGRC peptide-TNF alpha conjugate",{"EARLY_PHASE1":8230,"PHASE1":8232,"PHASE2":8240,"PHASE3":8242,"PHASE4":8244,"NA":8246},{"trials":8231,"activeCount":99},[],{"trials":8233,"activeCount":99},[8234],{"nctId":8235,"briefTitle":8236,"status":107,"phases":8237,"primaryCompletion":767,"start":2964,"enrollment":760,"conditions":8238,"interventions":8239},"NCT00098943","NGR-TNF in Treating Patients With Advanced Solid Tumors",[87],[29,1897,452,3352],[8228],{"trials":8241,"activeCount":99},[],{"trials":8243,"activeCount":99},[],{"trials":8245,"activeCount":99},[],{"trials":8247,"activeCount":99},[],{"intervention":715,"totalTrials":665,"cells":8249},{"EARLY_PHASE1":8250,"PHASE1":8252,"PHASE2":8258,"PHASE3":8260,"PHASE4":8262,"NA":8264},{"trials":8251,"activeCount":99},[],{"trials":8253,"activeCount":99},[8254],{"nctId":705,"briefTitle":706,"status":107,"phases":8255,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":8256,"interventions":8257},[87],[712,713],[715,716],{"trials":8259,"activeCount":99},[],{"trials":8261,"activeCount":99},[],{"trials":8263,"activeCount":99},[],{"trials":8265,"activeCount":99},[],{"intervention":8267,"totalTrials":665,"cells":8268},"BIBX 1382",{"EARLY_PHASE1":8269,"PHASE1":8271,"PHASE2":8279,"PHASE3":8281,"PHASE4":8283,"NA":8285},{"trials":8270,"activeCount":99},[],{"trials":8272,"activeCount":99},[8273],{"nctId":8274,"briefTitle":8275,"status":6412,"phases":8276,"start":2848,"enrollment":1749,"conditions":8277,"interventions":8278},"NCT00003980","BIBX 1382 in Treating Patients With Solid Tumors",[87],[3352],[8267],{"trials":8280,"activeCount":99},[],{"trials":8282,"activeCount":99},[],{"trials":8284,"activeCount":99},[],{"trials":8286,"activeCount":99},[],{"intervention":8288,"totalTrials":665,"cells":8289},"CHS 828",{"EARLY_PHASE1":8290,"PHASE1":8292,"PHASE2":8300,"PHASE3":8302,"PHASE4":8304,"NA":8306},{"trials":8291,"activeCount":99},[],{"trials":8293,"activeCount":99},[8294],{"nctId":8295,"briefTitle":8296,"status":786,"phases":8297,"start":347,"enrollment":99,"conditions":8298,"interventions":8299},"NCT00003979","CHS 828 in Treating Patients With Solid Tumors",[87],[3352],[8288],{"trials":8301,"activeCount":99},[],{"trials":8303,"activeCount":99},[],{"trials":8305,"activeCount":99},[],{"trials":8307,"activeCount":99},[],{"intervention":3354,"totalTrials":665,"cells":8309},{"EARLY_PHASE1":8310,"PHASE1":8312,"PHASE2":8318,"PHASE3":8320,"PHASE4":8322,"NA":8324},{"trials":8311,"activeCount":99},[],{"trials":8313,"activeCount":99},[8314],{"nctId":3348,"briefTitle":3349,"status":107,"phases":8315,"primaryCompletion":1869,"start":264,"enrollment":722,"conditions":8316,"interventions":8317},[87],[3352],[980,3354],{"trials":8319,"activeCount":99},[],{"trials":8321,"activeCount":99},[],{"trials":8323,"activeCount":99},[],{"trials":8325,"activeCount":99},[],{"intervention":270,"totalTrials":16,"cells":8327},{"EARLY_PHASE1":8328,"PHASE1":8330,"PHASE2":8336,"PHASE3":8386,"PHASE4":8448,"NA":8450},{"trials":8329,"activeCount":99},[],{"trials":8331,"activeCount":99},[8332],{"nctId":2960,"briefTitle":2961,"status":107,"phases":8333,"primaryCompletion":2963,"start":2964,"enrollment":2856,"conditions":8334,"interventions":8335},[87],[29],[2569,270,154,2967],{"trials":8337,"activeCount":99},[8338,8342,8346,8350,8354,8358,8362,8370,8374,8378,8382],{"nctId":2547,"briefTitle":2548,"status":188,"phases":8339,"primaryCompletion":489,"completion":2550,"start":2551,"enrollment":2552,"conditions":8340,"interventions":8341},[88],[1897],[2555,289,257,980,270,2556,2557,2558],{"nctId":2571,"briefTitle":2572,"status":107,"phases":8343,"primaryCompletion":699,"completion":2574,"start":2575,"enrollment":320,"conditions":8344,"interventions":8345},[87,88],[1897],[289,257,980,270,968,2578,2556,2579,2580,2558],{"nctId":2971,"briefTitle":2972,"status":188,"phases":8347,"primaryCompletion":346,"start":2974,"enrollment":2975,"conditions":8348,"interventions":8349},[88],[29,351],[935,2978,270,154,2967],{"nctId":2980,"briefTitle":2981,"status":361,"phases":8351,"start":2963,"enrollment":2983,"conditions":8352,"interventions":8353},[88],[29,351],[935,2555,270,154,2967],{"nctId":2588,"briefTitle":2589,"status":107,"phases":8355,"primaryCompletion":2591,"start":2592,"enrollment":2593,"conditions":8356,"interventions":8357},[88],[966],[257,270,154],{"nctId":2991,"briefTitle":2992,"status":107,"phases":8359,"primaryCompletion":2994,"start":1587,"conditions":8360,"interventions":8361},[88],[29],[270,2635,154,2967],{"nctId":8363,"briefTitle":8364,"status":188,"phases":8365,"primaryCompletion":2785,"start":304,"conditions":8366,"interventions":8369},"NCT00030511","Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer",[88],[8367,8368],"Extrahepatic Bile Duct Cancer","Liver Cancer",[270],{"nctId":3300,"briefTitle":3301,"status":786,"phases":8371,"primaryCompletion":3303,"start":3304,"enrollment":99,"conditions":8372,"interventions":8373},[88],[3306,3307,3308],[3310,3311,3312,796],{"nctId":2649,"briefTitle":2650,"status":188,"phases":8375,"primaryCompletion":1894,"start":213,"enrollment":2256,"conditions":8376,"interventions":8377},[88],[255],[257,270],{"nctId":959,"briefTitle":960,"status":188,"phases":8379,"primaryCompletion":863,"completion":962,"start":963,"enrollment":740,"conditions":8380,"interventions":8381},[88],[965,966],[955,257,217,270,968],{"nctId":1583,"briefTitle":1584,"status":107,"phases":8383,"primaryCompletion":721,"completion":1586,"start":1587,"enrollment":1588,"conditions":8384,"interventions":8385},[88],[15],[1591,1592,115,270,156],{"trials":8387,"activeCount":99},[8388,8392,8396,8400,8404,8408,8412,8416,8420,8424,8428,8432,8436,8440,8444],{"nctId":2702,"briefTitle":2703,"status":188,"phases":8389,"primaryCompletion":2705,"start":2678,"enrollment":2706,"conditions":8390,"interventions":8391},[89],[966],[257,270,154],{"nctId":261,"briefTitle":262,"status":107,"phases":8393,"primaryCompletion":264,"start":265,"enrollment":266,"conditions":8394,"interventions":8395},[89],[268],[41,257,270,271,156,272,176,273],{"nctId":2745,"briefTitle":2746,"status":107,"phases":8397,"primaryCompletion":49,"start":2748,"enrollment":2749,"conditions":8398,"interventions":8399},[89],[1897],[257,270],{"nctId":972,"briefTitle":973,"status":107,"phases":8401,"primaryCompletion":975,"start":976,"enrollment":977,"conditions":8402,"interventions":8403},[89],[15],[169,115,980,217,270,981],{"nctId":3008,"briefTitle":3009,"status":107,"phases":8405,"primaryCompletion":1894,"start":2678,"enrollment":3011,"conditions":8406,"interventions":8407},[89],[29],[3014,270,2635,154],{"nctId":3016,"briefTitle":3017,"status":107,"phases":8409,"primaryCompletion":191,"completion":3019,"start":3020,"enrollment":3021,"conditions":8410,"interventions":8411},[89],[29],[270,154],{"nctId":3025,"briefTitle":3026,"status":361,"phases":8413,"start":3028,"conditions":8414,"interventions":8415},[89],[29,351],[2978,270,154,2967],{"nctId":3032,"briefTitle":3033,"status":107,"phases":8417,"primaryCompletion":123,"start":823,"enrollment":3035,"conditions":8418,"interventions":8419},[89],[29],[3014,955,3038,270,2635,154],{"nctId":2761,"briefTitle":2762,"status":107,"phases":8421,"primaryCompletion":124,"completion":2764,"start":347,"enrollment":2765,"conditions":8422,"interventions":8423},[89],[1897],[257,980,270],{"nctId":3994,"briefTitle":3995,"status":107,"phases":8425,"primaryCompletion":110,"start":3997,"enrollment":2679,"conditions":8426,"interventions":8427},[89],[452],[1647,227,270],{"nctId":2782,"briefTitle":2783,"status":188,"phases":8429,"primaryCompletion":767,"start":2785,"enrollment":1826,"conditions":8430,"interventions":8431},[88,89],[2787],[257,270,272],{"nctId":3040,"briefTitle":3041,"status":107,"phases":8433,"primaryCompletion":124,"start":3043,"enrollment":3044,"conditions":8434,"interventions":8435},[89],[29],[2978,270,154,2967],{"nctId":3048,"briefTitle":3049,"status":107,"phases":8437,"primaryCompletion":2600,"start":145,"conditions":8438,"interventions":8439},[89],[29],[3038,270,154],{"nctId":2831,"briefTitle":2832,"status":107,"phases":8441,"primaryCompletion":2785,"start":2834,"enrollment":1033,"conditions":8442,"interventions":8443},[89],[2681],[257,270],{"nctId":2838,"briefTitle":2839,"status":786,"phases":8445,"enrollment":99,"conditions":8446,"interventions":8447},[89],[1897],[2843,257,270],{"trials":8449,"activeCount":99},[],{"trials":8451,"activeCount":99},[8452],{"nctId":8453,"briefTitle":8454,"status":107,"phases":8455,"primaryCompletion":8456,"start":517,"enrollment":1749,"conditions":8457,"interventions":8458},"NCT00003730","Vinorelbine Plus Fluorouracil in Treating Women With Metastatic Breast Cancer",[91],"2004-11",[15],[270,4043],{"intervention":8460,"totalTrials":192,"cells":8461},"Tumour markers testing",{"EARLY_PHASE1":8462,"PHASE1":8464,"PHASE2":8466,"PHASE3":8468,"PHASE4":8470,"NA":8472},{"trials":8463,"activeCount":99},[],{"trials":8465,"activeCount":99},[],{"trials":8467,"activeCount":99},[],{"trials":8469,"activeCount":99},[],{"trials":8471,"activeCount":99},[],{"trials":8473,"activeCount":99},[8474,8482,8491],{"nctId":8475,"briefTitle":8476,"status":786,"phases":8477,"primaryCompletion":8478,"completion":8478,"start":7973,"enrollment":99,"conditions":8479,"interventions":8481},"NCT02307604","SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access",[],"2019-01",[8480],"Brain Neoplasms",[8460],{"nctId":8483,"briefTitle":8484,"status":107,"phases":8485,"primaryCompletion":8486,"completion":5071,"start":5457,"enrollment":8487,"conditions":8488,"interventions":8490},"NCT01723969","Screening Platform for Clinical Trials in Advanced Colorectal Cancer",[],"2019-04-10",668,[29,8489],"Advanced Colorectal Cancer",[8460],{"nctId":8492,"briefTitle":8493,"status":107,"phases":8494,"primaryCompletion":8495,"completion":8496,"start":8497,"enrollment":8498,"conditions":8499,"interventions":8503},"NCT02214134","SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access",[],"2020-10-22","2021-05-12","2015-05-22",539,[8500,8501,8502],"Any Stage of Lung Cancer (Any Histotype)","Any Stage of Malignant Pleural Mesothelioma","Any Stage of Any Thymic Malignancy",[8460],{"intervention":6394,"totalTrials":192,"cells":8505},{"EARLY_PHASE1":8506,"PHASE1":8508,"PHASE2":8510,"PHASE3":8516,"PHASE4":8527,"NA":8529},{"trials":8507,"activeCount":99},[],{"trials":8509,"activeCount":99},[],{"trials":8511,"activeCount":99},[8512],{"nctId":6387,"briefTitle":6388,"status":107,"phases":8513,"primaryCompletion":2691,"start":6390,"enrollment":2741,"conditions":8514,"interventions":8515},[88],[27],[6393,2556,6394],{"trials":8517,"activeCount":99},[8518],{"nctId":8519,"briefTitle":8520,"status":361,"phases":8521,"primaryCompletion":8522,"completion":8523,"start":2563,"enrollment":8524,"conditions":8525,"interventions":8526},"NCT01099423","Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer",[89],"2016-04","2017-05",99,[452],[6394],{"trials":8528,"activeCount":99},[],{"trials":8530,"activeCount":99},[8531],{"nctId":8532,"briefTitle":8533,"status":361,"phases":8534,"primaryCompletion":2801,"completion":2801,"start":4960,"enrollment":6016,"conditions":8535,"interventions":8536},"NCT01185886","Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia",[],[18,21],[6394,8537,8538],"mutation analysis","polymorphism analysis",{"intervention":4043,"totalTrials":523,"cells":8540},{"EARLY_PHASE1":8541,"PHASE1":8543,"PHASE2":8545,"PHASE3":8547,"PHASE4":8553,"NA":8555},{"trials":8542,"activeCount":99},[],{"trials":8544,"activeCount":99},[],{"trials":8546,"activeCount":99},[],{"trials":8548,"activeCount":99},[8549],{"nctId":4038,"briefTitle":4039,"status":188,"phases":8550,"primaryCompletion":2601,"start":409,"enrollment":2552,"conditions":8551,"interventions":8552},[88,89],[15],[955,4043],{"trials":8554,"activeCount":99},[],{"trials":8556,"activeCount":99},[8557],{"nctId":8453,"briefTitle":8454,"status":107,"phases":8558,"primaryCompletion":8456,"start":517,"enrollment":1749,"conditions":8559,"interventions":8560},[91],[15],[270,4043],{"intervention":8537,"totalTrials":665,"cells":8562},{"EARLY_PHASE1":8563,"PHASE1":8565,"PHASE2":8567,"PHASE3":8569,"PHASE4":8571,"NA":8573},{"trials":8564,"activeCount":99},[],{"trials":8566,"activeCount":99},[],{"trials":8568,"activeCount":99},[],{"trials":8570,"activeCount":99},[],{"trials":8572,"activeCount":99},[],{"trials":8574,"activeCount":99},[8575],{"nctId":8532,"briefTitle":8533,"status":361,"phases":8576,"primaryCompletion":2801,"completion":2801,"start":4960,"enrollment":6016,"conditions":8577,"interventions":8578},[],[18,21],[6394,8537,8538],{"intervention":8538,"totalTrials":665,"cells":8580},{"EARLY_PHASE1":8581,"PHASE1":8583,"PHASE2":8585,"PHASE3":8587,"PHASE4":8589,"NA":8591},{"trials":8582,"activeCount":99},[],{"trials":8584,"activeCount":99},[],{"trials":8586,"activeCount":99},[],{"trials":8588,"activeCount":99},[],{"trials":8590,"activeCount":99},[],{"trials":8592,"activeCount":99},[8593],{"nctId":8532,"briefTitle":8533,"status":361,"phases":8594,"primaryCompletion":2801,"completion":2801,"start":4960,"enrollment":6016,"conditions":8595,"interventions":8596},[],[18,21],[6394,8537,8538],{"intervention":8598,"totalTrials":665,"cells":8599},"amoxicillin-clavulanate potassium",{"EARLY_PHASE1":8600,"PHASE1":8602,"PHASE2":8604,"PHASE3":8606,"PHASE4":8608,"NA":8610},{"trials":8601,"activeCount":99},[],{"trials":8603,"activeCount":99},[],{"trials":8605,"activeCount":99},[],{"trials":8607,"activeCount":99},[],{"trials":8609,"activeCount":99},[],{"trials":8611,"activeCount":99},[8612],{"nctId":8613,"briefTitle":8614,"status":188,"phases":8615,"primaryCompletion":398,"start":2875,"enrollment":6,"conditions":8616,"interventions":8619},"NCT00062231","Moxifloxacin Compared With Ciprofloxacin\u002FAmoxicillin in Treating Fever and Neutropenia in Patients With Cancer",[91],[8617,5305,5306,18,21,1635,1577,4837,1775,8618,3352],"Chronic Myeloproliferative Disorders","Precancerous Condition",[8598,8620,8621],"ciprofloxacin","moxifloxacin hydrochloride",{"intervention":8620,"totalTrials":665,"cells":8623},{"EARLY_PHASE1":8624,"PHASE1":8626,"PHASE2":8628,"PHASE3":8630,"PHASE4":8632,"NA":8634},{"trials":8625,"activeCount":99},[],{"trials":8627,"activeCount":99},[],{"trials":8629,"activeCount":99},[],{"trials":8631,"activeCount":99},[],{"trials":8633,"activeCount":99},[],{"trials":8635,"activeCount":99},[8636],{"nctId":8613,"briefTitle":8614,"status":188,"phases":8637,"primaryCompletion":398,"start":2875,"enrollment":6,"conditions":8638,"interventions":8639},[91],[8617,5305,5306,18,21,1635,1577,4837,1775,8618,3352],[8598,8620,8621],{"intervention":8621,"totalTrials":665,"cells":8641},{"EARLY_PHASE1":8642,"PHASE1":8644,"PHASE2":8646,"PHASE3":8648,"PHASE4":8650,"NA":8652},{"trials":8643,"activeCount":99},[],{"trials":8645,"activeCount":99},[],{"trials":8647,"activeCount":99},[],{"trials":8649,"activeCount":99},[],{"trials":8651,"activeCount":99},[],{"trials":8653,"activeCount":99},[8654],{"nctId":8613,"briefTitle":8614,"status":188,"phases":8655,"primaryCompletion":398,"start":2875,"enrollment":6,"conditions":8656,"interventions":8657},[91],[8617,5305,5306,18,21,1635,1577,4837,1775,8618,3352],[8598,8620,8621]]